Andrew Berchuck
James M. Ingram Distinguished Professor of Gynecologic Oncology
Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology
. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org
) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html
).
Current Appointments & Affiliations
- James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 2013
- Professor of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 1997
- Chief of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 2006
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1987
Contact Information
- 25171 Morris Bldg, Durham, NC 27710
- Box 3079 Med Ctr, Durham, NC 27710
-
berch001@mc.duke.edu
(919) 684-3765
- Background
-
Education, Training, & Certifications
- M.D., Case Western Reserve University 1980
-
Duke Appointment History
- Associate Professor of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 1994 - 1997
- Associate Professor of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 1992 - 1994
- Recognition
-
In the News
-
DEC 17, 2015 -
NOV 18, 2014 Duke Research Blog
-
- Expertise
-
Subject Headings
- 3' Untranslated Regions
- 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
- 5-Lipoxygenase-Activating Proteins
- ABO Blood-Group System
- ATP-Binding Cassette, Sub-Family B, Member 1
- Acetaminophen
- Actins
- Actomyosin
- Actuarial Analysis
- Adaptor Proteins, Signal Transducing
- Adenocarcinoma
- Adenocarcinoma, Clear Cell
- Adenocarcinoma, Mucinous
- Adnexa Uteri
- Adnexal Diseases
- Adolescent
- Adult
- African Americans
- African Continental Ancestry Group
- Age Distribution
- Age Factors
- Age of Onset
- Aged
- Aged, 80 and over
- Alcohol Dehydrogenase
- Algorithms
- Alkylating Agents
- Alleles
- Alternative Splicing
- Americas
- Amidohydrolases
- Amino Acid Sequence
- Aminopeptidases
- Amnion
- Analysis of Variance
- Anemia
- Aneuploidy
- Angiogenic Proteins
- Animals
- Anthropometry
- Anti-Inflammatory Agents, Non-Steroidal
- Antibodies
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm
- Antidepressive Agents
- Antigens, CD
- Antigens, CD31
- Antigens, CD45
- Antigens, CD80
- Antigens, Tumor-Associated, Carbohydrate
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Antineoplastic Combined Chemotherapy Protocols
- Apolipoprotein A-I
- Apoptosis
- Apoptosis Regulatory Proteins
- Arylamine N-Acetyltransferase
- Ascites
- Ascitic Fluid
- Autophagy
- Azacitidine
- BRCA1 Protein
- BRCA2 Protein
- Base Sequence
- Bayes Theorem
- Binding Sites
- Biopsy
- Biopsy, Needle
- Blood Coagulation
- Blood Coagulation Disorders
- Blood Coagulation Tests
- Blood Loss, Surgical
- Blood Transfusion
- Blotting, Northern
- Blotting, Southern
- Blotting, Western
- Body Height
- Body Mass Index
- Bone Marrow Transplantation
- Brachytherapy
- Brain Neoplasms
- Breast
- Breast Neoplasms
- CA-125 Antigen
- Cadherins
- Caloric Restriction
- Cancer
- Carbon-Nitrogen Ligases
- Carboplatin
- Carcinoembryonic Antigen
- Carcinoma
- Carcinoma in Situ
- Carcinoma, Adenoid Cystic
- Carcinoma, Endometrioid
- Carcinoma, Papillary
- Carcinoma, Signet Ring Cell
- Carcinoma, Small Cell
- Carcinoma, Squamous Cell
- Carcinosarcoma
- Carrier Proteins
- Case-Control Studies
- Caspase 3
- Caspase 8
- Catalytic Domain
- Cell Adhesion
- Cell Culture Techniques
- Cell Cycle
- Cell Cycle Proteins
- Cell Division
- Cell Growth Processes
- Cell Line
- Cell Line, Transformed
- Cell Line, Tumor
- Cell Lineage
- Cell Movement
- Cell Proliferation
- Cell Shape
- Cell Survival
- Cell Transformation, Neoplastic
- Cells, Cultured
- Cervix Uteri
- Cesarean Section
- Chemotherapy
- Chemotherapy, Adjuvant
- Chi-Square Distribution
- Chickens
- Child
- Child, Preschool
- Chloramphenicol O-Acetyltransferase
- Choriocarcinoma
- Chorionic Gonadotropin
- Chromatin
- Chromatography, Affinity
- Chromatography, Liquid
- Chromium
- Chromium Compounds
- Chromosome Aberrations
- Chromosome Deletion
- Chromosome Mapping
- Chromosomes, Human, Pair 1
- Chromosomes, Human, Pair 10
- Chromosomes, Human, Pair 17
- Chromosomes, Human, Pair 18
- Chromosomes, Human, Pair 19
- Chromosomes, Human, Pair 2
- Chromosomes, Human, Pair 3
- Chromosomes, Human, Pair 4
- Chromosomes, Human, Pair 5
- Chromosomes, Human, Pair 7
- Chromosomes, Human, Pair 8
- Chromosomes, Human, Pair 9
- Cisplatin
- Clinical Competence
- Clinical Trials as Topic
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Clone Cells
- Cloning, Molecular
- Cluster Analysis
- Codon
- Cohort Studies
- Coitus
- Colectomy
- Collagen
- Colon
- Colon, Sigmoid
- Colonic Neoplasms
- Colorectal Neoplasms
- Colorectal Neoplasms, Hereditary Nonpolyposis
- Combined Modality Therapy
- Comparative Effectiveness Research
- Comparative Genomic Hybridization
- Compliance
- Condylomata Acuminata
- Confidence Intervals
- Confounding Factors (Epidemiology)
- Contraception
- Contraceptives, Oral
- Contraceptives, Oral, Combined
- Contraceptives, Oral, Hormonal
- Cooperative Behavior
- Cost-Benefit Analysis
- Counseling
- CpG Islands
- Culture Media
- Cyclin E
- Cyclin-Dependent Kinase Inhibitor p16
- Cyclin-Dependent Kinase Inhibitor p21
- Cyclin-Dependent Kinases
- Cyclins
- Cyclophosphamide
- Cystadenocarcinoma
- Cystadenocarcinoma, Papillary
- Cystadenocarcinoma, Serous
- Cystadenoma, Mucinous
- Cystadenoma, Serous
- Cysts
- Cytochrome P-450 CYP1A1
- Cytochrome P-450 CYP3A
- Cytokines
- Cytostatic Agents
- DNA
- DNA (Cytosine-5-)-Methyltransferase
- DNA Copy Number Variations
- DNA Damage
- DNA Fingerprinting
- DNA Helicases
- DNA Ligases
- DNA Methylation
- DNA Mismatch Repair
- DNA Mutational Analysis
- DNA Polymerase II
- DNA Primers
- DNA Repair
- DNA, Complementary
- DNA, Neoplasm
- DNA, Satellite
- DNA, Single-Stranded
- DNA-Binding Proteins
- Dactinomycin
- Data Collection
- Decision Support Techniques
- Decision Trees
- Deoxyribonucleases, Type II Site-Specific
- Depression, Chemical
- Dermatologic Surgical Procedures
- Developed Countries
- Diacylglycerol Kinase
- Diagnosis, Differential
- Diet
- Dietary Supplements
- Diffusion of Innovation
- Dihydrouracil Dehydrogenase (NADP)
- Dinoprostone
- Diploidy
- Discriminant Analysis
- Disease Models, Animal
- Disease Progression
- Disease-Free Survival
- Diseases
- Dormancy
- Dosage Compensation, Genetic
- Dose-Response Relationship, Drug
- Down-Regulation
- Doxorubicin
- Drug Administration Schedule
- Drug Combinations
- Drug Design
- Drug Resistance
- Drug Resistance, Multiple
- Drug Resistance, Neoplasm
- Drug Synergism
- E2F Transcription Factors
- Early Detection of Cancer
- Education, Medical, Graduate
- Eflornithine
- Eggs
- Electrophoresis, Polyacrylamide Gel
- Endometrial Hyperplasia
- Endometrial Neoplasms
- Endometriosis
- Endometrium
- Endosomal Sorting Complexes Required for Transport
- Environmental Exposure
- Enzyme Induction
- Enzyme Inhibitors
- Enzyme-Linked Immunosorbent Assay
- Epidermal Growth Factor
- Epigenesis, Genetic
- Epigenomics
- Epithelial Cells
- Epithelium
- Epitopes
- Epoxide Hydrolases
- Estradiol
- Estrogen Antagonists
- Estrogen Receptor alpha
- Estrogen Receptor beta
- Estrogen Replacement Therapy
- Estrogens
- Ethics, Medical
- Ethnic Groups
- Etoposide
- Europe
- European Continental Ancestry Group
- Evaluation Studies as Topic
- Exome
- Exons
- Extracellular Space
- Factor IX
- Fallopian Tube Neoplasms
- Fallopian Tubes
- Family planning
- Fatigue
- Fellowships and Scholarships
- Female
- Fetal Diseases
- Fibrin Fibrinogen Degradation Products
- Fibroblast Growth Factor 2
- Fibroblast Growth Factors
- Fibroblasts
- Fibronectins
- Fistula
- Flow Cytometry
- Fluorescent Antibody Technique
- Fluorine Radioisotopes
- Fluorodeoxyglucose F18
- Folate Receptor 1
- Folate Receptors, GPI-Anchored
- Folic Acid
- Follow-Up Studies
- Forecasting
- Formaldehyde
- Frozen Sections
- G1 Phase
- GPI-Linked Proteins
- GTP Phosphohydrolases
- GTP-Binding Proteins
- Galectin 1
- Galectin 3
- Gastrointestinal Diseases
- Gene Amplification
- Gene Deletion
- Gene Dosage
- Gene Expression
- Gene Expression Profiling
- Gene Expression Regulation
- Gene Expression Regulation, Enzymologic
- Gene Expression Regulation, Neoplastic
- Gene Frequency
- Gene Silencing
- Gene Transfer Techniques
- Gene-Environment Interaction
- Genes, BRCA1
- Genes, BRCA2
- Genes, Neoplasm
- Genes, Tumor Suppressor
- Genes, cdc
- Genes, fms
- Genes, p16
- Genes, p53
- Genes, ras
- Genetic Association Studies
- Genetic Heterogeneity
- Genetic Linkage
- Genetic Loci
- Genetic Markers
- Genetic Predisposition to Disease
- Genetic Testing
- Genetic Therapy
- Genetic Variation
- Genetics
- Genital Diseases, Female
- Genital Neoplasms, Female
- Genome, Human
- Genome-Wide Association Study
- Genomic Imprinting
- Genomic Instability
- Genomics
- Genotype
- Germ-Line Mutation
- Glycoproteins
- Gonadotropins
- Granulocyte Colony-Stimulating Factor
- Gravity Suits
- Great Britain
- Green Fluorescent Proteins
- Growth Inhibitors
- Growth Substances
- Gynecologic Surgical Procedures
- Gynecology
- Half-Life
- Haplotypes
- HeLa Cells
- Head and Neck Neoplasms
- Health Care Costs
- Health Planning Guidelines
- Health Resources
- Hemagglutinins
- Hemorrhage
- Heparin
- Hepatocyte Nuclear Factor 1-beta
- Heterocyclic Compounds with 4 or More Rings
- Heterozygote
- Histones
- Homeodomain Proteins
- Homozygote
- Hormone Replacement Therapy
- Hormones
- Humans
- Hybrid Cells
- Hydatidiform Mole
- Hydrolysis
- Hyperthermia, Induced
- Hysterectomy
- Image Processing, Computer-Assisted
- Immunity
- Immunoassay
- Immunoblotting
- Immunoenzyme Techniques
- Immunohistochemistry
- Immunologic Factors
- Immunoradiometric Assay
- Immunosuppressive Agents
- Immunotherapy
- Immunotoxins
- In Situ Hybridization
- Incidence
- Infant
- Infant, Newborn
- Infection
- Inflammation
- Infusions, Parenteral
- Injections, Intramuscular
- Insulin-Like Growth Factor Binding Protein 1
- Insulin-Like Growth Factor Binding Protein 2
- Insulin-Like Growth Factor Binding Protein 3
- Insulin-Like Growth Factor Binding Proteins
- Insulin-Like Growth Factor I
- Insulin-Like Growth Factor II
- Integrins
- Intercellular Signaling Peptides and Proteins
- Interferon-gamma
- Interleukin-1
- Interleukin-18
- Interleukin-1alpha
- Interleukin-6
- International Agencies
- International Cooperation
- Internship and Residency
- Interviews as Topic
- Intracellular Signaling Peptides and Proteins
- Intraoperative Complications
- Introns
- Kaplan-Meier Estimate
- Keratins
- Ki-67 Antigen
- Kidney Diseases
- Kinetics
- Laminin
- Laparoscopy
- Laparotomy
- Leiomyoma
- Leiomyosarcoma
- Length of Stay
- Leucine Zippers
- Life Expectancy
- Life Tables
- Linear Models
- Linkage Disequilibrium
- Liver Diseases
- Logistic Models
- Longitudinal Studies
- Loss of Heterozygosity
- Lovastatin
- Luciferases
- Luminescent Proteins
- Lung Diseases
- Lung Neoplasms
- Lymph Node Excision
- Lymph Nodes
- Lymphatic Diseases
- Lymphatic Metastasis
- Lymphedema
- Lymphocyte Activation
- Lymphocytes
- Lymphocytes, Tumor-Infiltrating
- Lysophospholipids
- MAP Kinase Kinase 4
- MAP Kinase Signaling System
- Macaca fascicularis
- Macrophage Colony-Stimulating Factor
- Magnetics
- Male
- Mammary Neoplasms, Experimental
- Marketing
- Markov Chains
- Matrix Metalloproteinase 1
- Maximum Tolerated Dose
- Medical History Taking
- Medical Oncology
- Medicine
- Mefenamic Acid
- Membrane Glycoproteins
- Membrane Proteins
- Membrane Transport Proteins
- Menarche
- Menopause
- Menstrual Cycle
- Menstruation Disturbances
- Meta-Analysis as Topic
- Metabolic Clearance Rate
- Methods
- Methotrexate
- Methylation
- Methylenetetrahydrofolate Dehydrogenase (NADP)
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- MicroRNAs
- Microarray Analysis
- Microfilament Proteins
- Micromanipulation
- Microsatellite Instability
- Microsatellite Repeats
- Microscopy, Atomic Force
- Microscopy, Confocal
- Microscopy, Electron
- Microspheres
- Middle Aged
- Mitochondrial Proteins
- Mitosis
- Mitotic Index
- Mixed Tumor, Mesodermal
- Mixed Tumor, Mullerian
- Models, Biological
- Models, Economic
- Models, Genetic
- Models, Statistical
- Molecular Conformation
- Molecular Sequence Data
- Molecular Targeted Therapy
- Molecular Weight
- Morbidity
- Mucin-1
- Mullerian Ducts
- Multicenter Studies as Topic
- Multivariate Analysis
- Muscle, Skeletal
- MutS Homolog 2 Protein
- Mutagenesis, Insertional
- Mutation
- Mycobacterium bovis
- Myelin Proteins
- Myelin and Lymphocyte-Associated Proteolipid Proteins
- Myometrium
- Myosin Type II
- N-Acetylgalactosaminyltransferases
- NAD(P)H Dehydrogenase (Quinone)
- NF-kappa B
- Neoplasm Grading
- Neoplasm Invasiveness
- Neoplasm Metastasis
- Neoplasm Proteins
- Neoplasm Recurrence, Local
- Neoplasm Staging
- Neoplasm Transplantation
- Neoplasm, Residual
- Neoplasms
- Neoplasms, Cystic, Mucinous, and Serous
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Glandular and Epithelial
- Neoplasms, Multiple Primary
- Neoplasms, Second Primary
- Neoplastic Stem Cells
- Neoplastic Syndromes, Hereditary
- Neovascularization, Pathologic
- Nerve Tissue Proteins
- Neural Networks (Computer)
- Neuropeptides
- Neutropenia
- Nicotinic Acids
- North America
- North Carolina
- Nuclear Proteins
- Nuclear Receptor Co-Repressor 1
- Nuclear Receptor Co-Repressor 2
- Nucleic Acid Heteroduplexes
- Nucleic Acid Hybridization
- Nutrition Disorders
- Obesity
- Observer Variation
- Odds Ratio
- Oligodeoxyribonucleotides
- Oligonucleotide Array Sequence Analysis
- Oligonucleotide Probes
- Omentum
- Oncogene Proteins, Viral
- Oncogenes
- Oncology Service, Hospital
- Ornithine Decarboxylase
- Ovarian Cysts
- Ovarian Diseases
- Ovarian Neoplasms
- Ovariectomy
- Ovary
- Oviducts
- Ovulation
- Oxytocin
- PTEN Phosphohydrolase
- Paclitaxel
- Pain, Postoperative
- Palliative Care
- Papillomaviridae
- Paraffin Embedding
- Parity
- Patient Acceptance of Health Care
- Patient Selection
- Pedigree
- Pelvic Exenteration
- Pelvic Neoplasms
- Pelvis
- Peptide Elongation Factor Tu
- Peptide Termination Factors
- Peptides
- Peripheral Nervous System Diseases
- Peritoneal Cavity
- Peritoneal Diseases
- Peritoneal Lavage
- Peritoneal Neoplasms
- Peritoneum
- Peritonitis, Tuberculous
- Pharmacogenetics
- Phenotype
- Phosphates
- Phosphatidate Phosphatase
- Phosphatidylinositol 3-Kinases
- Phosphoproteins
- Phosphoric Monoester Hydrolases
- Phosphorus Radioisotopes
- Phosphorylation
- Physical Examination
- Pilot Projects
- Piperidines
- Placenta Accreta
- Platelet-Derived Growth Factor
- Platinum
- Platinum Compounds
- Ploidies
- Pneumoperitoneum
- Point Mutation
- Poly(ADP-ribose) Polymerases
- Polymerase Chain Reaction
- Polymorphism, Genetic
- Polymorphism, Restriction Fragment Length
- Polymorphism, Single Nucleotide
- Polymorphism, Single-Stranded Conformational
- Population Dynamics
- Population Surveillance
- Postmenopause
- Postoperative Complications
- Postoperative Period
- Powders
- Practice Guidelines as Topic
- Prealbumin
- Precancerous Conditions
- Precipitin Tests
- Predictive Value of Tests
- Pregnancy
- Pregnancy Complications
- Pregnancy Tests
- Pregnancy Trimester, Second
- Premenopause
- Prenatal Diagnosis
- Preoperative Care
- Prevalence
- Principal Component Analysis
- Probability
- Progesterone
- Progestins
- Prognosis
- Proliferating Cell Nuclear Antigen
- Promoter Regions, Genetic
- Proportional Hazards Models
- Prospective Studies
- Prostaglandins
- Prostaglandins E
- Prostatic Neoplasms
- Protamine Kinase
- Protective Agents
- Protein Array Analysis
- Protein Isoforms
- Protein Kinase C
- Protein Kinase C-delta
- Protein Kinase Inhibitors
- Protein Precursors
- Protein Processing, Post-Translational
- Protein Structure, Tertiary
- Protein Tyrosine Phosphatases
- Protein-Serine-Threonine Kinases
- Protein-Tyrosine Kinases
- Proteins
- Proteoglycans
- Proteolipids
- Proteomics
- Proto-Oncogene Proteins
- Proto-Oncogene Proteins B-raf
- Proto-Oncogene Proteins c-bcl-2
- Proto-Oncogene Proteins c-myb
- Proto-Oncogene Proteins pp60(c-src)
- Proto-Oncogenes
- Purines
- Pyrimidines
- Quality Control
- Quality of Life
- Quality-Adjusted Life Years
- Quantitative Trait Loci
- Questionnaires
- Quinone Reductases
- RNA
- RNA Splicing
- RNA, Antisense
- RNA, Messenger
- RNA, Neoplasm
- RNA, Small Interfering
- RNA, Untranslated
- ROC Curve
- Radiation Injuries
- Radioimmunoassay
- Radioimmunoprecipitation Assay
- Radiopharmaceuticals
- Radiotherapy
- Radiotherapy, Adjuvant
- Randomized Controlled Trials as Topic
- Rats
- Rats, Sprague-Dawley
- Real-Time Polymerase Chain Reaction
- Receptor Protein-Tyrosine Kinases
- Receptor, Epidermal Growth Factor
- Receptor, IGF Type 2
- Receptor, erbB-2
- Receptors, Androgen
- Receptors, Calcitriol
- Receptors, Cell Surface
- Receptors, Estrogen
- Receptors, Growth Factor
- Receptors, Interleukin-1
- Receptors, Interleukin-2
- Receptors, Laminin
- Receptors, Progesterone
- Receptors, Transforming Growth Factor beta
- Receptors, Tumor Necrosis Factor
- Reconstructive Surgical Procedures
- Rectus Abdominis
- Recurrence
- Reference Values
- Registries
- Regression Analysis
- Remission Induction
- Reoperation
- Repetitive Sequences, Amino Acid
- Repetitive Sequences, Nucleic Acid
- Repressor Proteins
- Reproducibility of Results
- Reproductive History
- Retinoblastoma Protein
- Retirement
- Retrospective Studies
- Reverse Transcriptase Polymerase Chain Reaction
- Ricin
- Risk
- Risk Assessment
- Risk Factors
- Risk Reduction Behavior
- Robotics
- SEER Program
- Sarcoma
- Second-Look Surgery
- Selective Estrogen Receptor Modulators
- Sensitivity and Specificity
- Sequence Analysis, DNA
- Sequence Deletion
- Serpins
- Signal Transduction
- Skin
- Societies, Medical
- Societies, Scientific
- Socioeconomic Factors
- Solubility
- Specialization
- Spheroids, Cellular
- Staining and Labeling
- Statistics, Nonparametric
- Staurosporine
- Sterilization, Tubal
- Stimulation, Chemical
- Stromal Cells
- Sulfites
- Surgical Flaps
- Surgical Wound Dehiscence
- Surgical Wound Infection
- Survival
- Survival Analysis
- Survival Rate
- Survivors
- Sutures
- T-Lymphocytes, Regulatory
- TNF-Related Apoptosis-Inducing Ligand
- Talc
- Tamoxifen
- Tandem Mass Spectrometry
- Taxoids
- Telomerase
- Telomere
- Terminal Care
- Testis
- Tetradecanoylphorbol Acetate
- Tetrahydronaphthalenes
- Therapies, Investigational
- Thiazoles
- Thigh
- Thioguanine
- Thiophenes
- Thiotepa
- Thrombocytosis
- Thrombophlebitis
- Thrombosis
- Thrombospondin 1
- Thymidine
- Thymidylate Synthase
- Time Factors
- Tissue Array Analysis
- Tissue Distribution
- Tissue Embedding
- Tissue Fixation
- Tomography, Emission-Computed
- Tomography, X-Ray Computed
- Trans-Activators
- Transcription Factors
- Transcription, Genetic
- Transcriptional Activation
- Transfection
- Transforming Growth Factor alpha
- Transforming Growth Factor beta
- Transforming Growth Factor beta1
- Transforming Growth Factors
- Transplantation, Autologous
- Treatment Outcome
- Tretinoin
- Trinucleotide Repeats
- Tritium
- Trophoblastic Neoplasms
- Tumor Cells, Cultured
- Tumor Markers, Biological
- Tumor Necrosis Factor-alpha
- Tumor Suppressor Protein p53
- Tumor Suppressor Proteins
- United States
- Up-Regulation
- Urologic Diseases
- Utah
- Uterine Cervical Diseases
- Uterine Cervical Incompetence
- Uterine Cervical Neoplasms
- Uterine Hemorrhage
- Uterine Neoplasms
- Uterine Rupture
- Uterus
- Vagina
- Vaginal Fistula
- Vaginal Neoplasms
- Vaginal Smears
- Vanadates
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factor Receptor-1
- Venous Thrombosis
- Vincristine
- Vulva
- Vulvar Neoplasms
- Wound Healing
- X Chromosome
- X-Linked Inhibitor of Apoptosis Protein
- Xenobiotics
- YY1 Transcription Factor
- Young Adult
- alpha-Fetoproteins
- bcl-Associated Death Protein
- ras Proteins
- rho GTP-Binding Proteins
- src-Family Kinases
- Research
-
Selected Grants
- Duke Women's Reproductive Health Research Scholars awarded by National Institutes of Health 2020 - 2025
- A Role of Multilevel Healthcare Access Dimensions in Ovarian Cancer Disparities awarded by National Institutes of Health 2019 - 2024
- Mutation analysis of pap smear samples and associated tissues for ovarian cancer diagnostics awarded by Genendeavor LLC 2017 - 2022
- Building Interdisciplinary Research Careers in Women's Health awarded by National Institutes of Health 2002 - 2022
- Kastan Gray Foundation Project awarded by Gray Foundation 2017 - 2021
- Translational Research in Surgical Oncology awarded by National Institutes of Health 2002 - 2021
- Tissue and Data Acquisition Activity for the Study of Gynecologic Disease awarded by Henry M. Jackson Foundation 2016 - 2021
- TCGA data use agreement with Tempus Labs awarded by Tempus Labs Inc. 2020 - 2021
- Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors awarded by MD Anderson Cancer Center 2016 - 2020
- Immune modulation of CaMKK2 in the ovarian tumor microenvironment awarded by American Association of Obstetricians and Gynecologists Foundation 2019 - 2020
- Janet Burros Ovarian Cancer Repository awarded by Cancer Data Initiative 2018 - 2019
- Triggering human anti-tumor stringent response to target recurrent ovarian cancer awarded by Department of Defense 2017 - 2019
- Tissue and Data Acquisition Activity for the Study of Gynecologic Disease awarded by Henry M. Jackson Foundation 2016 - 2017
- Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors awarded by MD Anderson Cancer Center 2015 - 2016
- Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
- Endometrial Cancer TCGA Project awarded by National Institutes of Health 2010 - 2015
- Epidemiology of Ovarian Cancer in African-American Women awarded by National Institutes of Health 2010 - 2015
- TGCA Purchase Order awarded by Leidos Biomedical Research, Inc. 2014
- Gene Regulation in Recurrent Ovarian Cancers awarded by Gynecologic Cancer Foundation 2011 - 2014
- The Molecular Epidemiology Of Ovarian Cancer awarded by National Institutes of Health 1998 - 2012
- Tissue and Data Acquisition Activity for the Study of Gynecologic Disease awarded by United States Army Medical Research and Materiel Command 2010 - 2011
- Society of Gynecologic Investigation Annual Meeting awarded by National Institutes of Health 2004 - 2009
- Genomics Tests for Ovarian Cancer Detection and Management awarded by Agency for Healthcare Research and Quality 2005 - 2006
- (CGN Supplement): CGN Ovarian Cancer Screening in High Risk Women Pilot 2 awarded by National Institutes of Health 2001 - 2003
- Spore In Breast Cancer awarded by National Institutes of Health 1995 - 1998
- Spore In Breast Cancer awarded by National Institutes of Health 1995 - 1998
- Spore In Breast Cancer awarded by National Institutes of Health 1995 - 1998
- Molecular Epidemiolgy Of Epithelial Ovarian Cancer awarded by National Institutes of Health 1994 - 1997
- Growth Regulation & Transformation Of Ovarian Cancer Epith awarded by National Institutes of Health 1994 - 1997
- Growth Regulation And Transformation Of Ovarian Epithelium awarded by National Institutes of Health 1992 - 1997
- Molecular Epidemiology Of Epithelial Ovarian Cancer awarded by National Institutes of Health 1994 - 1996
- Hyperthermia And Perfusion Effects In Cancer Therapy awarded by National Institutes of Health 1993 - 1995
-
External Relationships
- Coleman Research Group
- Health Advances
- Ovarian cancer research alliance
- Schlesinger Associates
- Tina Bronzman Foundation
- Publications & Artistic Works
-
Selected Publications
-
Books
-
Barakat, R. R., A. Berchuck, M. Markman, and M. E. Randall. Principles and practice of gynecologic oncology: Sixth edition, 2013.
-
Luesley, D. M., F. G. Lawton, and A. Berchuck. Preface, 2005.
-
Luesley, D. M., F. G. Lawton, and A. Berchuck. Uterine cancer, 2005.
-
-
Academic Articles
-
Ong, Jue-Sheng, Eske M. Derks, Mikael Eriksson, Jiyuan An, Liang-Dar Hwang, Douglas F. Easton, Paul P. Pharoah, et al. “Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses.” Int J Cancer 148, no. 6 (March 15, 2021): 1338–50. https://doi.org/10.1002/ijc.33308.Full Text Link to Item
-
Huang, Zhiqing, Eiji Kondoh, Zachary R. Visco, Tsukasa Baba, Noriomi Matsumura, Emma Dolan, Regina S. Whitaker, et al. “Targeting Dormant Ovarian Cancer Cells In Vitro and in an In Vivo Mouse Model of Platinum Resistance.” Mol Cancer Ther 20, no. 1 (January 2021): 85–95. https://doi.org/10.1158/1535-7163.MCT-20-0119.Full Text Link to Item
-
Gonzalez, Rafael, Laura J. Havrilesky, Evan R. Myers, Angeles Alvarez Secord, Joseph A. Dottino, Andrew Berchuck, and Haley A. Moss. “Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.” Gynecol Oncol 159, no. 2 (November 2020): 483–90. https://doi.org/10.1016/j.ygyno.2020.08.003.Full Text Link to Item
-
Modugno, Francesmary, Zhuxuan Fu, Susan J. Jordan, Aocs Group, Jenny Chang-Claude, Renée T. Fortner, Marc T. Goodman, et al. “Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies.” Eur J Epidemiol 35, no. 11 (November 2020): 1025–42. https://doi.org/10.1007/s10654-020-00682-9.Full Text Link to Item
-
Talhouk, Aline, Joshy George, Chen Wang, Timothy Budden, Tuan Zea Tan, Derek S. Chiu, Stefan Kommoss, et al. “Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).” Clin Cancer Res 26, no. 20 (October 15, 2020): 5411–23. https://doi.org/10.1158/1078-0432.CCR-20-0103.Full Text Link to Item
-
Watson, Catherine H., Lindsay Soo, Brittany A. Davidson, Laura J. Havrilesky, Paula S. Lee, Leah J. McNally, Rebecca A. Previs, Angeles Alvarez Secord, Andrew Berchuck, and Noah D. Kauff. “Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices.” International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 30, no. 10 (October 2020): 1583–88. https://doi.org/10.1136/ijgc-2020-001536.Full Text
-
Brieger, Katharine K., Siri Peterson, Alice W. Lee, Bhramar Mukherjee, Kelly M. Bakulski, Aliya Alimujiang, Hoda Anton-Culver, et al. “Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival.” Gynecol Oncol 158, no. 3 (September 2020): 702–9. https://doi.org/10.1016/j.ygyno.2020.06.481.Full Text Link to Item
-
Zhang, Yan Dora, Amber N. Hurson, Haoyu Zhang, Parichoy Pal Choudhury, Douglas F. Easton, Roger L. Milne, Jacques Simard, et al. “Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers.” Nat Commun 11, no. 1 (July 3, 2020): 3353. https://doi.org/10.1038/s41467-020-16483-3.Full Text Link to Item
-
Song, Honglin, Ed M. Dicks, Jonathan Tyrer, Maria Intermaggio, Georgia Chenevix-Trench, David D. Bowtell, Nadia Traficante, et al. “Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer.” J Med Genet, June 16, 2020. https://doi.org/10.1136/jmedgenet-2019-106739.Full Text Link to Item
-
Manichaikul, Ani, Lauren C. Peres, Xin-Qun Wang, Mollie E. Barnard, Deanna Chyn, Xin Sheng, Zhaohui Du, et al. “Identification of novel epithelial ovarian cancer loci in women of African ancestry.” Int J Cancer 146, no. 11 (June 1, 2020): 2987–98. https://doi.org/10.1002/ijc.32653.Full Text Link to Item
-
Lee, Alice W., Anna H. Wu, Ashley Wiensch, Bhramar Mukherjee, Kathryn L. Terry, Holly R. Harris, Michael E. Carney, et al. “Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored.” Epidemiology 31, no. 3 (May 2020): 402–8. https://doi.org/10.1097/EDE.0000000000001175.Full Text Link to Item
-
Bixel, K., M. Vetter, B. Davidson, A. Berchuck, D. Cohn, L. Copeland, J. M. Fowler, et al. “Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.” Gynecol Oncol 156, no. 3 (March 2020): 530–34. https://doi.org/10.1016/j.ygyno.2019.12.016.Full Text Link to Item
-
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Melanie. “Pan-cancer analysis of whole genomes.” Nature 578, no. 7793 (February 2020): 82–93. https://doi.org/10.1038/s41586-020-1969-6.Full Text Link to Item
-
VanDusen, Keith W., Sarada Eleswarpu, Eugene W. Moretti, Michael J. Devinney, Donna M. Crabtree, Daniel T. Laskowitz, Marty G. Woldorff, et al. “The MARBLE Study Protocol: Modulating ApoE Signaling to Reduce Brain Inflammation, DeLirium, and PostopErative Cognitive Dysfunction.” J Alzheimers Dis 75, no. 4 (2020): 1319–28. https://doi.org/10.3233/JAD-191185.Full Text Open Access Copy Link to Item
-
Havrilesky, Laura J., Jui-Chen Yang, Paula S. Lee, Angeles Alvarez Secord, Jessie A. Ehrisman, Brittany Davidson, Andrew Berchuck, Kathleen M. Darcy, G Larry Maxwell, and Shelby D. Reed. “Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer.” Cancer 125, no. 24 (December 15, 2019): 4399–4406. https://doi.org/10.1002/cncr.32447.Full Text Link to Item
-
Havrilesky, L. J., J. C. Yang, P. S. Lee, A. A. Secord, J. A. Ehrisman, B. Davidson, A. Berchuck, K. M. Darcy, G. L. Maxwell, and S. D. Reed. “Patient Preferences for Attributes of Primary Surgical Debulking Versus Neoadjuvant Chemotherapy for Treatment of Newly Diagnosed Ovarian Cancer.” Obstetrical and Gynecological Survey 74, no. 12 (December 1, 2019): 718–19. https://doi.org/10.1097/OGX.0000000000000743.Full Text
-
Jiang, Xia, Hilary K. Finucane, Fredrick R. Schumacher, Stephanie L. Schmit, Jonathan P. Tyrer, Younghun Han, Kyriaki Michailidou, et al. “Publisher Correction: Shared heritability and functional enrichment across six solid cancers.” Nat Commun 10, no. 1 (September 23, 2019): 4386. https://doi.org/10.1038/s41467-019-12095-8.Full Text Link to Item
-
Armstrong, Deborah K., Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, et al. “NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.” J Natl Compr Canc Netw 17, no. 8 (August 1, 2019): 896–909. https://doi.org/10.6004/jnccn.2019.0039.Full Text Link to Item
-
Gaillard, Stéphanie L., Kaitlyn J. Andreano, Laurie M. Gay, Meghan Steiner, Matthew S. Jorgensen, Brittany Anne Davidson, Laura J. Havrilesky, et al. “Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.” Gynecol Oncol 154, no. 1 (July 2019): 199–206. https://doi.org/10.1016/j.ygyno.2019.04.010.Full Text Link to Item
-
Harris, Holly R., Kara L. Cushing-Haugen, Penelope M. Webb, Christina M. Nagle, Susan J. Jordan, Susan J. Australian Ovarian Cancer Study Group, Harvey A. Risch, et al. “Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study.” Int J Epidemiol 48, no. 3 (June 1, 2019): 822–30. https://doi.org/10.1093/ije/dyz113.Full Text Link to Item
-
Saner, Flurina A. M., Alan Herschtal, Brad H. Nelson, Anna deFazio, Ellen L. Goode, Susan J. Ramus, Ahwan Pandey, et al. “Going to extremes: determinants of extraordinary response and survival in patients with cancer.” Nat Rev Cancer 19, no. 6 (June 2019): 339–48. https://doi.org/10.1038/s41568-019-0145-5.Full Text Link to Item
-
Veade, Ashley E., Jonathan Foote, Jessie Ehrisman, Gloria Broadwater, Brittany A. Davidson, Paula S. Lee, Angeles Alvarez Secord, Andrew Berchuck, and Laura J. Havrilesky. “Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma.” World J Surg Oncol 17, no. 1 (May 10, 2019): 80. https://doi.org/10.1186/s12957-019-1620-x.Full Text Link to Item
-
Grant, Delores J., Ani Manichaikul, Anthony J. Alberg, Elisa V. Bandera, Jill Barnholtz-Sloan, Melissa Bondy, Michele L. Cote, et al. “Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women.” Cancer Medicine 8, no. 5 (May 2019): 2503–13. https://doi.org/10.1002/cam4.1996.Full Text
-
Kim, Sehee, Miao Wang, Jonathan P. Tyrer, Allan Jensen, Ashley Wiensch, Gang Liu, Alice W. Lee, et al. “A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants.” Int J Cancer 144, no. 9 (May 1, 2019): 2192–2205. https://doi.org/10.1002/ijc.32029.Full Text Link to Item
-
Lawrenson, Kate, Fengju Song, Dennis J. Hazelett, Siddhartha P. Kar, Jonathan Tyrer, Catherine M. Phelan, Rosario I. Corona, et al. “Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women.” Gynecol Oncol 153, no. 2 (May 2019): 343–55. https://doi.org/10.1016/j.ygyno.2019.02.023.Full Text Open Access Copy Link to Item
-
Watson, Catherine H., Micael Lopez-Acevedo, Gloria Broadwater, Amy H. Kim, Jessie Ehrisman, Brittany A. Davidson, Paula S. Lee, Fidel Valea, Andrew Berchuck, and Laura J. Havrilesky. “A pilot study of lower extremity lymphedema, lower extremity function, and quality of life in women after minimally invasive endometrial cancer staging surgery.” Gynecol Oncol 153, no. 2 (May 2019): 399–404. https://doi.org/10.1016/j.ygyno.2019.02.021.Full Text Link to Item
-
Berger, Miles, Deborah Oyeyemi, Mobolaji O. Olurinde, Heather E. Whitson, Kent J. Weinhold, Marty G. Woldorff, Lewis A. Lipsitz, et al. “The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction.” J Am Geriatr Soc 67, no. 4 (April 2019): 794–98. https://doi.org/10.1111/jgs.15770.Full Text Open Access Copy Link to Item
-
Buckley, Melissa A., Nicholas T. Woods, Jonathan P. Tyrer, Gustavo Mendoza-Fandiño, Kate Lawrenson, Dennis J. Hazelett, Hamed S. Najafabadi, et al. “Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus.” Cancer Res 79, no. 3 (February 1, 2019): 467–81. https://doi.org/10.1158/0008-5472.CAN-17-3864.Full Text Link to Item
-
Yang, Yaohua, Lang Wu, Xiang Shu, Yingchang Lu, Xiao-Ou Shu, Qiuyin Cai, Alicia Beeghly-Fadiel, et al. “Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk.” Cancer Res 79, no. 3 (February 1, 2019): 505–17. https://doi.org/10.1158/0008-5472.CAN-18-2726.Full Text Link to Item
-
Jiang, Xia, Hilary K. Finucane, Fredrick R. Schumacher, Stephanie L. Schmit, Jonathan P. Tyrer, Younghun Han, Kyriaki Michailidou, et al. “Shared heritability and functional enrichment across six solid cancers.” Nat Commun 10, no. 1 (January 25, 2019): 431. https://doi.org/10.1038/s41467-018-08054-4.Full Text Link to Item
-
Peres, Lauren C., Kara L. Cushing-Haugen, Martin Köbel, Holly R. Harris, Andrew Berchuck, Mary Anne Rossing, Joellen M. Schildkraut, and Jennifer A. Doherty. “Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.” J Natl Cancer Inst 111, no. 1 (January 1, 2019): 60–68. https://doi.org/10.1093/jnci/djy071.Full Text Link to Item
-
Wang, Yumeng, Xiaoyan Xu, Dejan Maglic, Michael T. Dill, Kamalika Mojumdar, Patrick Kwok-Shing Ng, Kang Jin Jeong, et al. “Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.” Cell Rep 25, no. 5 (October 30, 2018): 1304-1317.e5. https://doi.org/10.1016/j.celrep.2018.10.001.Full Text Link to Item
-
Korkut, Anil, Sobia Zaidi, Rupa S. Kanchi, Shuyun Rao, Nancy R. Gough, Andre Schultz, Xubin Li, et al. “A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.” Cell Syst 7, no. 4 (October 24, 2018): 422-437.e7. https://doi.org/10.1016/j.cels.2018.08.010.Full Text Link to Item
-
Peres, Lauren C., Kara L. Cushing-Haugen, Michael Anglesio, Kristine Wicklund, Rex Bentley, Andrew Berchuck, Linda E. Kelemen, et al. “Histotype classification of ovarian carcinoma: A comparison of approaches.” Gynecol Oncol 151, no. 1 (October 2018): 53–60. https://doi.org/10.1016/j.ygyno.2018.08.016.Full Text Link to Item
-
Rambau, Peter F., Robert A. Vierkant, Maria P. Intermaggio, Linda E. Kelemen, Marc T. Goodman, Esther Herpel, Paul D. Pharoah, et al. “Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.” J Pathol Clin Res 4, no. 4 (October 2018): 250–61. https://doi.org/10.1002/cjp2.109.Full Text Link to Item
-
Lu, Yingchang, Alicia Beeghly-Fadiel, Lang Wu, Xingyi Guo, Bingshan Li, Joellen M. Schildkraut, Hae Kyung Im, et al. “A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk.” Cancer Res 78, no. 18 (September 15, 2018): 5419–30. https://doi.org/10.1158/0008-5472.CAN-18-0951.Full Text Link to Item
-
Kelemen, Linda E., Madalene Earp, Brooke L. Fridley, Georgia Chenevix-Trench, Georgia Australian Ovarian Cancer Study Group, Peter A. Fasching, Matthias W. Beckmann, et al. “rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.” Int J Mol Sci 19, no. 9 (August 21, 2018). https://doi.org/10.3390/ijms19092473.Full Text Link to Item
-
Kahles, André, Kjong-Van Lehmann, Nora C. Toussaint, Matthias Hüser, Stefan G. Stark, Timo Sachsenberg, Oliver Stegle, et al. “Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.” Cancer Cell 34, no. 2 (August 13, 2018): 211-224.e6. https://doi.org/10.1016/j.ccell.2018.07.001.Full Text Link to Item
-
Bailey, Matthew H., Collin Tokheim, Eduard Porta-Pardo, Sohini Sengupta, Denis Bertrand, Amila Weerasinghe, Antonio Colaprico, et al. “Comprehensive Characterization of Cancer Driver Genes and Mutations.” Cell 174, no. 4 (August 9, 2018): 1034–35. https://doi.org/10.1016/j.cell.2018.07.034.Full Text Link to Item
-
Ricketts, Christopher J., Aguirre A. De Cubas, Huihui Fan, Christof C. Smith, Martin Lang, Ed Reznik, Reanne Bowlby, et al. “The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.” Cell Rep 23, no. 12 (June 19, 2018): 3698. https://doi.org/10.1016/j.celrep.2018.06.032.Full Text Link to Item
-
Chenevix-Trench, Georgia, Jonathan Beesley, Paul D. P. Pharoah, and Andrew Berchuck. “The importance of using public data to validate reported associations.” Plos Genet 14, no. 6 (June 2018): e1007416. https://doi.org/10.1371/journal.pgen.1007416.Full Text Link to Item
-
Davidson, Brittany A., Jessie Ehrisman, Sara Abbott, Zach Harmon, Angeles A. Secord, Andrew Berchuck, Paula S. Lee, et al. “Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial Cancer.” Int J Gynecol Pathol 37, no. 3 (May 2018): 252–55. https://doi.org/10.1097/PGP.0000000000000418.Full Text Link to Item
-
Thorsson, Vésteinn, David L. Gibbs, Scott D. Brown, Denise Wolf, Dante S. Bortone, Tai-Hsien Ou Yang, Eduard Porta-Pardo, et al. “The Immune Landscape of Cancer.” Immunity 48, no. 4 (April 17, 2018): 812-830.e14. https://doi.org/10.1016/j.immuni.2018.03.023.Full Text Link to Item
-
Berger, Ashton C., Anil Korkut, Rupa S. Kanchi, Apurva M. Hegde, Walter Lenoir, Wenbin Liu, Yuexin Liu, et al. “A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.” Cancer Cell 33, no. 4 (April 9, 2018): 690-705.e9. https://doi.org/10.1016/j.ccell.2018.03.014.Full Text Link to Item
-
Liu, Yang, Nilay S. Sethi, Toshinori Hinoue, Barbara G. Schneider, Andrew D. Cherniack, Francisco Sanchez-Vega, Jose A. Seoane, et al. “Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.” Cancer Cell 33, no. 4 (April 9, 2018): 721-735.e8. https://doi.org/10.1016/j.ccell.2018.03.010.Full Text Link to Item
-
Taylor, Alison M., Juliann Shih, Gavin Ha, Galen F. Gao, Xiaoyang Zhang, Ashton C. Berger, Steven E. Schumacher, et al. “Genomic and Functional Approaches to Understanding Cancer Aneuploidy.” Cancer Cell 33, no. 4 (April 9, 2018): 676-689.e3. https://doi.org/10.1016/j.ccell.2018.03.007.Full Text Link to Item
-
Wang, Zehua, Bo Yang, Min Zhang, Weiwei Guo, Zhiyuan Wu, Yue Wang, Lin Jia, et al. “lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer.” Cancer Cell 33, no. 4 (April 9, 2018): 706-720.e9. https://doi.org/10.1016/j.ccell.2018.03.006.Full Text Link to Item
-
Bailey, Matthew H., Collin Tokheim, Eduard Porta-Pardo, Sohini Sengupta, Denis Bertrand, Amila Weerasinghe, Antonio Colaprico, et al. “Comprehensive Characterization of Cancer Driver Genes and Mutations.” Cell 173, no. 2 (April 5, 2018): 371-385.e18. https://doi.org/10.1016/j.cell.2018.02.060.Full Text Link to Item
-
Chen, Han, Chunyan Li, Xinxin Peng, Zhicheng Zhou, John N. Weinstein, John N. Cancer Genome Atlas Research Network, and Han Liang. “A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.” Cell 173, no. 2 (April 5, 2018): 386-399.e12. https://doi.org/10.1016/j.cell.2018.03.027.Full Text Link to Item
-
Ding, Li, Matthew H. Bailey, Eduard Porta-Pardo, Vesteinn Thorsson, Antonio Colaprico, Denis Bertrand, David L. Gibbs, et al. “Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.” Cell 173, no. 2 (April 5, 2018): 305-320.e10. https://doi.org/10.1016/j.cell.2018.03.033.Full Text Link to Item
-
Hoadley, Katherine A., Christina Yau, Toshinori Hinoue, Denise M. Wolf, Alexander J. Lazar, Esther Drill, Ronglai Shen, et al. “Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.” Cell 173, no. 2 (April 5, 2018): 291-304.e6. https://doi.org/10.1016/j.cell.2018.03.022.Full Text Link to Item
-
Huang, Kuan-Lin, R Jay Mashl, Yige Wu, Deborah I. Ritter, Jiayin Wang, Clara Oh, Marta Paczkowska, et al. “Pathogenic Germline Variants in 10,389 Adult Cancers.” Cell 173, no. 2 (April 5, 2018): 355-370.e14. https://doi.org/10.1016/j.cell.2018.03.039.Full Text Link to Item
-
Liu, Jianfang, Tara Lichtenberg, Katherine A. Hoadley, Laila M. Poisson, Alexander J. Lazar, Andrew D. Cherniack, Albert J. Kovatich, et al. “An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.” Cell 173, no. 2 (April 5, 2018): 400-416.e11. https://doi.org/10.1016/j.cell.2018.02.052.Full Text Link to Item
-
Malta, Tathiane M., Artem Sokolov, Andrew J. Gentles, Tomasz Burzykowski, Laila Poisson, John N. Weinstein, Bożena Kamińska, et al. “Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation.” Cell 173, no. 2 (April 5, 2018): 338-354.e15. https://doi.org/10.1016/j.cell.2018.03.034.Full Text Link to Item
-
Sanchez-Vega, Francisco, Marco Mina, Joshua Armenia, Walid K. Chatila, Augustin Luna, Konnor C. La, Sofia Dimitriadoy, et al. “Oncogenic Signaling Pathways in The Cancer Genome Atlas.” Cell 173, no. 2 (April 5, 2018): 321-337.e10. https://doi.org/10.1016/j.cell.2018.03.035.Full Text Link to Item
-
Campbell, Joshua D., Christina Yau, Reanne Bowlby, Yuexin Liu, Kevin Brennan, Huihui Fan, Alison M. Taylor, et al. “Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.” Cell Rep 23, no. 1 (April 3, 2018): 194-212.e6. https://doi.org/10.1016/j.celrep.2018.03.063.Full Text Link to Item
-
Chiu, Hua-Sheng, Sonal Somvanshi, Ektaben Patel, Ting-Wen Chen, Vivek P. Singh, Barry Zorman, Sagar L. Patil, et al. “Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context.” Cell Rep 23, no. 1 (April 3, 2018): 297-312.e12. https://doi.org/10.1016/j.celrep.2018.03.064.Full Text Link to Item
-
Gao, Qingsong, Wen-Wei Liang, Steven M. Foltz, Gnanavel Mutharasu, Reyka G. Jayasinghe, Song Cao, Wen-Wei Liao, et al. “Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.” Cell Rep 23, no. 1 (April 3, 2018): 227-238.e3. https://doi.org/10.1016/j.celrep.2018.03.050.Full Text Link to Item
-
Ge, Zhongqi, Jake S. Leighton, Yumeng Wang, Xinxin Peng, Zhongyuan Chen, Hu Chen, Yutong Sun, et al. “Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types.” Cell Rep 23, no. 1 (April 3, 2018): 213-226.e3. https://doi.org/10.1016/j.celrep.2018.03.047.Full Text Link to Item
-
Jayasinghe, Reyka G., Song Cao, Qingsong Gao, Michael C. Wendl, Nam Sy Vo, Sheila M. Reynolds, Yanyan Zhao, et al. “Systematic Analysis of Splice-Site-Creating Mutations in Cancer.” Cell Rep 23, no. 1 (April 3, 2018): 270-281.e3. https://doi.org/10.1016/j.celrep.2018.03.052.Full Text Link to Item
-
Knijnenburg, Theo A., Linghua Wang, Michael T. Zimmermann, Nyasha Chambwe, Galen F. Gao, Andrew D. Cherniack, Huihui Fan, et al. “Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.” Cell Rep 23, no. 1 (April 3, 2018): 239-254.e6. https://doi.org/10.1016/j.celrep.2018.03.076.Full Text Link to Item
-
Peng, Xinxin, Zhongyuan Chen, Farshad Farshidfar, Xiaoyan Xu, Philip L. Lorenzi, Yumeng Wang, Feixiong Cheng, et al. “Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.” Cell Rep 23, no. 1 (April 3, 2018): 255-269.e4. https://doi.org/10.1016/j.celrep.2018.03.077.Full Text Link to Item
-
Ricketts, Christopher J., Aguirre A. De Cubas, Huihui Fan, Christof C. Smith, Martin Lang, Ed Reznik, Reanne Bowlby, et al. “The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.” Cell Rep 23, no. 1 (April 3, 2018): 313-326.e5. https://doi.org/10.1016/j.celrep.2018.03.075.Full Text Link to Item
-
Saltz, Joel, Rajarsi Gupta, Le Hou, Tahsin Kurc, Pankaj Singh, Vu Nguyen, Dimitris Samaras, et al. “Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images.” Cell Rep 23, no. 1 (April 3, 2018): 181-193.e7. https://doi.org/10.1016/j.celrep.2018.03.086.Full Text Link to Item
-
Seiler, Michael, Shouyong Peng, Anant A. Agrawal, James Palacino, Teng Teng, Ping Zhu, Peter G. Smith, Peter G. Cancer Genome Atlas Research Network, Silvia Buonamici, and Lihua Yu. “Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.” Cell Rep 23, no. 1 (April 3, 2018): 282-296.e4. https://doi.org/10.1016/j.celrep.2018.01.088.Full Text Link to Item
-
Way, Gregory P., Francisco Sanchez-Vega, Konnor La, Joshua Armenia, Walid K. Chatila, Augustin Luna, Chris Sander, et al. “Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.” Cell Rep 23, no. 1 (April 3, 2018): 172-180.e3. https://doi.org/10.1016/j.celrep.2018.03.046.Full Text Link to Item
-
Dixon-Suen, Suzanne C., Christina M. Nagle, Aaron P. Thrift, Paul D. P. Pharoah, Ailith Ewing, Celeste Leigh Pearce, Wei Zheng, et al. “Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.” Br J Cancer 118, no. 8 (April 2018): 1123–29. https://doi.org/10.1038/s41416-018-0011-3.Full Text Link to Item
-
Kar, Siddhartha P., Andrew Berchuck, Simon A. Gayther, Ellen L. Goode, Kirsten B. Moysich, Celeste Leigh Pearce, Susan J. Ramus, Joellen M. Schildkraut, Thomas A. Sellers, and Paul D. P. Pharoah. “Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions.” Cancer Epidemiol Biomarkers Prev 27, no. 4 (April 2018): 395–404. https://doi.org/10.1158/1055-9965.EPI-17-0315.Full Text Link to Item
-
Ong, Jue-Sheng, Liang-Dar Hwang, Gabriel Cuellar-Partida, Nicholas G. Martin, Georgia Chenevix-Trench, Michael C. J. Quinn, Marilyn C. Cornelis, et al. “Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study.” Int J Epidemiol 47, no. 2 (April 1, 2018): 450–59. https://doi.org/10.1093/ije/dyx236.Full Text Link to Item
-
Peres, Lauren C., Harvey Risch, Kathryn L. Terry, Penelope M. Webb, Marc T. Goodman, Anna H. Wu, Anthony J. Alberg, et al. “Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies.” Int J Epidemiol 47, no. 2 (April 1, 2018): 460–72. https://doi.org/10.1093/ije/dyx252.Full Text Link to Item
-
Ellrott, Kyle, Matthew H. Bailey, Gordon Saksena, Kyle R. Covington, Cyriac Kandoth, Chip Stewart, Julian Hess, et al. “Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines.” Cell Syst 6, no. 3 (March 28, 2018): 271-281.e7. https://doi.org/10.1016/j.cels.2018.03.002.Full Text Link to Item
-
Schaub, Franz X., Varsha Dhankani, Ashton C. Berger, Mihir Trivedi, Anne B. Richardson, Reid Shaw, Wei Zhao, et al. “Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.” Cell Syst 6, no. 3 (March 28, 2018): 282-300.e2. https://doi.org/10.1016/j.cels.2018.03.003.Full Text Link to Item
-
Babic, Ana, Holly R. Harris, Allison F. Vitonis, Linda J. Titus, Susan J. Jordan, Penelope M. Webb, Penelope M. Australian Ovarian Cancer Study Group, et al. “Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium.” Int J Cancer 142, no. 3 (February 1, 2018): 460–69. https://doi.org/10.1002/ijc.31010.Full Text Link to Item
-
Harris, Holly R., Ana Babic, Penelope M. Webb, Christina M. Nagle, Susan J. Jordan, Harvey A. Risch, Mary Anne Rossing, et al. “Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium.” Cancer Epidemiol Biomarkers Prev 27, no. 2 (February 2018): 174–82. https://doi.org/10.1158/1055-9965.EPI-17-0655.Full Text Link to Item
-
Johnson, Omari K., Andrew Berchuck, Angeles A. Secord, and Andrew C. Peterson. “Urinary diversion in the genitourinary cancer survivor.” Gynecol Oncol 148, no. 2 (February 2018): 414–21. https://doi.org/10.1016/j.ygyno.2017.10.021.Full Text Link to Item
-
Liu, Gang, Bhramar Mukherjee, Seunggeun Lee, Alice W. Lee, Anna H. Wu, Elisa V. Bandera, Allan Jensen, et al. “Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence.” Am J Epidemiol 187, no. 2 (February 1, 2018): 366–77. https://doi.org/10.1093/aje/kwx243.Full Text Link to Item
-
Moss, Haley A., Andrew Berchuck, Megan L. Neely, Evan R. Myers, and Laura J. Havrilesky. “Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).” Jama Oncol 4, no. 2 (February 1, 2018): 190–95. https://doi.org/10.1001/jamaoncol.2017.4211.Full Text Link to Item
-
Ugai, Tomotaka, Linda E. Kelemen, Mika Mizuno, Jue-Sheng Ong, Penelope M. Webb, Georgia Chenevix-Trench, Georgia Australian Ovarian Cancer Study Group, et al. “Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium.” Cancer Sci 109, no. 2 (February 2018): 435–45. https://doi.org/10.1111/cas.13470.Full Text Link to Item
-
Earp, Madalene, Jonathan P. Tyrer, Stacey J. Winham, Hui-Yi Lin, Ganna Chornokur, Joe Dennis, Katja K. H. Aben, et al. “Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility.” Plos One 13, no. 7 (2018): e0197561. https://doi.org/10.1371/journal.pone.0197561.Full Text Link to Item
-
Berchuck, Andrew, Angeles Alvarez Secord, Haley A. Moss, and Laura J. Havrilesky. “Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?” J Clin Oncol 35, no. 36 (December 20, 2017): 3999–4002. https://doi.org/10.1200/JCO.2017.74.5752.Full Text Link to Item
-
Moore, Kathleen N., David Tritchler, Kenneth M. Kaufman, Heather Lankes, Michael C. J. Quinn, Michael C. J. Ovarian Cancer Association Consortium, Linda Van Le, et al. “Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.” Gynecol Oncol 147, no. 2 (November 2017): 396–401. https://doi.org/10.1016/j.ygyno.2017.08.024.Full Text Link to Item
-
Bateman, Nicholas W., Elizabeth A. Dubil, Guisong Wang, Brian L. Hood, Julie M. Oliver, Tracy A. Litzi, Glenn D. Gist, et al. “Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients.” Cancer 123, no. 20 (October 15, 2017): 4004–12. https://doi.org/10.1002/cncr.30813.Full Text Link to Item
-
Glubb, Dylan M., Sharon E. Johnatty, Michael C. J. Quinn, Tracy A. O’Mara, Jonathan P. Tyrer, Bo Gao, Peter A. Fasching, et al. “Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci.” Oncotarget 8, no. 39 (September 12, 2017): 64670–84. https://doi.org/10.18632/oncotarget.18501.Full Text Link to Item
-
Janouskova, Hana, Geniver El Tekle, Elisa Bellini, Namrata D. Udeshi, Anna Rinaldi, Anna Ulbricht, Tiziano Bernasocchi, et al. “Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.” Nat Med 23, no. 9 (September 2017): 1046–54. https://doi.org/10.1038/nm.4372.Full Text Link to Item
-
Skates, Steven J., Mark H. Greene, Saundra S. Buys, Phuong L. Mai, Powel Brown, Marion Piedmonte, Gustavo Rodriguez, et al. “Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.” Clin Cancer Res 23, no. 14 (July 15, 2017): 3628–37. https://doi.org/10.1158/1078-0432.CCR-15-2750.Full Text Link to Item
-
Witkowski, Leora, Nancy Donini, Rebecca Byler-Dann, James A. Knost, Steffen Albrecht, Andrew Berchuck, W Glenn McCluggage, Martin Hasselblatt, and William D. Foulkes. “The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases.” Fam Cancer 16, no. 3 (July 2017): 395–99. https://doi.org/10.1007/s10689-016-9957-6.Full Text Link to Item
-
“RE: “RISK PREDICTION FOR EPITHELIAL OVARIAN CANCER IN 11 UNITED STATES–BASED CASE-CONTROL STUDIES: INCORPORATION OF EPIDEMIOLOGIC RISK FACTORS AND 17 CONFIRMED GENETIC LOCI”.” American Journal of Epidemiology 186, no. 1 (July 1, 2017): 130–130. https://doi.org/10.1093/aje/kwx151.Full Text
-
Glubb, Dylan M., Sharon E. Johnatty, Michael C. J. Quinn, Tracy A. O’Mara, Jonathan P. Tyrer, Bo Gao, Peter A. Fasching, et al. “Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci.” Oncotarget, June 15, 2017. https://doi.org/10.18632/oncotarget.18501.Full Text Link to Item
-
Praestegaard, Camilla, Allan Jensen, Signe M. Jensen, Thor S. S. Nielsen, Penelope M. Webb, Christina M. Nagle, Anna DeFazio, et al. “Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies.” Int J Cancer 140, no. 11 (June 1, 2017): 2422–35. https://doi.org/10.1002/ijc.30600.Full Text Link to Item
-
Berchuck, Andrew, Laura J. Havrilesky, and Noah D. Kauff. “Is There a Role for Ovarian Cancer Screening in High-Risk Women?” J Clin Oncol 35, no. 13 (May 1, 2017): 1384–86. https://doi.org/10.1200/JCO.2016.72.0045.Full Text Link to Item
-
Minlikeeva, Albina N., Jo L. Freudenheim, Rikki A. Cannioto, J Brian Szender, Kevin H. Eng, Francesmary Modugno, Roberta B. Ness, et al. “History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium.” Cancer Causes Control 28, no. 5 (May 2017): 469–86. https://doi.org/10.1007/s10552-017-0867-1.Full Text Link to Item
-
Phelan, Catherine M., Karoline B. Kuchenbaecker, Jonathan P. Tyrer, Siddhartha P. Kar, Kate Lawrenson, Stacey J. Winham, Joe Dennis, et al. “Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.” Nat Genet 49, no. 5 (May 2017): 680–91. https://doi.org/10.1038/ng.3826.Full Text Link to Item
-
Dixon, Suzanne C., Christina M. Nagle, Nicolas Wentzensen, Britton Trabert, Alicia Beeghly-Fadiel, Joellen M. Schildkraut, Kirsten B. Moysich, et al. “Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.” Br J Cancer 116, no. 9 (April 25, 2017): 1223–28. https://doi.org/10.1038/bjc.2017.68.Full Text Link to Item
-
Zuber, Verena, Francesco Bettella, Aree Witoelar, Aree PRACTICAL Consortium, Aree CRUK GWAS, Aree BCAC Consortium, Aree TRICL Consortium, Ole A. Andreassen, Ian G. Mills, and Alfonso Urbanucci. “Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer.” Bmc Genomics 18, no. 1 (March 31, 2017): 270. https://doi.org/10.1186/s12864-017-3620-y.Full Text Link to Item
-
Sucheston-Campbell, Lara E., Rikki Cannioto, Alyssa I. Clay, John Lewis Etter, Kevin H. Eng, Song Liu, Sebastiano Battaglia, et al. “No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.” Cancer Epidemiol Biomarkers Prev 26, no. 3 (March 2017): 420–24. https://doi.org/10.1158/1055-9965.EPI-16-0631.Full Text Link to Item
-
Kar, Siddhartha P., Emily Adler, Jonathan Tyrer, Dennis Hazelett, Hoda Anton-Culver, Elisa V. Bandera, Matthias W. Beckmann, et al. “Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.” Br J Cancer 116, no. 4 (February 14, 2017): 524–35. https://doi.org/10.1038/bjc.2016.426.Full Text Link to Item
-
Amos, Christopher I., Joe Dennis, Zhaoming Wang, Jinyoung Byun, Fredrick R. Schumacher, Simon A. Gayther, Graham Casey, et al. “The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers.” Cancer Epidemiol Biomarkers Prev 26, no. 1 (January 2017): 126–35. https://doi.org/10.1158/1055-9965.EPI-16-0106.Full Text Link to Item
-
Rasmussen, Christina B., Susanne K. Kjaer, Vanna Albieri, Elisa V. Bandera, Jennifer A. Doherty, Estrid Høgdall, Penelope M. Webb, et al. “Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies.” Am J Epidemiol 185, no. 1 (January 1, 2017): 8–20. https://doi.org/10.1093/aje/kww161.Full Text Link to Item
-
Reid, Brett M., Jennifer B. Permuth, Y Ann Chen, Jamie K. Teer, Alvaro N. A. Monteiro, Zhihua Chen, Jonathan Tyrer, et al. “Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci.” Cancer Epidemiol Biomarkers Prev 26, no. 1 (January 2017): 116–25. https://doi.org/10.1158/1055-9965.EPI-16-0341.Full Text Link to Item
-
Karami, Sara, Younghun Han, Mala Pande, Iona Cheng, James Rudd, Brandon L. Pierce, Ellen L. Nutter, et al. “Telomere structure and maintenance gene variants and risk of five cancer types.” Int J Cancer 139, no. 12 (December 15, 2016): 2655–70. https://doi.org/10.1002/ijc.30288.Full Text Link to Item
-
Lee, Alice W., Ashley Bomkamp, Elisa V. Bandera, Allan Jensen, Susan J. Ramus, Marc T. Goodman, Mary Anne Rossing, et al. “A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer.” Int J Cancer 139, no. 12 (December 15, 2016): 2646–54. https://doi.org/10.1002/ijc.30274.Full Text Link to Item
-
Cass, I., L. R. Duska, S. V. Blank, G. Cheng, N. C. Dupont, P. J. Frederick, E. K. Hill, et al. “Stress and burnout among gynecologic oncologists: A society of gynecologic oncology evidence-based review and recommendations.” Obstetrical and Gynecological Survey 71, no. 12 (December 1, 2016): 715–17. https://doi.org/10.1097/OGX.0000000000000382.Full Text
-
Southey, Melissa C., David E. Goldgar, Robert Winqvist, Katri Pylkäs, Fergus Couch, Marc Tischkowitz, William D. Foulkes, et al. “PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.” J Med Genet 53, no. 12 (December 2016): 800–811. https://doi.org/10.1136/jmedgenet-2016-103839.Full Text Link to Item
-
Permuth, Jennifer B., Brett Reid, Madalene Earp, Y Ann Chen, Alvaro N. A. Monteiro, Zhihua Chen, Zhihua AOCS Study Group, et al. “Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration.” Oncotarget 7, no. 45 (November 8, 2016): 72381–94. https://doi.org/10.18632/oncotarget.10546.Full Text Link to Item
-
Cass, Ilana, Linda R. Duska, Stephanie V. Blank, Georgina Cheng, Nefertiti C. duPont, Peter J. Frederick, Emily K. Hill, et al. “Stress and burnout among gynecologic oncologists: A Society of Gynecologic Oncology Evidence-based Review and Recommendations.” Gynecol Oncol 143, no. 2 (November 2016): 421–27. https://doi.org/10.1016/j.ygyno.2016.08.319.Full Text Link to Item
-
Hampras, Shalaka S., Lara E. Sucheston-Campbell, Rikki Cannioto, Jenny Chang-Claude, Francesmary Modugno, Thilo Dörk, Peter Hillemanns, et al. “Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.” Oncotarget 7, no. 43 (October 25, 2016): 69097–110. https://doi.org/10.18632/oncotarget.10215.Full Text Link to Item
-
Clyde, Merlise A., Rachel Palmieri Weber, Edwin S. Iversen, Elizabeth M. Poole, Jennifer A. Doherty, Marc T. Goodman, Roberta B. Ness, et al. “Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci.” Am J Epidemiol 184, no. 8 (October 15, 2016): 579–89. https://doi.org/10.1093/aje/kww091.Full Text Open Access Copy Link to Item
-
Ong, Jue-Sheng, Gabriel Cuellar-Partida, Yi Lu, Yi Australian Ovarian Cancer Study, Peter A. Fasching, Alexander Hein, Stefanie Burghaus, et al. “Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study.” Int J Epidemiol 45, no. 5 (October 2016): 1619–30. https://doi.org/10.1093/ije/dyw207.Full Text Link to Item
-
Lawrenson, Kate, Siddhartha Kar, Karen McCue, Karoline Kuchenbaeker, Kyriaki Michailidou, Jonathan Tyrer, Jonathan Beesley, et al. “Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.” Nat Commun 7 (September 7, 2016): 12675. https://doi.org/10.1038/ncomms12675.Full Text Link to Item
-
Cannioto, R., M. J. LaMonte, H. A. Risch, C. C. Hong, L. E. Sucheston-Campbell, K. H. Eng, J. B. Szender, et al. “Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium.” Obstetrical and Gynecological Survey 71, no. 9 (September 1, 2016): 528–30. https://doi.org/10.1097/OGX.0000000000000357.Full Text
-
Gaillard, Stephanie, John Yi, Chelsae Dumbauld, Jessie Ehrisman, Andrew Berchuck, and Kent Weinhold. “Evaluating the Repertoire of Immune Checkpoint Markers Expressed Within Ovarian Cancers.” Journal of Womens Health 25, no. 9 (September 1, 2016): 962–962.Link to Item
-
Kar, Siddhartha P., Jonathan Beesley, Ali Amin Al Olama, Kyriaki Michailidou, Jonathan Tyrer, ZSofia Kote-Jarai, Kate Lawrenson, et al. “Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.” Cancer Discov 6, no. 9 (September 2016): 1052–67. https://doi.org/10.1158/2159-8290.CD-15-1227.Full Text Link to Item
-
Permuth, Jennifer B., Ailith Pirie, Y. Ann Chen, Hui-Yi Lin, Brett M. Reid, Zhihua Chen, Alvaro Monteiro, et al. “Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk.” Hum Mol Genet 25, no. 16 (August 15, 2016): 3600–3612. https://doi.org/10.1093/hmg/ddw196.Full Text Link to Item
-
Ehrisman, Jessie, Angeles Alvarez Secord, Andrew Berchuck, Paula S. Lee, Nicola Di Santo, Micael Lopez-Acevedo, Gloria Broadwater, Fidel A. Valea, and Laura J. Havrilesky. “Performance of sentinel lymph node biopsy in high-risk endometrial cancer.” Gynecol Oncol Rep 17 (August 2016): 69–71. https://doi.org/10.1016/j.gore.2016.04.002.Full Text Link to Item
-
Lee, A. W., R. B. Ness, L. D. Roman, K. L. Terry, J. M. Schildkraut, J. Chang-Claude, J. A. Doherty, et al. “Association between menopausal estrogen-only therapy and ovarian carcinoma risk.” Obstetrical and Gynecological Survey 71, no. 8 (August 1, 2016): 470–71. https://doi.org/10.1097/01.ogx.0000489579.62561.b8.Full Text
-
Cannioto, Rikki, Michael J. LaMonte, Harvey A. Risch, Chi-Chen Hong, Lara E. Sucheston-Campbell, Kevin H. Eng, J. Brian Szender, et al. “Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium.” Cancer Epidemiol Biomarkers Prev 25, no. 7 (July 2016): 1114–24. https://doi.org/10.1158/1055-9965.EPI-15-1330.Full Text Link to Item
-
Cuellar-Partida, Gabriel, Yi Lu, Suzanne C. Dixon, Suzanne C. Australian Ovarian Cancer Study, Peter A. Fasching, Alexander Hein, Stefanie Burghaus, et al. “Assessing the genetic architecture of epithelial ovarian cancer histological subtypes.” Hum Genet 135, no. 7 (July 2016): 741–56. https://doi.org/10.1007/s00439-016-1663-9.Full Text Link to Item
-
Cannioto, Rikki A., Michael J. LaMonte, Linda E. Kelemen, Harvey A. Risch, Kevin H. Eng, Albina N. Minlikeeva, Chi-Chen Hong, et al. “Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium.” Br J Cancer 115, no. 1 (June 28, 2016): 95–101. https://doi.org/10.1038/bjc.2016.153.Full Text Link to Item
-
Dixon, Suzanne C., Christina M. Nagle, Aaron P. Thrift, Paul Dp Pharoah, Celeste Leigh Pearce, Wei Zheng, Jodie N. Painter, et al. “Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study.” Int J Epidemiol 45, no. 3 (June 2016): 884–95. https://doi.org/10.1093/ije/dyw158.Full Text Link to Item
-
Erondu, Chioma O., Anthony J. Alberg, Elisa V. Bandera, Jill Barnholtz-Sloan, Melissa Bondy, Michele L. Cote, Ellen Funkhouser, et al. “The Association Between Body Mass Index and Presenting Symptoms in African American Women with Ovarian Cancer.” J Womens Health (Larchmt) 25, no. 6 (June 2016): 571–78. https://doi.org/10.1089/jwh.2015.5359.Full Text Link to Item
-
Witkowski, Leora, Catherine Goudie, Pilar Ramos, Talia Boshari, Jean-Sebastien Brunet, Anthony N. Karnezis, Michel Longy, et al. “The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.” Gynecol Oncol 141, no. 3 (June 2016): 454–60. https://doi.org/10.1016/j.ygyno.2016.03.013.Full Text Link to Item
-
“What Women and Their Physicians Need to Know About the UKCTOCS Study and Ovarian Cancer Screening.” Am Fam Physician 93, no. 11 (June 1, 2016): 903–4.Link to Item
-
Lee, Alice W., Roberta B. Ness, Lynda D. Roman, Kathryn L. Terry, Joellen M. Schildkraut, Jenny Chang-Claude, Jennifer A. Doherty, et al. “Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk.” Obstet Gynecol 127, no. 5 (May 2016): 828–36. https://doi.org/10.1097/AOG.0000000000001387.Full Text Link to Item
-
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Ellen L., Antoinette Hollestelle, Frederieke H. van der Baan, Andrew Berchuck, Sharon E. Johnatty, Katja K. Aben, Bjarni A. Agnarsson, et al. “No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.” Gynecol Oncol 141, no. 2 (May 2016): 386–401. https://doi.org/10.1016/j.ygyno.2015.04.034.Full Text Link to Item
-
Usset, Joseph L., Rama Raghavan, Jonathan P. Tyrer, Valerie McGuire, Weiva Sieh, Penelope Webb, Jenny Chang-Claude, et al. “Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors.” Cancer Epidemiol Biomarkers Prev 25, no. 5 (May 2016): 780–90. https://doi.org/10.1158/1055-9965.EPI-15-1039.Full Text Link to Item
-
Præstegaard, Camilla, Susanne K. Kjaer, Thor S. S. Nielsen, Signe M. Jensen, Penelope M. Webb, Christina M. Nagle, Estrid Høgdall, et al. “The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies.” Cancer Epidemiol 41 (April 2016): 71–79. https://doi.org/10.1016/j.canep.2016.01.012.Full Text Link to Item
-
Brancu, Mira, Monica Mann-Wrobel, Jean C. Beckham, H Ryan Wagner, Alyssa Elliott, Allison T. Robbins, Madrianne Wong, Ania E. Berchuck, and Jennifer J. Runnals. “Subthreshold posttraumatic stress disorder: A meta-analytic review of DSM-IV prevalence and a proposed DSM-5 approach to measurement.” Psychol Trauma 8, no. 2 (March 2016): 222–32. https://doi.org/10.1037/tra0000078.Full Text Link to Item
-
Winham, Stacey J., Ailith Pirie, Yian Ann Chen, Melissa C. Larson, Zachary C. Fogarty, Madalene A. Earp, Hoda Anton-Culver, et al. “Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer.” Cancer Epidemiol Biomarkers Prev 25, no. 3 (March 2016): 446–54. https://doi.org/10.1158/1055-9965.EPI-15-0240.Full Text Link to Item
-
Earp, Madalene, Stacey J. Winham, Nicholas Larson, Jennifer B. Permuth, Hugues Sicotte, Jeremy Chien, Hoda Anton-Culver, et al. “A targeted genetic association study of epithelial ovarian cancer susceptibility.” Oncotarget 7, no. 7 (February 16, 2016): 7381–89. https://doi.org/10.18632/oncotarget.7121.Full Text Link to Item
-
French, Juliet D., Sharon E. Johnatty, Yi Lu, Jonathan Beesley, Bo Gao, Murugan Kalimutho, Michelle J. Henderson, et al. “Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.” Oncotarget 7, no. 6 (February 9, 2016): 6353–68. https://doi.org/10.18632/oncotarget.7047.Full Text Link to Item
-
Lin, Hui-Yi, Yin Xiong, Jonathan Tyrer, Douglas C. Marchion, Alvaro N. A. Monteiro, Andrew Berchuck, Joellen M. Schildkraut, et al. “Abstract B27: Investigation of small GTPase genes in epithelial ovarian cancer.” Prevention, Screening, Early Diagnostics, and Epidemiology, January 15, 2016. https://doi.org/10.1158/1557-3265.ovca15-b27.Full Text
-
Lee, Alice W., Claire Templeman, Douglas A. Stram, Jonathan Beesley, Jonathan Tyrer, Andrew Berchuck, Paul P. Pharoah, Georgia Chenevix-Trench, Celeste Leigh Pearce, and Celeste Leigh Ovarian Cancer Association Consortium. “Evidence of a genetic link between endometriosis and ovarian cancer.” Fertil Steril 105, no. 1 (January 2016): 35-43.e1-10. https://doi.org/10.1016/j.fertnstert.2015.09.023.Full Text Link to Item
-
Bolton, K. L., J. Tyrer, H. Song, S. J. Ramus, M. Notaridou, C. Jones, T. Sher, et al. “Erratum: Common variants at 19p13 are associated with susceptibility to ovarian cancer (Nature Genetics (2010) 42 (880-884)).” Nature Genetics 48, no. 1 (December 29, 2015): 101. https://doi.org/10.1038/ng0116-101b.Full Text
-
Amankwah, Ernest K., Hui-Yi Lin, Jonathan P. Tyrer, Kate Lawrenson, Joe Dennis, Ganna Chornokur, Katja K. H. Aben, et al. “Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk.” Genet Epidemiol 39, no. 8 (December 2015): 689–97. https://doi.org/10.1002/gepi.21921.Full Text Link to Item
-
Johnatty, Sharon E., Jonathan P. Tyrer, Siddhartha Kar, Jonathan Beesley, Yi Lu, Bo Gao, Peter A. Fasching, et al. “Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.” Clin Cancer Res 21, no. 23 (December 1, 2015): 5264–76. https://doi.org/10.1158/1078-0432.CCR-15-0632.Full Text Link to Item
-
Lawrenson, Kate, Edwin S. Iversen, Jonathan Tyrer, Rachel Palmieri Weber, Patrick Concannon, Dennis J. Hazelett, Qiyuan Li, et al. “Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer.” Carcinogenesis 36, no. 11 (November 2015): 1341–53. https://doi.org/10.1093/carcin/bgv138.Full Text Link to Item
-
Richards, Edward J., Jennifer Permuth-Wey, Yajuan Li, Y Ann Chen, Domenico Coppola, Brett M. Reid, Hui-Yi Lin, et al. “A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer.” Oncotarget 6, no. 33 (October 27, 2015): 34745–57. https://doi.org/10.18632/oncotarget.5784.Full Text Link to Item
-
Lu, Yi, Gabriel Cuellar-Partida, Jodie N. Painter, Dale R. Nyholt, Dale R. Australian Ovarian Cancer Study, Dale R. International Endogene Consortium (IEC), Andrew P. Morris, et al. “Shared genetics underlying epidemiological association between endometriosis and ovarian cancer.” Hum Mol Genet 24, no. 20 (October 15, 2015): 5955–64. https://doi.org/10.1093/hmg/ddv306.Full Text Link to Item
-
Kar, Siddhartha P., Jonathan P. Tyrer, Qiyuan Li, Kate Lawrenson, Katja K. H. Aben, Hoda Anton-Culver, Natalia Antonenkova, et al. “Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk.” Cancer Epidemiol Biomarkers Prev 24, no. 10 (October 2015): 1574–84. https://doi.org/10.1158/1055-9965.EPI-14-1270.Full Text Link to Item
-
Siamakpour-Reihani, Sharareh, Kouros Owzar, Chen Jiang, Taylor Turner, Yiwen Deng, Sarah M. Bean, Janet K. Horton, et al. “Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.” Gynecol Oncol 139, no. 1 (October 2015): 23–29. https://doi.org/10.1016/j.ygyno.2015.08.001.Full Text Link to Item
-
Lawrenson, Kate, Qiyuan Li, Siddhartha Kar, Ji-Heui Seo, Jonathan Tyrer, Tassja J. Spindler, Janet Lee, et al. “Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer.” Nat Commun 6 (September 22, 2015): 8234. https://doi.org/10.1038/ncomms9234.Full Text Link to Item
-
Kelemen, Linda E., Kate Lawrenson, Jonathan Tyrer, Qiyuan Li, Janet M. Lee, Ji-Heui Seo, Catherine M. Phelan, et al. “Genome-wide significant risk associations for mucinous ovarian carcinoma.” Nat Genet 47, no. 8 (August 2015): 888–97. https://doi.org/10.1038/ng.3336.Full Text Link to Item
-
Coetzee, Simon G., Howard C. Shen, Dennis J. Hazelett, Kate Lawrenson, Karoline Kuchenbaecker, Jonathan Tyrer, Suhn K. Rhie, et al. “Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci.” Hum Mol Genet 24, no. 13 (July 1, 2015): 3595–3607. https://doi.org/10.1093/hmg/ddv101.Full Text Link to Item
-
Ness, R., C. Pearce, D. Stram, A. Berchuck, M. Pike, and P. Pharoah. “LIFETIME RISK OF OVARIAN CANCER BASED ON ENDOMETRIOSIS AND OTHER RISK FACTORS: IGCS-0014 06. Ovarian Cancer.” Int J Gynecol Cancer 25 Suppl 1 (May 2015): 50. https://doi.org/10.1097/00009577-201505001-00039.Full Text Link to Item
-
Berchuck, Andrew, Leora Witkowski, Martin Hasselblatt, and William D. Foulkes. “Prophylactic oophorectomy for hereditary small cell carcinoma of the ovary, hypercalcemic type.” Gynecol Oncol Rep 12 (April 2015): 20–22. https://doi.org/10.1016/j.gore.2015.02.002.Full Text Link to Item
-
Pearce, Celeste Leigh, Daniel O. Stram, Roberta B. Ness, Douglas A. Stram, Lynda D. Roman, Claire Templeman, Alice W. Lee, et al. “Population distribution of lifetime risk of ovarian cancer in the United States.” Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 24, no. 4 (April 2015): 671–76. https://doi.org/10.1158/1055-9965.epi-14-1128.Full Text
-
Lee, Alice W., Jonathan P. Tyrer, Jennifer A. Doherty, Douglas A. Stram, Jolanta Kupryjanczyk, Agnieszka Dansonka-Mieszkowska, Joanna Plisiecka-Halasa, et al. “Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study.” Gynecol Oncol 136, no. 3 (March 2015): 542–48. https://doi.org/10.1016/j.ygyno.2014.12.017.Full Text Link to Item
-
Mo, Lihong, Robin E. Bachelder, Margaret Kennedy, Po-Han Chen, Jen-Tsan Chi, Andrew Berchuck, George Cianciolo, and Salvatore V. Pizzo. “Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78.” Mol Cancer Ther 14, no. 3 (March 2015): 747–56. https://doi.org/10.1158/1535-7163.MCT-14-0579.Full Text Link to Item
-
Kuchenbaecker, Karoline B., Susan J. Ramus, Jonathan Tyrer, Andrew Lee, Howard C. Shen, Jonathan Beesley, Kate Lawrenson, et al. “Identification of six new susceptibility loci for invasive epithelial ovarian cancer.” Nat Genet 47, no. 2 (February 2015): 164–71. https://doi.org/10.1038/ng.3185.Full Text Link to Item
-
Maxwell, G Larry, Yutaka Shoji, Kathleen Darcy, Tracy Litzi, Andrew Berchuck, Chad A. Hamilton, Thomas P. Conrads, and John I. Risinger. “MicroRNAs in endometrial cancers from black and white patients.” Am J Obstet Gynecol 212, no. 2 (February 2015): 191.e1-191.10. https://doi.org/10.1016/j.ajog.2014.08.028.Full Text Link to Item
-
Chornokur, Ganna, Hui-Yi Lin, Jonathan P. Tyrer, Kate Lawrenson, Joe Dennis, Ernest K. Amankwah, Xiaotao Qu, et al. “Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk.” Plos One 10, no. 6 (2015): e0128106. https://doi.org/10.1371/journal.pone.0128106.Full Text Link to Item
-
Dunlap, C. “Foreword,” 2015.
-
Jim, Heather S. L., Hui-Yi Lin, Jonathan P. Tyrer, Kate Lawrenson, Joe Dennis, Ganna Chornokur, Zhihua Chen, et al. “Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC).” J Genet Genome Res 2, no. 2 (2015). https://doi.org/10.23937/2378-3648/1410017.Full Text Link to Item
-
Havrilesky, Laura J., Angeles Alvarez Secord, Jessie A. Ehrisman, Andrew Berchuck, Fidel A. Valea, Paula S. Lee, Stephanie L. Gaillard, et al. “Patient preferences in advanced or recurrent ovarian cancer.” Cancer 120, no. 23 (December 1, 2014): 3651–59. https://doi.org/10.1002/cncr.28940.Full Text Link to Item
-
Berchuck, A., K. Kuchenbaecker, S. J. Ramus, J. P. Tyrer, S. A. Gayther, P. D. P. Pharoah, A. C. Antoniou, and G. Chenevix-Trench. “IDENTIFICATION OF SIX NOVEL, COMMON VARIANT GENETIC SUSCEPTIBILITY LOCI FOR INVASIVE EPITHELIAL OVARIAN CANCER.” International Journal of Gynecological Cancer 24, no. 9 (November 1, 2014): 13–13.Link to Item
-
Berchuck, A., L. Witkowski, M. Hasselblatt, A. Wallace, B. A. Clarke, and W. D. Foulkes. “PROPHYLACTIC OOPHORECTOMY FOR HEREDITARY SMALL-CELL CARCINOMA OF THE OVARY, HYPERCALCEMIC TYPE.” International Journal of Gynecological Cancer 24, no. 9 (November 1, 2014): 961–62.Link to Item
-
Ness, R., CP Celeste Pearce, CT Claire Templeman, AW Anna Wu, and AB Andrew Berchuck. “ENDOMETRIOSIS AND OVARIAN CANCER: AN INTERNATIONAL POOLED ANALYSIS.” International Journal of Gynecological Cancer 24, no. 9 (November 1, 2014): 439–40.Link to Item
-
Ness, R., CP Celeste Pearce, DS Daniel Stram, AB Andrew Berchuck, MP Malcolm Pike, and PP Paul Pharoah. “LIFETIME RISK OF OVARIAN CANCER BASED ON ENDOMETRIOSIS AND OTHER RISK FACTORS.” International Journal of Gynecological Cancer 24, no. 9 (November 1, 2014): 441–42.Link to Item
-
Kelemen, Linda E., Kathryn L. Terry, Marc T. Goodman, Penelope M. Webb, Elisa V. Bandera, Valerie McGuire, Mary Anne Rossing, et al. “Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.” Mol Nutr Food Res 58, no. 10 (October 2014): 2023–35. https://doi.org/10.1002/mnfr.201400068.Full Text Link to Item
-
Yamaguchi, Ken, Zhiqing Huang, Noriomi Matsumura, Masaki Mandai, Takako Okamoto, Tsukasa Baba, Ikuo Konishi, Andrew Berchuck, and Susan K. Murphy. “Epigenetic determinants of ovarian clear cell carcinoma biology.” Int J Cancer 135, no. 3 (August 1, 2014): 585–97. https://doi.org/10.1002/ijc.28701.Full Text Link to Item
-
Block, Matthew S., Bridget Charbonneau, Robert A. Vierkant, Zachary Fogarty, William R. Bamlet, Paul D. P. Pharoah, Paul D. P. Georgia Chenevix-Trench, et al. “Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer.” Cancer Epidemiol Biomarkers Prev 23, no. 7 (July 2014): 1421–27. https://doi.org/10.1158/1055-9965.EPI-13-0962.Full Text Link to Item
-
Hedditch, Ellen L., Bo Gao, Amanda J. Russell, Yi Lu, Catherine Emmanuel, Jonathan Beesley, Sharon E. Johnatty, et al. “ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.” J Natl Cancer Inst 106, no. 7 (July 2014). https://doi.org/10.1093/jnci/dju149.Full Text Link to Item
-
Earp, Madalene A., Linda E. Kelemen, Anthony M. Magliocco, Kenneth D. Swenerton, Georgia Chenevix-Trench, Georgia Australian Cancer Study, Georgia Australian Ovarian Cancer Study Group, et al. “Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.” Hum Genet 133, no. 5 (May 2014): 481–97. https://doi.org/10.1007/s00439-013-1383-3.Full Text Link to Item
-
Witkowski, Leora, Jian Carrot-Zhang, Steffen Albrecht, Somayyeh Fahiminiya, Nancy Hamel, Eva Tomiak, David Grynspan, et al. “Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.” Nat Genet 46, no. 5 (May 2014): 438–43. https://doi.org/10.1038/ng.2931.Full Text Link to Item
-
Zhang, Chelsea, Laura J. Havrilesky, Gloria Broadwater, Nicola Di Santo, Jessie A. Ehrisman, Paula S. Lee, Andrew Berchuck, et al. “Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: a single institution study of 458 patients.” Gynecol Oncol 133, no. 2 (May 2014): 211–15. https://doi.org/10.1016/j.ygyno.2014.02.025.Full Text Link to Item
-
Charbonneau, Bridget, Kirsten B. Moysich, Kimberly R. Kalli, Ann L. Oberg, Robert A. Vierkant, Zachary C. Fogarty, Matthew S. Block, et al. “Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.” Cancer Immunol Res 2, no. 4 (April 2014): 332–40. https://doi.org/10.1158/2326-6066.CIR-13-0136.Full Text Link to Item
-
Charbonneau, Bridget, Matthew S. Block, William R. Bamlet, Robert A. Vierkant, Kimberly R. Kalli, Zachary Fogarty, David N. Rider, et al. “Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10.” Cancer Res 74, no. 3 (February 1, 2014): 852–61. https://doi.org/10.1158/0008-5472.CAN-13-1051.Full Text Link to Item
-
Trabert, Britton, Roberta B. Ness, Wei-Hsuan Lo-Ciganic, Megan A. Murphy, Ellen L. Goode, Elizabeth M. Poole, Louise A. Brinton, et al. “Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium.” J Natl Cancer Inst 106, no. 2 (February 2014): djt431. https://doi.org/10.1093/jnci/djt431.Full Text Link to Item
-
Davidson, Brittany Anne, Jennifer M. Rubatt, David L. Corcoran, Deanna K. Teoh, Marcus Q. Bernardini, Lisa A. Grace, William John Soper, et al. “Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines.” Front Oncol 4 (2014): 163. https://doi.org/10.3389/fonc.2014.00163.Full Text Link to Item
-
Kokosis, G., R. Schmitz, A. A. Secord, L. J. Havrilesky, A. Berchuck, C. R. Mantyh, and D. Erdmann. “A modified bipedicle VRAM flap for simultaneous reconstruction of a perineal and posterior vaginal defect.” Gynakologe 47, no. 10 (January 1, 2014): 784–87. https://doi.org/10.1007/s00129-014-3448-3.Full Text
-
Pooley, Karen A., Stig E. Bojesen, Maren Weischer, Sune F. Nielsen, Deborah Thompson, Ali Amin Al Olama, Kyriaki Michailidou, et al. “A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk.” Hum Mol Genet 22, no. 24 (December 15, 2013): 5056–64. https://doi.org/10.1093/hmg/ddt355.Full Text Link to Item
-
Rodriguez, Gustavo C., H John Barnes, Kenneth E. Anderson, Regina S. Whitaker, Andrew Berchuck, James N. Petitte, Johnathan M. Lancaster, et al. “Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying hen.” Cancer Prev Res (Phila) 6, no. 12 (December 2013): 1283–92. https://doi.org/10.1158/1940-6207.CAPR-12-0426.Full Text Link to Item
-
Johnatty, Sharon E., Jonathan Beesley, Bo Gao, Xiaoqing Chen, Yi Lu, Matthew H. Law, Michelle J. Henderson, et al. “ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.” Gynecol Oncol 131, no. 1 (October 2013): 8–14. https://doi.org/10.1016/j.ygyno.2013.07.107.Full Text Link to Item
-
Schildkraut, Joellen M., Edwin S. Iversen, Lucy Akushevich, Regina Whitaker, Rex C. Bentley, Andrew Berchuck, and Jeffrey R. Marks. “Molecular signatures of epithelial ovarian cancer: analysis of associations with tumor characteristics and epidemiologic risk factors.” Cancer Epidemiol Biomarkers Prev 22, no. 10 (October 2013): 1709–21. https://doi.org/10.1158/1055-9965.EPI-13-0192.Full Text Link to Item
-
Terry, Kathryn L., Stalo Karageorgi, Yurii B. Shvetsov, Melissa A. Merritt, Galina Lurie, Pamela J. Thompson, Michael E. Carney, et al. “Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls.” Cancer Prev Res (Phila) 6, no. 8 (August 2013): 811–21. https://doi.org/10.1158/1940-6207.CAPR-13-0037.Full Text Link to Item
-
Lopez-Acevedo, Micael, Laura J. Havrilesky, Gloria Broadwater, Arif H. Kamal, Amy P. Abernethy, Andrew Berchuck, Angeles Alvarez Secord, James A. Tulsky, Fidel Valea, and Paula S. Lee. “Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer.” Gynecol Oncol 130, no. 1 (July 2013): 156–61. https://doi.org/10.1016/j.ygyno.2013.04.010.Full Text Link to Item
-
Maxwell, G Larry, Jay Allard, Chandramouli V. R. Gadisetti, Tracy Litzi, Yovanni Casablanca, Uma Chandran, Kathleen M. Darcy, et al. “Transcript expression in endometrial cancers from Black and White patients.” Gynecologic Oncology 130, no. 1 (July 2013): 169–73. https://doi.org/10.1016/j.ygyno.2013.04.017.Full Text
-
Barakat, R. R., A. Berchuck, M. Markman, and M. E. Randall. “Preface.” Principles and Practice of Gynecologic Oncology: Sixth Edition, May 8, 2013, xi–xii.
-
Cancer Genome Atlas Research Network, Douglas A., Cyriac Kandoth, Nikolaus Schultz, Andrew D. Cherniack, Rehan Akbani, Yuexin Liu, Hui Shen, et al. “Integrated genomic characterization of endometrial carcinoma.” Nature 497, no. 7447 (May 2, 2013): 67–73. https://doi.org/10.1038/nature12113.Full Text Link to Item
-
Pearce, Celeste Leigh, Mary Anne Rossing, Alice W. Lee, Roberta B. Ness, Penelope M. Webb, Penelope M. for Australian Cancer Study (Ovarian Cancer), Penelope M. Australian Ovarian Cancer Study Group, et al. “Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer.” Cancer Epidemiol Biomarkers Prev 22, no. 5 (May 2013): 880–90. https://doi.org/10.1158/1055-9965.EPI-12-1030-T.Full Text Link to Item
-
White, Kristin L., Robert A. Vierkant, Zachary C. Fogarty, Bridget Charbonneau, Matthew S. Block, Paul D. P. Pharoah, Georgia Chenevix-Trench, et al. “Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome.” Cancer Epidemiol Biomarkers Prev 22, no. 5 (May 2013): 987–92. https://doi.org/10.1158/1055-9965.EPI-13-0028.Full Text Link to Item
-
Bojesen, Stig E., Karen A. Pooley, Sharon E. Johnatty, Jonathan Beesley, Kyriaki Michailidou, Jonathan P. Tyrer, Stacey L. Edwards, et al. “Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.” Nat Genet 45, no. 4 (April 2013): 371-384e2. https://doi.org/10.1038/ng.2566.Full Text Link to Item
-
Grant, Delores J., Cathrine Hoyo, Lucy Akushevich, Edwin S. Iversen, Regina Whitaker, Jeffrey Marks, Andrew Berchuck, and Joellen M. Schildkraut. “Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women.” Gynecol Oncol 129, no. 1 (April 2013): 173–78. https://doi.org/10.1016/j.ygyno.2012.12.027.Full Text Link to Item
-
Pharoah, Paul D. P., Ya-Yu Tsai, Susan J. Ramus, Catherine M. Phelan, Ellen L. Goode, Kate Lawrenson, Melissa Buckley, et al. “GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.” Nat Genet 45, no. 4 (April 2013): 362-370e2. https://doi.org/10.1038/ng.2564.Full Text Link to Item
-
Sfakianos, Gregory P., Edwin S. Iversen, Regina Whitaker, Liudmila Akushevich, Joellen M. Schildkraut, Susan K. Murphy, Jeffrey R. Marks, and Andrew Berchuck. “Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues.” Gynecologic Oncology 129, no. 1 (April 2013): 159–64. https://doi.org/10.1016/j.ygyno.2012.12.030.Full Text
-
Sieh, Weiva, Shannon Salvador, Valerie McGuire, Rachel Palmieri Weber, Kathryn L. Terry, Mary Anne Rossing, Harvey Risch, et al. “Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies.” Int J Epidemiol 42, no. 2 (April 2013): 579–89. https://doi.org/10.1093/ije/dyt042.Full Text Link to Item
-
Garg, Karuna, Douglas A. Levine, Narciso Olvera, Fanny Dao, Maria Bisogna, Angeles Alvarez Secord, Andrew Berchuck, Ethan Cerami, Nikolaus Schultz, and Robert A. Soslow. “BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.” Am J Surg Pathol 37, no. 1 (January 2013): 138–46. https://doi.org/10.1097/PAS.0b013e31826cabbd.Full Text Link to Item
-
Goode, Ellen L., Melissa DeRycke, Kimberly R. Kalli, Ann L. Oberg, Julie M. Cunningham, Matthew J. Maurer, Brooke L. Fridley, et al. “Inherited variants in regulatory T cell genes and outcome of ovarian cancer.” Plos One 8, no. 1 (2013): e53903. https://doi.org/10.1371/journal.pone.0053903.Full Text Link to Item
-
Permuth-Wey, Jennifer, Kate Lawrenson, Howard C. Shen, Aneliya Velkova, Jonathan P. Tyrer, Zhihua Chen, Hui-Yi Lin, et al. “Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.” Nat Commun 4 (2013): 1627. https://doi.org/10.1038/ncomms2613.Full Text Link to Item
-
Risinger, John I., Jay Allard, Uma Chandran, Roger Day, Gadisetti V. R. Chandramouli, Caela Miller, Christopher Zahn, et al. “Gene expression analysis of early stage endometrial cancers reveals unique transcripts associated with grade and histology but not depth of invasion.” Front Oncol 3 (2013): 139. https://doi.org/10.3389/fonc.2013.00139.Full Text Link to Item
-
Shen, Hui, Brooke L. Fridley, Honglin Song, Kate Lawrenson, Julie M. Cunningham, Susan J. Ramus, Mine S. Cicek, et al. “Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer.” Nat Commun 4 (2013): 1628. https://doi.org/10.1038/ncomms2629.Full Text Link to Item
-
Lopez-Acevedo, Micael, Chelsea Zhang, Angeles Alvarez Secord, Paula S. Lee, Laura Jean Havrilesky, and Andrew Berchuck. “Predictors of failure to perform pelvic peritoneal cytology in endometrial cancer staging surgery.” Journal of Clinical Oncology 30, no. 34 (December 1, 2012). https://doi.org/10.1200/jco.2012.30.34_suppl.201.Full Text Link to Item
-
Zhang, C., A. A. Secord, P. S. Lee, L. J. Havrilesky, and A. Berchuck. “Predictors of failure to perform pelvic peritoneal cytology in endometrial cancer staging surgery.” J Clin Oncol 30, no. 34_suppl (December 2012): 201. https://doi.org/10.1200/jco.2012.30.34_suppl.201.Full Text Link to Item
-
Secord, Angeles Alvarez, Deanna K. Teoh, William T. Barry, Miao Yu, Gloria Broadwater, Laura J. Havrilesky, Paula S. Lee, Andrew Berchuck, Johnathan Lancaster, and Robert M. Wenham. “A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.” Clin Cancer Res 18, no. 19 (October 1, 2012): 5489–98. https://doi.org/10.1158/1078-0432.CCR-12-0507.Full Text Link to Item
-
Berchuck, Andrew. “Genetic testing in ovarian cancer: getting better, and maybe not just for disease susceptibility anymore.” Obstetrics and Gynecology 120, no. 2 Pt 1 (August 2012): 221–22. https://doi.org/10.1097/aog.0b013e3182602599.Full Text
-
Alvarez Secord, Angeles, Andrew Berchuck, Robert V. Higgins, Lawrence R. Nycum, Matthew F. Kohler, Larry E. Puls, Robert W. Holloway, George S. Lewandowski, Fidel A. Valea, and Laura J. Havrilesky. “A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.” Cancer 118, no. 13 (July 2012): 3283–93. https://doi.org/10.1002/cncr.26610.Full Text
-
Pearce, C. L., and A. Berchuck. “Endometriosis and ovarian cancer - Authors' reply.” The Lancet Oncology 13, no. 5 (May 1, 2012). https://doi.org/10.1016/S1470-2045(12)70103-1.Full Text
-
Charbonneau, Bridget, Kristin L. White, Joellen M. Schildkraut, Rachel T. Palmieri, Ed Iversen, Andrew Berchuck, Robert A. Vierkant, et al. “Abstract 2603: Subtype-specific ovarian cancer risk associated with SNPs inIL1A.” Epidemiology, April 15, 2012. https://doi.org/10.1158/1538-7445.am2012-2603.Full Text
-
Huang, Zhiqing, William J. Lowery, Andrew Berchuck, and Susan K. Murphy. “Abstract 5363: Aggregation rather than monoclonal expansion explains ovarian cancer spheroid formation.” Tumor Biology, April 15, 2012. https://doi.org/10.1158/1538-7445.am2012-5363.Full Text
-
Okamoto, Takako, Ken Yamaguchi, Zhiqing Huang, Regina Whitaker, Ikuo Konishi, Andrew Berchuck, and Susan K. Murphy. “Abstract LB-87: Methylated-mediated repression ofZNF154in ovarian cancer is associated with poor overall survival.” Molecular and Cellular Biology, April 15, 2012. https://doi.org/10.1158/1538-7445.am2012-lb-87.Full Text
-
Bolton, K. L., C. Ganda, A. Berchuck, P. D. P. Pharaoh, and S. A. Gayther. “Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC).” J Intern Med 271, no. 4 (April 2012): 366–78. https://doi.org/10.1111/j.1365-2796.2011.02509.x.Full Text Link to Item
-
Chino, Junzo P., Ellen Jones, Andrew Berchuck, Angeles Alvarez Secord, and Laura J. Havrilesky. “The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer.” Int J Radiat Oncol Biol Phys 82, no. 5 (April 1, 2012): 1872–79. https://doi.org/10.1016/j.ijrobp.2011.03.054.Full Text Link to Item
-
Pearce, Celeste Leigh, Claire Templeman, Mary Anne Rossing, Alice Lee, Aimee M. Near, Penelope M. Webb, Christina M. Nagle, et al. “Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.” Lancet Oncol 13, no. 4 (April 2012): 385–94. https://doi.org/10.1016/S1470-2045(11)70404-1.Full Text Link to Item
-
Berchuck, A., G. Sfakianos, R. Whitaker, D. Levine, S. Murphy, J. Marks, and E. Iversen. “Frequency of the cancer genome atlas expression subtypes differs between early and advanced stage high grade serous ovarian cancers.” Gynecologic Oncology 125 (March 2012): S133–S133. https://doi.org/10.1016/j.ygyno.2011.12.325.Full Text
-
Berchuck, Andrew, Angeles Alvarez Secord, and Laura J. Havrilesky. “Minimally invasive surgery for endometrial cancer: the horse is already out of the barn.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 7 (March 2012): 681–82. https://doi.org/10.1200/jco.2011.40.5506.Full Text
-
Murphy, S., H. Yang, K. Yamaguchi, Z. Huang, I. Konishi, and A. Berchuck. “DNA Methylation Profiles Distinguish Serous, Mucinous and Clear Cell but not Endometrioid Epithelial Ovarian Cancers.” Gynecologic Oncology 125 (March 2012): S99–S99. https://doi.org/10.1016/j.ygyno.2011.12.237.Full Text
-
Rodriguez, Gustavo C., Jane M. Turbov, Andrew Berchuck, M Sharon Stack, Jean A. Hurteau, Larry G. Thaete, and Catherine P. Barry. “Nonsteroidal antiinflammatory drugs and progestins synergistically enhance cell death in ovarian epithelial cells.” American Journal of Obstetrics and Gynecology 206, no. 3 (March 2012): 253.e1-253.e9. https://doi.org/10.1016/j.ajog.2011.11.012.Full Text
-
Sfakianos, G., E. Iversen, W. Lowery, R. Whitaker, L. Akushevich, J. Schildkraut, J. Marks, and A. Berchuck. “Clinical translation of the cancer genome atlas signature for ovarian cancer survival.” Gynecologic Oncology 125 (March 2012): S42–S42. https://doi.org/10.1016/j.ygyno.2011.12.101.Full Text
-
Stevens, Kristen N., Linda E. Kelemen, Xianshu Wang, Brooke L. Fridley, Robert A. Vierkant, Zachary Fredericksen, Sebastian M. Armasu, et al. “Common variation in Nemo-like kinase is associated with risk of ovarian cancer.” Cancer Epidemiol Biomarkers Prev 21, no. 3 (March 2012): 523–28. https://doi.org/10.1158/1055-9965.EPI-11-0797.Full Text Link to Item
-
Wallace, A., K. Darcy, A. Alvarez-Secord, A. Hutson, D. Tritchler, L. Kirchgraber, L. Grace, R. Whitaker, A. Berchuck, and L. Havrilesky. “Loss of p16 in advanced stage epithelial ovarian cancer is associated with chemoresistant disease, suboptimal debulking and poor progression-free survival: A Gynecologic Oncology Group study.” Gynecologic Oncology 125 (March 2012): S37–S37. https://doi.org/10.1016/j.ygyno.2011.12.084.Full Text
-
White, Kristin L., Joellen M. Schildkraut, Rachel T. Palmieri, Edwin S. Iversen, Andrew Berchuck, Robert A. Vierkant, David N. Rider, et al. “Ovarian cancer risk associated with inherited inflammation-related variants.” Cancer Research 72, no. 5 (March 2012): 1064–69. https://doi.org/10.1158/0008-5472.can-11-3512.Full Text
-
Allard, Jay E., Gadisetti V. R. Chandramouli, Katherine Stagliano, Brian L. Hood, Tracy Litzi, Yutaka Shoji, Jeff Boyd, et al. “Analysis of PSPHL as a Candidate Gene Influencing the Racial Disparity in Endometrial Cancer.” Front Oncol 2 (2012): 65. https://doi.org/10.3389/fonc.2012.00065.Full Text Link to Item
-
Havrilesky, Laura J., Robin Pokrzywinski, Dennis Revicki, Robert V. Higgins, Lawrence R. Nycum, Matthew F. Kohler, Andrew Berchuck, Evan R. Myers, and Angeles Alvarez Secord. “Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.” Cancer 118, no. 2 (January 2012): 386–91. https://doi.org/10.1002/cncr.26199.Full Text
-
Kelemen, Linda E., Qinggang Wang, Irina Dinu, Robert A. Vierkant, Ya-Yu Tsai, Julie M. Cunningham, Catherine M. Phelan, et al. “Regular Multivitamin Supplement Use, Single Nucleotide Polymorphisms in ATIC, SHMT2, and SLC46A1, and Risk of Ovarian Carcinoma.” Front Genet 3 (2012): 33. https://doi.org/10.3389/fgene.2012.00033.Full Text Link to Item
-
Lowery, William J., Joellen M. Schildkraut, Liudmila Akushevich, Rex Bentley, Jeffrey R. Marks, David Huntsman, and Andrew Berchuck. “Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.” Int J Gynecol Cancer 22, no. 1 (January 2012): 9–14. https://doi.org/10.1097/IGC.0b013e318231f140.Full Text Link to Item
-
Bondurant, Amy E., Zhiqing Huang, Regina S. Whitaker, Lauren R. Simel, Andrew Berchuck, and Susan K. Murphy. “Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.” Gynecol Oncol 123, no. 3 (December 2011): 581–87. https://doi.org/10.1016/j.ygyno.2011.08.029.Full Text Link to Item
-
Murphy, S. K., and A. Berchuck. “Ovarian cancer progenitor/stem cells: Therapeutic potential,” December 1, 2011, 223–44. https://doi.org/10.1007/978-1-4419-7216-3_11.Full Text
-
Chino, J. P., A. Berchuck, and L. Havrilesky. “What Are The Causes Of Death For Women With Early-stage Endometrial Cancer?” International Journal of Radiation Oncology*Biology*Physics 81, no. 2 (October 2011): S470–S470. https://doi.org/10.1016/j.ijrobp.2011.06.1009.Full Text
-
Marchion, Douglas C., Hope M. Cottrill, Yin Xiong, Ning Chen, Elona Bicaku, William J. Fulp, Nisha Bansal, et al. “BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.” Clin Cancer Res 17, no. 19 (October 1, 2011): 6356–66. https://doi.org/10.1158/1078-0432.CCR-11-0735.Full Text Link to Item
-
Risch, Harvey A., Andrew Berchuck, and Paul D. P. Pharoah. “Response to Weidhaas and Slack re: Comments on "The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implication for clinical testing".” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 17, no. 20 (October 2011). https://doi.org/10.1158/1078-0432.ccr-11-1504.Full Text
-
Vaughan, Sebastian, Jermaine I. Coward, Robert C. Bast, Andy Berchuck, Jonathan S. Berek, James D. Brenton, George Coukos, et al. “Rethinking ovarian cancer: recommendations for improving outcomes.” Nat Rev Cancer 11, no. 10 (September 23, 2011): 719–25. https://doi.org/10.1038/nrc3144.Full Text Link to Item
-
Skates, Steven J., Phuong Mai, Nora K. Horick, Marion Piedmonte, Charles W. Drescher, Claudine Isaacs, Deborah K. Armstrong, et al. “Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.” Cancer Prev Res (Phila) 4, no. 9 (September 2011): 1401–8. https://doi.org/10.1158/1940-6207.CAPR-10-0402.Full Text Link to Item
-
Teoh, Deanna, Andrew Berchuck, Angeles Alvarez Secord, Paula S. Lee, William J. Lowery, Gregory P. Sfakianos, Fidel A. Valea, Evan R. Myers, and Laura J. Havrilesky. “Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer.” Gynecol Oncol 122, no. 3 (September 2011): 467–72. https://doi.org/10.1016/j.ygyno.2011.06.014.Full Text Link to Item
-
Barnett, Jason C., Laura J. Havrilesky, Amy E. Bondurant, Nicole D. Fleming, Paula S. Lee, Angeles Alvarez Secord, Andrew Berchuck, and Fidel A. Valea. “Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer.” American Journal of Obstetrics and Gynecology 205, no. 2 (August 2011): 143.e1-143.e6. https://doi.org/10.1016/j.ajog.2011.03.012.Full Text
-
Permuth-Wey, Jennifer, Zhihua Chen, Ya-Yu Tsai, Hui-Yi Lin, Y Ann Chen, Jill Barnholtz-Sloan, Michael J. Birrer, et al. “MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium.” Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 20, no. 8 (August 2011): 1793–97. https://doi.org/10.1158/1055-9965.epi-11-0397.Full Text
-
Pharoah, Paul, Antonis Antoniou, Andrew Berchuck, Georgia Chenevix-Trench, Simon Gayther, Ellen Goode, Roger Milne, Tom Sellers, and Jonathan Tyrer. “Association between KRAS rs61764370 and triple-negative breast cancer--a false positive?” Lancet Oncol 12, no. 8 (August 2011): 723–24. https://doi.org/10.1016/S1470-2045(11)70156-5.Full Text Link to Item
-
Swaminathan, Vinay, Karthikeyan Mythreye, E Tim O’Brien, Andrew Berchuck, Gerard C. Blobe, and Richard Superfine. “Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines.” Cancer Res 71, no. 15 (August 1, 2011): 5075–80. https://doi.org/10.1158/0008-5472.CAN-11-0247.Full Text Link to Item
-
Cancer Genome Atlas Research Network, Wojciech. “Integrated genomic analyses of ovarian carcinoma.” Nature 474, no. 7353 (June 29, 2011): 609–15. https://doi.org/10.1038/nature10166.Full Text Link to Item
-
Maxwell, G Larry, Brian L. Hood, Roger Day, Uma Chandran, David Kirchner, VS Kumar Kolli, Nicolas W. Bateman, et al. “Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation.” Gynecol Oncol 121, no. 3 (June 1, 2011): 586–94. https://doi.org/10.1016/j.ygyno.2011.02.031.Full Text Link to Item
-
Pearce, Celeste Leigh, Jennifer A. Doherty, David J. Van Den Berg, Kirsten Moysich, Chris Hsu, Kara L. Cushing-Haugen, David V. Conti, et al. “Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk.” Hum Mol Genet 20, no. 11 (June 1, 2011): 2263–72. https://doi.org/10.1093/hmg/ddr087.Full Text Link to Item
-
Pharoah, Paul D. P., Rachel T. Palmieri, Susan J. Ramus, Simon A. Gayther, Irene L. Andrulis, Hoda Anton-Culver, Natalia Antonenkova, et al. “The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.” Clin Cancer Res 17, no. 11 (June 1, 2011): 3742–50. https://doi.org/10.1158/1078-0432.CCR-10-3405.Full Text Link to Item
-
Amankwah, Ernest K., Linda E. Kelemen, Qinggang Wang, Honglin Song, Georgia Chenevix-Trench, Georgia Australian Ovarian Cancer Study Group, Jonathan Beesley, et al. “Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer.” Cancer Epidemiol Biomarkers Prev 20, no. 5 (May 2011): 1028–31. https://doi.org/10.1158/1055-9965.EPI-11-0053.Full Text Link to Item
-
Berchuck, A., P. Pharoah, S. Ramus, S. Gayther, R. Palmieri, C. Pearce, F. Couch, et al. “Association of KRAS SNP rs61764370 with risk of invasive epithelial ovarian cancer: Implications for clinical testing.” Gynecologic Oncology 121, no. 2 (May 2011): S2–3. https://doi.org/10.1016/j.ygyno.2011.02.028.Full Text
-
Goode, Ellen L., Kristin L. White, Robert A. Vierkant, Catherine M. Phelan, Julie M. Cunningham, Joellen M. Schildkraut, Andrew Berchuck, et al. “Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk.” Molecular Carcinogenesis 50, no. 5 (May 2011): 397–402. https://doi.org/10.1002/mc.20714.Full Text
-
Notaridou, Maria, Lydia Quaye, Dimitra Dafou, Chris Jones, Honglin Song, Estrid Høgdall, Susanne K. Kjaer, et al. “Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer.” Int J Cancer 128, no. 9 (May 1, 2011): 2063–74. https://doi.org/10.1002/ijc.25554.Full Text Link to Item
-
Huang, Zhiqing, Ken Yamaguchi, Andrew Berchuck, and Susan K. Murphy. “Abstract 3014: Quantitative accuracy of Illumina HumanMethylation27 Infinium BeadChip data assessed by pyrosequencing.” Cellular and Molecular Biology, April 15, 2011. https://doi.org/10.1158/1538-7445.am2011-3014.Full Text
-
Berchuck, Andrew, and Mark H. Einstein. “Prevention and early detection of cancer.” Gynecologic Oncology 121, no. 1 (April 2011): 1. https://doi.org/10.1016/j.ygyno.2011.02.009.Full Text
-
Carver, Donna K., H John Barnes, Kenneth E. Anderson, James N. Petitte, Regina Whitaker, Andrew Berchuck, and Gustavo C. Rodriguez. “Reduction of ovarian and oviductal cancers in calorie-restricted laying chickens.” Cancer Prev Res (Phila) 4, no. 4 (April 2011): 562–67. https://doi.org/10.1158/1940-6207.CAPR-10-0294.Full Text Link to Item
-
Teoh, Deanna, Tina A. Ayeni, Jennifer M. Rubatt, David J. Adams, Lisa Grace, Mark D. Starr, William T. Barry, Andrew Berchuck, Susan K. Murphy, and Angeles Alvarez Secord. “Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.” Gynecol Oncol 121, no. 1 (April 2011): 187–92. https://doi.org/10.1016/j.ygyno.2010.11.017.Full Text Link to Item
-
Berchuck, A., M. Pike, J. Schildkraut, and C. Pearce. “Common single-nucleotide polymorphisms in the BNC2, HOXD1 and MERIT40 regions contribute significantly to racial differences in ovarian cancer incidence.” Gynecologic Oncology 120 (March 2011): S7–S7. https://doi.org/10.1016/j.ygyno.2010.12.019.Full Text
-
Chandavarkar, U., M. Campan, S. Houshdaran, C. Pearce, H. Shen, M. Widschwendter, A. Berchuck, L. Roman, and P. Laird. “DNA methylation markers associated with serous ovarian cancer subtypes.” Gynecologic Oncology 120 (March 2011): S48–S48. https://doi.org/10.1016/j.ygyno.2010.12.117.Full Text
-
Lancaster, J., D. Chen, D. Marchion, Y. Xiong, A. Berchuck, P. Judson, J. Gonzalez Bosquet, R. Wenham, S. Apte, and W. Fulp. “BAD apoptosis pathway expression and survival from cancer.” Gynecologic Oncology 120 (March 2011): S24–S24. https://doi.org/10.1016/j.ygyno.2010.12.060.Full Text
-
Lowery, W., J. Schildkraut, L. Akushevich, R. Bentley, D. Huntsman, J. Marks, and A. Berchuck. “Loss of ARID1A is a frequent event in clear cell and endometrioid ovarian cancers.” Gynecologic Oncology 120 (March 2011): S21–S21. https://doi.org/10.1016/j.ygyno.2010.12.054.Full Text
-
Sfakianos, G., J. Yan, R. Whitaker, S. Murphy, and A. Berchuck. “Concordant gene expression profiles in matched primary and recurrent serous ovarian cancers predict platinum response.” Gynecologic Oncology 120 (March 2011): S46–S46. https://doi.org/10.1016/j.ygyno.2010.12.112.Full Text
-
Teoh, D., E. Myers, A. Berchuck, A. Alvarez-Secord, P. Lee, W. Lowery, G. Sfakianos, and L. Havrilesky. “Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer.” Gynecologic Oncology 120 (March 2011): S11–S11. https://doi.org/10.1016/j.ygyno.2010.12.031.Full Text
-
Yamaguchi, K., T. Baba, I. Konishi, N. Matsumura, S. Murphy, Z. Huang, and A. Berchuck. “Genes functionally regulated by methylation in ovarian cancer are involved in cell proliferation, development and morphogenesis.” Gynecologic Oncology 120 (March 2011): S69–S69. https://doi.org/10.1016/j.ygyno.2010.12.165.Full Text
-
Yamaguchi, K., T. Baba, N. Matsumura, M. Mandai, I. Konishi, A. Berchuck, and S. Murphy. “Genomewide methylation analyses reveal a prominent role of HINF1 network genes, via hypomethylation, in ovarian clear cell carcinoma.” Gynecologic Oncology 120 (March 2011): S8–S8. https://doi.org/10.1016/j.ygyno.2010.12.021.Full Text
-
Havrilesky, Laura J., Gillian D. Sanders, Shalini Kulasingam, Junzo P. Chino, Andrew Berchuck, Jeffrey R. Marks, and Evan R. Myers. “Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction.” Cancer 117, no. 3 (February 1, 2011): 545–53. https://doi.org/10.1002/cncr.25624.Full Text Link to Item
-
Amankwah, Ernest K., Qinggang Wang, Joellen M. Schildkraut, Ya-Yu Tsai, Susan J. Ramus, Brooke L. Fridley, Jonathan Beesley, et al. “Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium.” Plos One 6, no. 5 (2011): e19642. https://doi.org/10.1371/journal.pone.0019642.Full Text Link to Item
-
Campan, Mihaela, Melissa Moffitt, Sahar Houshdaran, Hui Shen, Martin Widschwendter, Günter Daxenbichler, Tiffany Long, et al. “Genome-scale screen for DNA methylation-based detection markers for ovarian cancer.” Plos One 6, no. 12 (January 2011): e28141. https://doi.org/10.1371/journal.pone.0028141.Full Text
-
Lurie, Galina, Lynne R. Wilkens, Pamela J. Thompson, Yurii B. Shvetsov, Rayna K. Matsuno, Michael E. Carney, Rachel T. Palmieri, et al. “Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium.” Plos One 6, no. 6 (2011): e20703. https://doi.org/10.1371/journal.pone.0020703.Full Text Link to Item
-
Matsumura, Noriomi, Zhiqing Huang, Seiichi Mori, Tsukasa Baba, Shingo Fujii, Ikuo Konishi, Edwin S. Iversen, Andrew Berchuck, and Susan K. Murphy. “Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer.” Genome Res 21, no. 1 (January 2011): 74–82. https://doi.org/10.1101/gr.108803.110.Full Text Link to Item
-
Near, Aimee M., Anna H. Wu, Claire Templeman, David J. Van Den Berg, Jennifer A. Doherty, Mary Anne Rossing, Ellen L. Goode, et al. “Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort.” Fertil Steril 95, no. 1 (January 2011): 40–45. https://doi.org/10.1016/j.fertnstert.2010.06.059.Full Text Link to Item
-
Wallace, Amy H., Laura J. Havrilesky, Fidel A. Valea, Jason C. Barnett, Andrew Berchuck, and Evan R. Myers. “Projecting the need for gynecologic oncologists for the next 40 years.” Obstet Gynecol 116, no. 6 (December 2010): 1366–72. https://doi.org/10.1097/AOG.0b013e3181fc3a22.Full Text Link to Item
-
Bolton, Kelly L., Jonathan Tyrer, Honglin Song, Susan J. Ramus, Maria Notaridou, Chris Jones, Tanya Sher, et al. “Common variants at 19p13 are associated with susceptibility to ovarian cancer.” Nat Genet 42, no. 10 (October 2010): 880–84. https://doi.org/10.1038/ng.666.Full Text Link to Item
-
Goode, Ellen L., Georgia Chenevix-Trench, Honglin Song, Susan J. Ramus, Maria Notaridou, Kate Lawrenson, Martin Widschwendter, et al. “A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.” Nat Genet 42, no. 10 (October 2010): 874–79. https://doi.org/10.1038/ng.668.Full Text Link to Item
-
Berek, Jonathan S., Eva Chalas, Mitchell Edelson, David H. Moore, William M. Burke, William A. Cliby, Andrew Berchuck, and Andrew Society of Gynecologic Oncologists Clinical Practice Committee. “Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer.” Obstet Gynecol 116, no. 3 (September 2010): 733–43. https://doi.org/10.1097/AOG.0b013e3181ec5fc1.Full Text Link to Item
-
Johnatty, Sharon E., Jonathan Beesley, Xiaoqing Chen, Stuart Macgregor, David L. Duffy, Amanda B. Spurdle, Anna deFazio, et al. “Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot".” Plos Genet 6, no. 7 (July 8, 2010): e1001016. https://doi.org/10.1371/journal.pgen.1001016.Full Text Link to Item
-
Dafou, Dimitra, Barbara Grun, John Sinclair, Kate Lawrenson, Elizabeth C. Benjamin, Estrid Hogdall, Susanne Kruger-Kjaer, et al. “Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers.” Neoplasia 12, no. 7 (July 2010): 579–89. https://doi.org/10.1593/neo.10340.Full Text Link to Item
-
Johnatty, S. E., J. Beesley, X. Chen, S. Macgregor, D. L. Duffy, A. B. Spurdle, A. deFazio, et al. “Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot".” Plos Genetics 6, no. 7 (July 1, 2010).
-
Kelemen, Linda E., Marc T. Goodman, Valerie McGuire, Mary Anne Rossing, Penelope M. Webb, Penelope M. Australian Cancer Study (Ovarian Cancer) Study Group, Martin Köbel, et al. “Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium.” Cancer Epidemiol Biomarkers Prev 19, no. 7 (July 2010): 1822–30. https://doi.org/10.1158/1055-9965.EPI-09-1317.Full Text Link to Item
-
Bernardini, Marcus Q., Tsukasa Baba, Paula S. Lee, Jason C. Barnett, Gregory P. Sfakianos, Angeles Alvarez Secord, Susan K. Murphy, Edwin Iversen, Jeffrey R. Marks, and Andrew Berchuck. “Expression signatures of TP53 mutations in serous ovarian cancers.” Bmc Cancer 10 (May 26, 2010): 237. https://doi.org/10.1186/1471-2407-10-237.Full Text Open Access Copy Link to Item
-
Chino, J. P., E. Jones, A. Berchuck, and L. Havrilesky. “Influence of radiation modality and nodal dissection on survival in high-risk early-stage endometrial cancer.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 5027–5027. https://doi.org/10.1200/jco.2010.28.15_suppl.5027.Full Text
-
Kondoh, Eiji, Seiichi Mori, Ken Yamaguchi, Tsukasa Baba, Noriomi Matsumura, J. Cory Barnett, Regina S. Whitaker, et al. “Targeting slow-proliferating ovarian cancer cells.” Int J Cancer 126, no. 10 (May 15, 2010): 2448–56. https://doi.org/10.1002/ijc.24919.Full Text Link to Item
-
Schildkraut, Joellen M., Edwin S. Iversen, Melanie A. Wilson, Merlise A. Clyde, Patricia G. Moorman, Rachel T. Palmieri, Regina Whitaker, Rex C. Bentley, Jeffrey R. Marks, and Andrew Berchuck. “Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer.” Plos One 5, no. 4 (April 8, 2010): e10061. https://doi.org/10.1371/journal.pone.0010061.Full Text Open Access Copy Link to Item
-
Lee, Paula S., Vanessa S. Teaberry, Amy E. Bland, Zhiqing Huang, Regina S. Whitaker, Tsukasa Baba, Shingo Fujii, Angeles Alvarez Secord, Andrew Berchuck, and Susan K. Murphy. “Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.” Int J Cancer 126, no. 6 (March 15, 2010): 1378–89. https://doi.org/10.1002/ijc.24797.Full Text Link to Item
-
Alvarez-Secord, A., A. Berchuck, R. Higgins, L. Nycum, M. Kohler, L. Puls, R. Holloway, G. Lewandowski, F. Valea, and L. Havrilesky. “A multicenter, randomized, phase II study evaluating the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.” Gynecologic Oncology 116, no. 3 (March 1, 2010): S3–S3.Link to Item
-
Barnett, J., L. Havrilesky, N. Flemming, A. Bland, P. Lee, A. Alvarez-Secord, A. Berchuck, and F. Valea. “Adverse events associated with laparoscopy versus laparotomy in the treatment of stage I endometrial cancer.” Gynecologic Oncology 116, no. 3 (March 1, 2010): S147–S147.Link to Item
-
Barnett, Jason C., Sarah M. Bean, Regina S. Whitaker, Eiji Kondoh, Tsukasa Baba, Shingo Fujii, Jeffrey R. Marks, Holly K. Dressman, Susan K. Murphy, and Andrew Berchuck. “Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype.” Gynecol Oncol 116, no. 3 (March 2010): 556–62. https://doi.org/10.1016/j.ygyno.2009.11.020.Full Text Link to Item
-
Havrilesky, L., G. Sanders, S. Kulasingam, A. Berchuck, H. Dressman, J. Lancaster, J. Marks, and E. Myers. “Indolent and aggressive phenotypes of epithelial ovarian cancer: Implications for screening.” Gynecologic Oncology 116, no. 3 (March 1, 2010): S107–S107.Link to Item
-
Humphrey, M., N. Chen, Y. Xiong, D. Marchion, E. Bicaku, H. Chon, A. Berchuck, et al. “Genomic analysis defines biological pathway differences between early- and advanced-stage ovarian cancers.” Gynecologic Oncology 116, no. 3 (March 1, 2010): S22–S22.Link to Item
-
Sfakianos, G., K. Yamaguchi, S. Murphy, and A. Berchuck. “Gene expression profiling of invasive serous ovarian cancers from formalin-fixed, paraffin-embedded tissues using DASL.” Gynecologic Oncology 116, no. 3 (March 1, 2010): S136–37.Link to Item
-
Teoh, D., T. Ayeni, J. Rubatt, D. Adams, L. Grace, M. Starr, H. Dressman, A. Berchuck, and A. Alvarez-Secord. “Genomic SRC signature and SRC protein expression in ovarian cancers may predict response to the SRC inhibitor dasatinib.” Gynecologic Oncology 116, no. 3 (March 1, 2010): S151–52.Link to Item
-
Wallace, A., L. Havrilesky, F. Valea, J. Barnett, A. Berchuck, and E. Myers. “Projecting the need for gynecologic oncologists for the next 40 years: Not enough, too many or just right?” Gynecologic Oncology 116, no. 3 (March 1, 2010): S52–53.Link to Item
-
Phelan, Catherine M., Ya-Yu Tsai, Ellen L. Goode, Robert A. Vierkant, Brooke L. Fridley, Jonathan Beesley, Xiao Qing Chen, et al. “Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium.” Cancer Epidemiol Biomarkers Prev 19, no. 2 (February 2010): 600–604. https://doi.org/10.1158/1055-9965.EPI-09-0861.Full Text Link to Item
-
White, Kristin L., Thomas A. Sellers, Brooke L. Fridley, Robert A. Vierkant, Catherine M. Phelan, Ya-Yu Tsai, Kimberly R. Kalli, et al. “Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer.” Twin Res Hum Genet 13, no. 1 (February 2010): 43–56. https://doi.org/10.1375/twin.13.1.43.Full Text Link to Item
-
Peedicayil, Abraham, Robert A. Vierkant, Lynn C. Hartmann, Brooke L. Fridley, Zachary S. Fredericksen, Kristin L. White, Elaine A. Elliott, et al. “Risk of ovarian cancer and inherited variants in relapse-associated genes.” Plos One 5, no. 1 (January 27, 2010): e8884. https://doi.org/10.1371/journal.pone.0008884.Full Text Open Access Copy Link to Item
-
Barnett, Jason C., Sarah M. Bean, John M. Nakayama, Eiji Kondoh, Susan K. Murphy, and Andrew Berchuck. “High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer.” Obstet Gynecol 115, no. 1 (January 2010): 49–54. https://doi.org/10.1097/AOG.0b013e3181c2d294.Full Text Link to Item
-
Doherty, Jennifer A., Mary Anne Rossing, Kara L. Cushing-Haugen, Chu Chen, David J. Van Den Berg, Anna H. Wu, Malcolm C. Pike, et al. “ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study.” Cancer Epidemiol Biomarkers Prev 19, no. 1 (January 2010): 245–50. https://doi.org/10.1158/1055-9965.EPI-09-0729.Full Text Link to Item
-
Jewell, Elizabeth L., Kathleen M. Darcy, Alan Hutson, Paula S. Lee, Laura J. Havrilesky, Lisa A. Grace, Andrew Berchuck, and Angeles Alvarez Secord. “Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.” Gynecol Oncol 115, no. 3 (December 2009): 424–29. https://doi.org/10.1016/j.ygyno.2009.07.035.Full Text Link to Item
-
Pearce, C. L., A. M. Near, D. J. Van Den Berg, S. J. Ramus, A. Gentry-Maharaj, U. Menon, S. A. Gayther, et al. “Erratum: Validating genetic risk associations for ovarian cancer through the International Ovarian Cancer Association Consortium (British Journal of Cancer (2009) 100 (412-420) DOI: 10.1038/sj.bjc.6604820 www.bjcancer.com).” British Journal of Cancer 101, no. 10 (November 1, 2009): 1805. https://doi.org/10.1038/sj.bjc.6605431.Full Text
-
Cunningham, J. M., R. A. Vierkant, T. A. Sellers, C. Phelan, D. N. Rider, M. Liebow, J. Schildkraut, et al. “Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.” Br J Cancer 101, no. 8 (October 20, 2009): 1461–68. https://doi.org/10.1038/sj.bjc.6605284.Full Text Link to Item
-
Lee, Paula S., Amy Bland, Fidel A. Valea, Laura J. Havrilesky, Andrew Berchuck, and Angeles Alvarez Secord. “Robotic-assisted laparoscopic gynecologic procedures in a fellowship training program.” Jsls 13, no. 4 (October 2009): 467–72. https://doi.org/10.4293/108680809X12589998403921.Full Text Link to Item
-
Moorman, Patricia G., Rachel T. Palmieri, Lucy Akushevich, Andrew Berchuck, and Joellen M. Schildkraut. “Ovarian cancer risk factors in African-American and white women.” Am J Epidemiol 170, no. 5 (September 1, 2009): 598–606. https://doi.org/10.1093/aje/kwp176.Full Text Link to Item
-
Song, Honglin, Susan J. Ramus, Jonathan Tyrer, Kelly L. Bolton, Aleksandra Gentry-Maharaj, Eva Wozniak, Hoda Anton-Culver, et al. “A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.” Nat Genet 41, no. 9 (September 2009): 996–1000. https://doi.org/10.1038/ng.424.Full Text Link to Item
-
Ding, X., A. B. Mohd, Z. Huang, T. Baba, M. Q. Bernardini, H. K. Lyerly, A. Berchuck, S. K. Murphy, A. B. Buermeyer, and G. R. Devi. “MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition.” Br J Cancer 101, no. 2 (July 21, 2009): 269–77. https://doi.org/10.1038/sj.bjc.6605180.Full Text Link to Item
-
Berchuck, Andrew. “Microarray analysis of gene expression in gynecologic cancers--still only the beginning.” Gynecol Oncol 114, no. 1 (July 2009): 1–2. https://doi.org/10.1016/j.ygyno.2009.05.002.Full Text Link to Item
-
Bernardini, Marcus Q., Taymaa May, Mahmoud A. Khalifa, Amy E. Bland, Sharon Nofech-Mozes, Andrew Berchuck, Al Covens, and Laura Havrilesky. “Evaluation of two management strategies for preoperative grade 1 endometrial cancer.” Obstet Gynecol 114, no. 1 (July 2009): 7–15. https://doi.org/10.1097/AOG.0b013e3181aa97fc.Full Text Link to Item
-
Song, Honglin, Susan J. Ramus, Susanne Krüger Kjaer, Richard A. DiCioccio, Georgia Chenevix-Trench, Celeste Leigh Pearce, Estrid Hogdall, et al. “Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.” Hum Mol Genet 18, no. 12 (June 15, 2009): 2297–2304. https://doi.org/10.1093/hmg/ddp138.Full Text Link to Item
-
Huang, Zhiqing, Yaqing Wen, Lauren Simel, Thomas Price, Andrew Berchuck, and Susan K. Murphy. “CTCF binding at a novel intragenic binding site is associated with elevated IGF2 expression in serous epithelial ovarian cancer.” Cancer Research 69 (May 1, 2009).Link to Item
-
Kondoh, Eiji, Tsukasa Baba, Noriomi Matsumura, Ikuo Konishi, Shingo Fujii, Andrew Berchuck, and Susan Murphy. “UCN-01 is effective in targeting ovarian cancer spheroids.” Cancer Research 69 (May 1, 2009).Link to Item
-
Schildkraut, Joellen, Edwin Iversen, Jeffrey Marks, Melanie Wilson, Merlise Clyde, Rachel Palmieri, Patricia Moorman, and Andrew Berchuck. “Association between serous invasive ovarian cancer and variants in candidate DNA damage response genes.” Cancer Research 69 (May 1, 2009).Link to Item
-
Teoh, Deanna, Tina Ayeni, Jennifer Rubatt, Regina Whitaker, Holly Dressman, Andrew Berchuck, and Angeles Secord. “In vitro characterization of the antitumor effects of dasatinib (BMS-354825) in combination with paclitaxel and carboplatin in human ovarian cancer cell lines.” Cancer Research 69 (May 1, 2009).Link to Item
-
Berchuck, Andrew, Edwin S. Iversen, Jingqin Luo, Jennifer P. Clarke, Hisani Horne, Douglas A. Levine, Jeff Boyd, et al. “Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.” Clin Cancer Res 15, no. 7 (April 1, 2009): 2448–55. https://doi.org/10.1158/1078-0432.CCR-08-2430.Full Text Link to Item
-
Fasching, Peter A., Simon Gayther, Leigh Pearce, Joellen M. Schildkraut, Ellen Goode, Falk Thiel, Georgia Chenevix-Trench, et al. “Role of genetic polymorphisms and ovarian cancer susceptibility.” Mol Oncol 3, no. 2 (April 2009): 171–81. https://doi.org/10.1016/j.molonc.2009.01.008.Full Text Link to Item
-
Schildkraut, Joellen M., Ellen L. Goode, Merlise A. Clyde, Edwin S. Iversen, Patricia G. Moorman, Andrew Berchuck, Jeffrey R. Marks, et al. “Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer.” Cancer Res 69, no. 6 (March 15, 2009): 2349–57. https://doi.org/10.1158/0008-5472.CAN-08-2902.Full Text Link to Item
-
Rubatt, Jennifer M., Kathleen M. Darcy, Alan Hutson, Sarah M. Bean, Laura J. Havrilesky, Lisa A. Grace, Andrew Berchuck, and Angeles Alvarez Secord. “Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.” Gynecol Oncol 112, no. 3 (March 2009): 469–74. https://doi.org/10.1016/j.ygyno.2008.11.030.Full Text Link to Item
-
Baba, T., H. S. Kang, N. Matsumura, J. Hamanishi, M. Mandai, A. Berchuck, S. K. Murphy, and I. Konishi. “Loss of GPR54 correlates with stem cell activity in high-grade endometrial cancer.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S78–S78.Link to Item
-
Barnett, J. C., E. Iverson, H. Dressman, R. Whitaker, S. K. Murphy, J. Lancaster, and A. Berchuck. “Validation of the MAL gene as a predictor of survival in advanced-stage high-grade serous ovarian cancer.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S123–24.Link to Item
-
Barnett, J. C., E. Kondoh, R. Whitaker, S. K. Murphy, and A. Berchuck. “High poly (ADP-ribose) polymerase (PARP) expression is associated with poor survival in advanced-stage serous ovarian cancer.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S107–S107.Link to Item
-
Barnett, J. C., R. Whitaker, E. Kondoh, T. Baba, S. K. Murphy, and A. Berchuck. “Ovarian cancer tumor-infiltrating regulatory T cells are associated with a metastatic phenotype.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S11–S11.Link to Item
-
Cragun, J., Y. Xiong, T. P. Boren, M. D. Indermaur, R. Sayer, M. M. Humphrey, H. M. Cottrill, et al. “Genomic predictors of ovarian cancer response to salvage therapy.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S133–S133.Link to Item
-
Hakim, Amy A., Catherine P. Barry, H John Barnes, Kenneth E. Anderson, James Petitte, Regina Whitaker, Jonathan M. Lancaster, et al. “Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.” Cancer Prev Res (Phila) 2, no. 2 (February 2009): 114–21. https://doi.org/10.1158/1940-6207.CAPR-08-0065.Full Text Link to Item
-
Kondoh, E., T. Baba, N. Malsumura, I. Konishi, S. Fujii, A. Berchuck, and S. K. Murphy. “7-hydroxystaurosporine (UCN-01) is effective in targeting ovarian cancer spheroids.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S161–62.Link to Item
-
Matsumura, Noriomi, Zhiqing Huang, Tsukasa Baba, Paula S. Lee, Jason C. Barnett, Seiichi Mori, Jeffrey T. Chang, et al. “Yin yang 1 modulates taxane response in epithelial ovarian cancer.” Mol Cancer Res 7, no. 2 (February 2009): 210–20. https://doi.org/10.1158/1541-7786.MCR-08-0255.Full Text Link to Item
-
Murphy, S. K., Z. Huang, Y. Wen, L. R. Simel, T. M. Price, and A. Berchuck. “Intragenic methylation at a novel CTCF binding site is associated with elevated IGF2 expression in serous epithelial ovarian cancer.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S138–S138.Link to Item
-
Yamaguchi, K., M. Mandai, N. Matsumura, T. Baba, T. Oura, S. Matsui, S. K. Murphy, A. Berchuck, S. Fujii, and I. Konishi. “Gene signature specific for ovarian clear cell carcinoma is induced by the contents of endometriotic cysts.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S132–S132.Link to Item
-
Pearce, C. L., A. M. Near, D. J. Van Den Berg, S. J. Ramus, A. Gentry-Maharaj, U. Menon, S. A. Gayther, et al. “Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.” Br J Cancer 100, no. 2 (January 27, 2009): 412–20. https://doi.org/10.1038/sj.bjc.6604820.Full Text Link to Item
-
Pearce, C. L., A. M. Near, D. J. Van Den Berg, S. J. Ramus, A. Gentry-Maharaj, U. Menon, S. A. Gayther, et al. “Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.” British Journal of Cancer 100, no. 2 (January 27, 2009): 412–20. https://doi.org/10.1038/sj.bjc.6604820.Full Text
-
Baba, T., P. A. Convery, N. Matsumura, R. S. Whitaker, E. Kondoh, T. Perry, Z. Huang, et al. “Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.” Oncogene 28, no. 2 (January 15, 2009): 209–18. https://doi.org/10.1038/onc.2008.374.Full Text Link to Item
-
Bland, Amy E., Brian Calingaert, Angeles Alvarez Secord, Paula S. Lee, Fidel A. Valea, Andrew Berchuck, John T. Soper, and Laura Havrilesky. “Relationship between tamoxifen use and high risk endometrial cancer histologic types.” Gynecol Oncol 112, no. 1 (January 2009): 150–54. https://doi.org/10.1016/j.ygyno.2008.08.035.Full Text Link to Item
-
Palmieri, Rachel T., Melanie A. Wilson, Edwin S. Iversen, Merlise A. Clyde, Brian Calingaert, Patricia G. Moorman, Charles Poole, et al. “Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women.” Cancer Epidemiol Biomarkers Prev 17, no. 12 (December 2008): 3567–72. https://doi.org/10.1158/1055-9965.EPI-08-0548.Full Text Link to Item
-
Havrilesky, Laura J., Clark M. Whitehead, Jennifer M. Rubatt, Robert L. Cheek, John Groelke, Qin He, Douglas P. Malinowski, Timothy J. Fischer, and Andrew Berchuck. “Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.” Gynecol Oncol 110, no. 3 (September 2008): 374–82. https://doi.org/10.1016/j.ygyno.2008.04.041.Full Text Link to Item
-
Ramus, Susan J., Robert A. Vierkant, Sharon E. Johnatty, Malcolm C. Pike, David J. Van Den Berg, Anna H. Wu, Celeste Leigh Pearce, et al. “Consortium analysis of 7 candidate SNPs for ovarian cancer.” Int J Cancer 123, no. 2 (July 15, 2008): 380–88. https://doi.org/10.1002/ijc.23448.Full Text Link to Item
-
Risch, Harvey A. “Cyclin E overexpression relates to ovarian cancer histology but not to risk factors.” Cancer Epidemiol Biomarkers Prev 17, no. 7 (July 2008): 1841. https://doi.org/10.1158/1055-9965.EPI-08-0271.Full Text Link to Item
-
Berchuck, Andrew. “Scientific innovation--pathway to progress in women's cancer.” Gynecol Oncol 109, no. 3 (June 2008): 316–22. https://doi.org/10.1016/j.ygyno.2008.04.020.Full Text Link to Item
-
Cragun, J. M., T. Boren, Y. Xiong, M. Indermaur, S. Kamath, H. Cottrill, L. Balducci, et al. “Gene expression determinants of ovarian cancer platinum-response in older women.” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 22059.Link to Item
-
Cragun, J. M., T. Boren, Y. Xiong, M. Indermaur, S. Kamath, H. Cottrill, L. Balducci, et al. “Gene expression determinants of ovarian cancer platinum-response in older women.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 22059–22059. https://doi.org/10.1200/jco.2008.26.15_suppl.22059.Full Text
-
Moorman, Patricia G., Brian Calingaert, Rachel T. Palmieri, Edwin S. Iversen, Rex C. Bentley, Susan Halabi, Andrew Berchuck, and Joellen M. Schildkraut. “Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women.” Am J Epidemiol 167, no. 9 (May 1, 2008): 1059–69. https://doi.org/10.1093/aje/kwn006.Full Text Link to Item
-
Wright, J. D., A. A. Secord, T. M. Numnum, R. P. Rocconi, M. A. Powell, A. Berchuck, R. D. Alvarez, et al. “A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer.” Int J Gynecol Cancer 18, no. 3 (May 2008): 400–406. https://doi.org/10.1111/j.1525-1438.2007.01027.x.Full Text Link to Item
-
Allard, J., J. I. Risinger, R. Day, U. Chandran, T. Litzi, G. Rose, A. Berchuck, and G. Maxwell. “Microarray analysis of microdissected stage I endometrial cancers reveals gene expression patterns associated with inflammation.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S80–81.Link to Item
-
Baba, T., S. Mori, N. Matsumura, M. Bernardini, S. Fujii, A. Berchuck, and S. K. Murphy. “Microarray analysis identifies NSC668814 as a potentially active chemotherapeutic agent for platinum-resistant ovarian cancers with TP53 mutations.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S72–S72.Link to Item
-
Barnett, J. C., A. Bland, R. Whitaker, B. Calingaert, R. C. Bentley, P. S. Lee, P. C. Moorman, J. M. Schildkraut, and A. Berchuck. “The prognostic significance of p53 and cyclin E overexpression in ovarian cancer: A population-based study.” Gynecologic Oncology 108, no. 3 (March 2008): S125–S125.Link to Item
-
Bernardini, M. Q., P. Lee, T. Baba, R. S. Whitaker, S. K. Murphy, and A. Berchuck. “Microarray analysis defines patterns of gene expression associated with mutation of TP53 in ovarian cancer.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S84–S84.Link to Item
-
Kondoh, E., T. Baba, N. Matsumura, S. Fujii, A. Berchuck, and S. K. Murphy. “Targeting dormant ovarian cancer cells.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S13–14.Link to Item
-
Matsumura, N., Z. Huang, T. Perry, D. Kroyer, T. Baba, S. Mori, S. Fujii, A. Berchuck, and S. K. Murphy. “Methylation in ovarian cancer is related to poor prognosis and suppression of the transforming growth factor signaling pathway.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S104–S104.Link to Item
-
Ramus, S. J., R. A. Vierkant, S. Jonhatty, J. M. Schildkraut, P. D. Pharoah, G. Chenevix-Trench, C. L. Pearce, A. Berchuck, and E. L. Goode. “Ovarian Cancer Association Consortium analysis of seven candidate ovarian cancer susceptibility polymorphisms.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S29–30.Link to Item
-
Risinger, J. I., J. Allard, R. Day, U. Chandran, T. Litzi, G. Rose, A. Berchuck, and G. Maxwell. “Gene expression analysis of stage I serous and endornetrioid endometrial cancers.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S76–S76.Link to Item
-
Rubatt, J. M., A Alvarez Secord, E. Iversen, L. Grace, W. Soper, and A. Berchuck. “Regulation of angiogenic gene expression in p53 wild type and mutant ovarian cancer cells by hypoxia and radiation.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S84–S84.Link to Item
-
Schildkraut, Joellen M., Patricia G. Moorman, Amy E. Bland, Susan Halabi, Brian Calingaert, Regina Whitaker, Paula S. Lee, et al. “Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup.” Cancer Epidemiol Biomarkers Prev 17, no. 3 (March 2008): 585–93. https://doi.org/10.1158/1055-9965.EPI-07-0596.Full Text Link to Item
-
Pearce, C. L., A. H. Wu, S. A. Gayther, A. E. Bale, A. E. Australian Cancer Study (Ovarian Cancer) and Australian Cancer Study Group, P. A. Beck, J. Beesley, et al. “Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis.” Br J Cancer 98, no. 2 (January 29, 2008): 282–88. https://doi.org/10.1038/sj.bjc.6604170.Full Text Link to Item
-
Berchuck, Andrew, Joellen M. Schildkraut, C Leigh Pearce, Georgia Chenevix-Trench, and Paul D. Pharoah. “Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium.” Adv Exp Med Biol 622 (2008): 53–67. https://doi.org/10.1007/978-0-387-68969-2_5.Full Text Link to Item
-
Zhang, Zhen, Yinhua Yu, Fengji Xu, Andrew Berchuck, Carolien van Haaften-Day, Laura J. Havrilesky, Henk W. A. de Bruijn, et al. “Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.” Gynecol Oncol 107, no. 3 (December 2007): 526–31. https://doi.org/10.1016/j.ygyno.2007.08.009.Full Text Link to Item
-
Alvarez Secord, Angeles, Laura J. Havrilesky, Victoria Bae-Jump, Jeanette Chin, Brian Calingaert, Amy Bland, Teresa L. Rutledge, Andrew Berchuck, Daniel L. Clarke-Pearson, and Paola A. Gehrig. “The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.” Gynecol Oncol 107, no. 2 (November 2007): 285–91. https://doi.org/10.1016/j.ygyno.2007.06.014.Full Text Link to Item
-
Lancaster, Johnathan M., C Bethan Powell, Noah D. Kauff, Ilana Cass, Lee-May Chen, Karen H. Lu, David G. Mutch, et al. “Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.” Gynecol Oncol 107, no. 2 (November 2007): 159–62. https://doi.org/10.1016/j.ygyno.2007.09.031.Full Text Link to Item
-
Allard, Jay E., John I. Risinger, Carl Morrison, Gregory Young, G Scott Rose, Jeff Fowler, Andrew Berchuck, and G Larry Maxwell. “Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas.” Gynecol Oncol 107, no. 1 (October 2007): 52–57. https://doi.org/10.1016/j.ygyno.2007.05.018.Full Text Link to Item
-
Berchuck, Andrew. “Chemotherapy administration for ovarian cancer by gynecologic oncologists and medical oncologists.” J Clin Oncol 25, no. 23 (August 10, 2007): 3552. https://doi.org/10.1200/JCO.2007.12.2960.Full Text Link to Item
-
Karlan, Beth Y., Andrew Berchuck, and David Mutch. “The role of genetic testing for cancer susceptibility in gynecologic practice.” Obstet Gynecol 110, no. 1 (July 2007): 155–67. https://doi.org/10.1097/01.AOG.0000269050.79143.84.Full Text Link to Item
-
Secord, Angeles Alvarez, Kathleen M. Darcy, Alan Hutson, Paula S. Lee, Laura J. Havrilesky, Lisa A. Grace, Andrew Berchuck, and Andrew Gynecologic Oncology Group study. “Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.” Gynecol Oncol 106, no. 1 (July 2007): 221–32. https://doi.org/10.1016/j.ygyno.2007.03.021.Full Text Link to Item
-
Dainty, Louis A., John I. Risinger, Carl Morrison, G. V. R. Chandramouli, Michael A. Bidus, Chris Zahn, G Scott Rose, Jeff Fowler, Andrew Berchuck, and G Larry Maxwell. “Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma.” Gynecol Oncol 105, no. 3 (June 2007): 563–70. https://doi.org/10.1016/j.ygyno.2006.10.063.Full Text Link to Item
-
Havrilesky, Laura J., Angeles Alvarez Secord, Victoria Bae-Jump, Tina Ayeni, Brian Calingaert, Daniel L. Clarke-Pearson, Andrew Berchuck, and Paola A. Gehrig. “Outcomes in surgical stage I uterine papillary serous carcinoma.” Gynecol Oncol 105, no. 3 (June 2007): 677–82. https://doi.org/10.1016/j.ygyno.2007.01.041.Full Text Link to Item
-
Spillman, Monique A., Judith Lacy, Susan K. Murphy, Regina S. Whitaker, Lisa Grace, Vanessa Teaberry, Jeffrey R. Marks, and Andrew Berchuck. “Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.” Gynecol Oncol 105, no. 2 (May 2007): 312–20. https://doi.org/10.1016/j.ygyno.2006.12.017.Full Text Link to Item
-
Gayther, Simon A., Honglin Song, Susan J. Ramus, Susan Krüger Kjaer, Alice S. Whittemore, Lydia Quaye, Jonathan Tyrer, et al. “Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer.” Cancer Res 67, no. 7 (April 1, 2007): 3027–35. https://doi.org/10.1158/0008-5472.CAN-06-3261.Full Text Link to Item
-
Risinger, John Ian, Gadisetti V. R. Chandramouli, G Larry Maxwell, Mary Custer, Svetlana Pack, Dmitri Loukinov, Olga Aprelikova, et al. “Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression.” Clin Cancer Res 13, no. 6 (March 15, 2007): 1713–19. https://doi.org/10.1158/1078-0432.CCR-05-2569.Full Text Link to Item
-
Alvarez Secord, Angeles, Paola A. Gehrig, Laura J. Havrilesky, Victoria Bae-Jump, Jeannette Chin, Brian Calingaert, Amy Bland, Teresa Rutledge, Andrew Berchuck, and Daniel L. Clarke-Pearson. “The role of multimodality adjuvant chemotherapy and radiation in women with advanced-stage endometrial cancer.” Gynecologic Oncology 104, no. 3 (March 1, 2007): S6–S6.Link to Item
-
Berchuck, A. “Society of gynecologic oncologists.” Journal of Oncology Practice 3, no. 2 (March 1, 2007): 108–9. https://doi.org/10.1200/JOP.0728001.Full Text
-
Havrilesky, Laura J., Clark Whitehead, Jennifer Rubatt, Robert L. Cheek, John Groelke, Qin He, Douglas P. Malinowski, Timothy J. Fischer, and Andrew Berchuck. “Preclinical evaluation of biomarkers for ovarian cancer detection and monitoring for disease recurrence.” Gynecologic Oncology 104, no. 3 (March 1, 2007): S12–S12.Link to Item
-
Schildkraut, Joellen M., Susan K. Murphy, Rachel T. Palmieri, Edwin Iversen, Patricia G. Moorman, Zhiqing Huang, Susan Halabi, et al. “Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer.” Cancer Epidemiol Biomarkers Prev 16, no. 3 (March 2007): 473–80. https://doi.org/10.1158/1055-9965.EPI-06-0868.Full Text Link to Item
-
Kingsley, Chris B., Wen-Lin Kuo, Daniel Polikoff, Andy Berchuck, Joe W. Gray, and Ajay N. Jain. “Magellan: a web based system for the integrated analysis of heterogeneous biological data and annotations; application to DNA copy number and expression data in ovarian cancer.” Cancer Inform 2 (February 5, 2007): 10–21.Link to Item
-
Havrilesky, Laura J., Janiel M. Cragun, Brian Calingaert, Angeles Alvarez Secord, Fidel A. Valea, Daniel L. Clarke-Pearson, Andrew Berchuck, and John T. Soper. “The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer.” Gynecol Oncol 104, no. 2 (February 2007): 401–5. https://doi.org/10.1016/j.ygyno.2006.08.027.Full Text Link to Item
-
Secord, Angeles Alvarez, Laura J. Havrilesky, Michael E. Carney, John T. Soper, Daniel L. Clarke-Pearson, Gustavo C. Rodriguez, and Andrew Berchuck. “Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.” Int J Clin Oncol 12, no. 1 (February 2007): 31–36. https://doi.org/10.1007/s10147-006-0619-9.Full Text Link to Item
-
Soper, J. T., A. A. Secord, L. J. Havrilesky, A. Berchuck, and D. L. Clarke-Pearson. “Comparison of gracilis and rectus abdominis myocutaneous flap neovaginal reconstruction performed during radical pelvic surgery: flap-specific morbidity.” Int J Gynecol Cancer 17, no. 1 (January 2007): 298–303. https://doi.org/10.1111/j.1525-1438.2007.00784.x.Full Text Link to Item
-
Maxwell, G. L., J. M. Schildkraut, B. Calingaert, J. I. Risinger, L. Dainty, P. A. Marchbanks, A. Berchuck, J. C. Barrett, and G. C. Rodriguez. “Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.” Gynecol Oncol 103, no. 2 (November 2006): 535–40. https://doi.org/10.1016/j.ygyno.2006.03.046.Full Text Link to Item
-
McDaniel, M. L., and A. Berchuck. “... what about this mole?” Contemporary Ob/Gyn 51, no. 11 (November 1, 2006): 44–46.
-
Guillem, José G., William C. Wood, Jeffrey F. Moley, Andrew Berchuck, Beth Y. Karlan, David G. Mutch, Robert F. Gagel, et al. “ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.” J Clin Oncol 24, no. 28 (October 1, 2006): 4642–60. https://doi.org/10.1200/JCO.2005.04.5260.Full Text Link to Item
-
Guillem, José G., William C. Wood, Jeffrey F. Moley, Andrew Berchuck, Beth Y. Karlan, David G. Mutch, Robert F. Gagel, et al. “ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.” Ann Surg Oncol 13, no. 10 (October 2006): 1296–1321. https://doi.org/10.1245/s10434-006-9036-6.Full Text Link to Item
-
Myers, Evan R., Laura J. Havrilesky, Shalini L. Kulasingam, Gillian D. Sanders, Kathryn E. Cline, Rebecca N. Gray, Andrew Berchuck, and Douglas C. McCrory. “Genomic tests for ovarian cancer detection and management.” Evid Rep Technol Assess (Full Rep), no. 145 (October 2006): 1–100.Link to Item
-
Secord, A. A., and A. Berchuck. “Targeted bio weapons in the war against gynecologic cancers.” Contemporary Ob/Gyn 51, no. 10 (October 1, 2006): 48–54.
-
Lancaster, J. M., H. K. Dressman, J. P. Clarke, R. A. Sayer, M. A. Martino, J. M. Cragun, A. H. Henriott, et al. “Identification of genes associated with ovarian cancer metastasis using microarray expression analysis.” Int J Gynecol Cancer 16, no. 5 (September 2006): 1733–45. https://doi.org/10.1111/j.1525-1438.2006.00660.x.Full Text Link to Item
-
Lancaster, J. M., R. A. Sayer, C. Blanchette, B. Calingaert, I. Konidari, J. Gray, J. Schildkraut, D. W. Schomberg, J. R. Marks, and A. Berchuck. “High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.” Int J Gynecol Cancer 16, no. 4 (July 2006): 1529–35. https://doi.org/10.1111/j.1525-1438.2006.00623.x.Full Text Link to Item
-
Lutman, Christopher V., Laura J. Havrilesky, Janiel M. Cragun, Angeles Alvarez Secord, Brian Calingaert, Andrew Berchuck, Daniel L. Clarke-Pearson, and John T. Soper. “Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.” Gynecol Oncol 102, no. 1 (July 2006): 92–97. https://doi.org/10.1016/j.ygyno.2005.11.032.Full Text Link to Item
-
Alvarez Secord, A., L. J. Havrilesky, R. V. Higgins, L. R. Nycum, M. F. Kohler, L. E. Puls, R. Holloway, J. T. Soper, F. A. Valea, and A. Berchuck. “A comparison of combination docetaxel/carboplatin versus sequential docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 5092.Link to Item
-
Wright, J. D., A. Alvarezsecord, T. M. Numnum, R. P. Rocconi, M. A. Powell, A. Berchuck, R. D. Alvarez, K. Trinkaus, J. S. Rader, and D. G. Mutch. “A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 5019.Link to Item
-
Gynecologic Oncology Group, Andrew, Angeles Alvarez Secord, Paula S. Lee, Kathleen M. Darcy, Laura J. Havrilesky, Lisa A. Grace, Jeffrey R. Marks, and Andrew Berchuck. “Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.” Gynecol Oncol 101, no. 3 (June 2006): 390–97. https://doi.org/10.1016/j.ygyno.2006.02.014.Full Text Link to Item
-
Jewell, E., A. A. Secord, T. Brotherton, and A. Berchuck. “Use of trastuzumab in the treatment of metastatic endometrial cancer.” Int J Gynecol Cancer 16, no. 3 (May 2006): 1370–73. https://doi.org/10.1111/j.1525-1438.2006.00543.x.Full Text Link to Item
-
Jones, Monica Brown, Aletta P. Houwink, Brandi K. Freeman, Tammy M. Greenwood, Jacqueline M. Lafky, Wilma L. Lingle, Andrew Berchuck, G Lawrence Maxwell, Karl C. Podratz, and Nita J. Maihle. “The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer.” J Soc Gynecol Investig 13, no. 4 (May 2006): 304–11. https://doi.org/10.1016/j.jsgi.2006.03.003.Full Text Link to Item
-
Murphy, Susan K., Zhiqing Huang, Yaqing Wen, Monique A. Spillman, Regina S. Whitaker, Lauren R. Simel, Teresa D. Nichols, Jeffrey R. Marks, and Andrew Berchuck. “Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer.” Mol Cancer Res 4, no. 4 (April 2006): 283–92. https://doi.org/10.1158/1541-7786.MCR-05-0138.Full Text Link to Item
-
Jones, Ellen, Angeles Alvarez Secord, Leonard R. Prosnitz, Thaddeus V. Samulski, James R. Oleson, Andrew Berchuck, Daniel Clarke-Pearson, John Soper, Mark W. Dewhirst, and Zeljko Vujaskovic. “Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma.” Int J Hyperthermia 22, no. 2 (March 2006): 161–72. https://doi.org/10.1080/02656730500515270.Full Text Link to Item
-
Bild, Andrea H., Guang Yao, Jeffrey T. Chang, Quanli Wang, Anil Potti, Dawn Chasse, Mary-Beth Joshi, et al. “Oncogenic pathway signatures in human cancers as a guide to targeted therapies.” Nature 439, no. 7074 (January 19, 2006): 353–57. https://doi.org/10.1038/nature04296.Full Text Link to Item
-
Bidus, Michael A., John I. Risinger, Gadisetti V. R. Chandramouli, Lou A. Dainty, Tracy J. Litzi, Andrew Berchuck, J Carl Barrett, and G Larry Maxwell. “Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray.” Clin Cancer Res 12, no. 1 (January 1, 2006): 83–88. https://doi.org/10.1158/1078-0432.CCR-05-0835.Full Text Link to Item
-
Huang, Zhiqing, Yaqing Wen, Ruby Shandilya, Jeffrey R. Marks, Andrew Berchuck, and Susan K. Murphy. “High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer.” Nucleic Acids Res 34, no. 2 (2006): 555–63. https://doi.org/10.1093/nar/gkj468.Full Text Link to Item
-
Risinger, John I., G. V. R. Chandramouli, G Larry Maxwell, Tracy Litzi, Andrew Berchuck, and Asad Umar. “Gene expression analysis of tumor infiltrating lymphocyte markers in endometrial cancers indicates no significant increases in those cases with microsatellite instability.” Cancer Biomark 2, no. 1–2 (2006): 61–68. https://doi.org/10.3233/cbm-2006-21-207.Full Text Link to Item
-
Schildkraut, Joellen M., Patricia G. Moorman, Susan Halabi, Brian Calingaert, Jeffrey R. Marks, and Andrew Berchuck. “Analgesic drug use and risk of ovarian cancer.” Epidemiology 17, no. 1 (January 2006): 104–7. https://doi.org/10.1097/01.ede.0000190538.55645.f8.Full Text Link to Item
-
Havrilesky, Laura J., Janiel M. Cragun, Brian Calingaert, Ingrid Synan, Angeles Alvarez Secord, John T. Soper, Daniel L. Clarke-Pearson, and Andrew Berchuck. “Resection of lymph node metastases influences survival in stage IIIC endometrial cancer.” Gynecol Oncol 99, no. 3 (December 2005): 689–95. https://doi.org/10.1016/j.ygyno.2005.07.014.Full Text Link to Item
-
Hoyo, Cathrine, Andrew Berchuck, Susan Halabi, Rex C. Bentley, Patricia Moorman, Brian Calingaert, and Joellen M. Schildkraut. “Anthropometric measurements and epithelial ovarian cancer risk in African-American and White women.” Cancer Causes Control 16, no. 8 (October 2005): 955–63. https://doi.org/10.1007/s10552-005-3205-y.Full Text Link to Item
-
Marquez, Rebecca T., Keith A. Baggerly, Andrea P. Patterson, Jinsong Liu, Russell Broaddus, Michael Frumovitz, Edward N. Atkinson, et al. “Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.” Clin Cancer Res 11, no. 17 (September 1, 2005): 6116–26. https://doi.org/10.1158/1078-0432.CCR-04-2509.Full Text Link to Item
-
Moorman, Patricia G., Joellen M. Schildkraut, Brian Calingaert, Susan Halabi, and Andrew Berchuck. “Menopausal hormones and risk of ovarian cancer.” Am J Obstet Gynecol 193, no. 1 (July 2005): 76–82. https://doi.org/10.1016/j.ajog.2004.11.013.Full Text Link to Item
-
Risinger, John I., G Larry Maxwell, Gadisetti V. R. Chandramouli, Olga Aprelikova, Tracy Litzi, Asad Umar, Andrew Berchuck, and J Carl Barrett. “Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling.” Cancer Res 65, no. 12 (June 15, 2005): 5031–37. https://doi.org/10.1158/0008-5472.CAN-04-0850.Full Text Link to Item
-
Alvarez Secord, A., E. L. Jones, C. A. Hahn, W. P. Petros, D. Yu, L. J. Havrilesky, J. T. Soper, et al. “Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer.” Int J Hyperthermia 21, no. 4 (June 2005): 333–47. https://doi.org/10.1080/02656730500110155.Full Text Link to Item
-
Cragun, Janiel M., Laura J. Havrilesky, Brian Calingaert, Ingrid Synan, Angeles Alvarez Secord, John T. Soper, Daniel L. Clarke-Pearson, and Andrew Berchuck. “Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer.” J Clin Oncol 23, no. 16 (June 1, 2005): 3668–75. https://doi.org/10.1200/JCO.2005.04.144.Full Text Link to Item
-
Kelemen, Livia, Michael James, Amanda Spurdle, Ian Campbell, Jenny Chang-Claude, David Peel, Hoda Anton-Culver, et al. “BRAF polymorphisms and the risk of ovarian cancer of low malignant potential.” Gynecol Oncol 97, no. 3 (June 2005): 807–12. https://doi.org/10.1016/j.ygyno.2005.03.007.Full Text Link to Item
-
Martino, M. A., A. Elahi, R. Sutphen, C. Klippel, T. Boren, H. K. Dressman, A. Berchuck, and J. M. Lancaster. “Expression analysis of genes involved in ovarian cancer metastasis.” J Clin Oncol 23, no. 16_suppl (June 2005): 5038.Link to Item
-
Maxwell, G Larry, G. V. R. Chandramouli, Lou Dainty, Tracy J. Litzi, Andrew Berchuck, J Carl Barrett, and John I. Risinger. “Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.” Clin Cancer Res 11, no. 11 (June 1, 2005): 4056–66. https://doi.org/10.1158/1078-0432.CCR-04-2001.Full Text Link to Item
-
Moorman, P. G., A. Berchuck, B. Calingaert, S. Halabi, and A. M. Schildkraut. “Antidepressant medication use for and risk of ovarian cancer (vol 105, pg 725, 2005).” Obstetrics and Gynecology 105, no. 6 (June 2005): 1495–1495.Link to Item
-
Berchuck, Andrew, Edwin S. Iversen, Johnathan M. Lancaster, Jennifer Pittman, Jingqin Luo, Paula Lee, Susan Murphy, et al. “Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.” Clin Cancer Res 11, no. 10 (May 15, 2005): 3686–96. https://doi.org/10.1158/1078-0432.CCR-04-2398.Full Text Link to Item
-
Soper, J. T., L. J. Havrilesky, A. A. Secord, A. Berchuck, and D. L. Clarke-Pearson. “Rectus abdominis myocutaneous flaps for neovaginal reconstruction after radical pelvic surgery.” Int J Gynecol Cancer 15, no. 3 (May 2005): 542–48. https://doi.org/10.1111/j.1525-1438.2005.15322.x.Full Text Link to Item
-
Soper, John T., Angeles Alvarez Secord, Laura J. Havrilesky, Andrew Berchuck, and Daniel L. Clarke-Pearson. “Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison of flap-related morbidity.” Gynecol Oncol 97, no. 2 (May 2005): 596–601. https://doi.org/10.1016/j.ygyno.2005.01.032.Full Text Link to Item
-
Spillman, Monique A., Joellen M. Schildkraut, Susan Halabi, Patricia Moorman, Brian Calingaert, Rex C. Bentley, Jeffrey R. Marks, Susan Murphy, and Andrew Berchuck. “Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk.” Gynecol Oncol 97, no. 2 (May 2005): 543–49. https://doi.org/10.1016/j.ygyno.2005.01.025.Full Text Link to Item
-
Moorman, Patricia G., Andrew Berchuck, Brian Calingaert, Susan Halabi, and Joellen M. Schildkraut. “Antidepressant medication use [corrected] and risk of ovarian cancer.” Obstet Gynecol 105, no. 4 (April 2005): 725–30. https://doi.org/10.1097/01.AOG.0000157113.98061.eb.Full Text Link to Item
-
Sayer, Robyn A., Johnathan M. Lancaster, Jennifer Pittman, Jonathon Gray, Regina Whitaker, Jeffrey R. Marks, and Andrew Berchuck. “High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.” Gynecol Oncol 96, no. 2 (February 2005): 355–61. https://doi.org/10.1016/j.ygyno.2004.10.012.Full Text Link to Item
-
Vanbeek, Marta J., John S. Strauss, and Ingrid Nygaard. “Flushing and papules in a middle-aged woman.” Obstet Gynecol 105, no. 2 (February 2005): 397–401. https://doi.org/10.1097/01.AOG.0000151956.00804.78.Full Text Link to Item
-
Berchuck, Andrew, Joellen M. Schildkraut, Robert M. Wenham, Brian Calingaert, Shazia Ali, Amy Henriott, Susan Halabi, et al. “Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.” Cancer Epidemiol Biomarkers Prev 13, no. 12 (December 2004): 2141–47.Link to Item
-
Spillman, Monique A., and Andrew Berchuck. “Stretching the surface epithelium.” J Soc Gynecol Investig 11, no. 8 (December 2004): 501–2. https://doi.org/10.1016/j.jsgi.2004.09.001.Full Text Link to Item
-
Skates, Steven J., Nora Horick, Yinhua Yu, Feng-Ji Xu, Andrew Berchuck, Laura J. Havrilesky, Henk W. A. de Bruijn, et al. “Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.” J Clin Oncol 22, no. 20 (October 15, 2004): 4059–66. https://doi.org/10.1200/JCO.2004.03.091.Full Text Link to Item
-
Bast, R., Y. Yu, J. Li, L. Sokoll, A. Rai, J. Rosenzweig, B. Cameron, et al. “Serum proteomics yield new biomarkers for ovarian cancer.” Cancer Biology and Therapy 3, no. 9 (September 1, 2004): 794–95.
-
Zhang, Zhen, Robert C. Bast, Yinhua Yu, Jinong Li, Lori J. Sokoll, Alex J. Rai, Jason M. Rosenzweig, et al. “Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.” Cancer Res 64, no. 16 (August 15, 2004): 5882–90. https://doi.org/10.1158/0008-5472.CAN-04-0746.Full Text Link to Item
-
Berchuck, A., A. A. Secord, L. J. Havrilesky, R. Wenham, J. T. Soper, and D. L. Clarke-Pearson. “Phase I/II trial of combination topotecan and vinorelbine in patients with refractory gynecologic cancer.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 5152.Link to Item
-
Jones, E. L., L. R. Prosnitz, T. V. Samulski, J. Soper, A. Berchuck, D. Clarke-Pearson, M. W. Dewhirst, and Z. Vujaskovic. “Intraperitoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 5038.Link to Item
-
Secord, A. A., E. Jones, C. A. Hahn, L. J. Havrilesky, J. T. Soper, A. Berchuck, D. L. Clarke-Pearson, L. R. Prosnitz, and M. W. Dewhirst. “Phase I/II trial of intravenous liposomal doxorubicin and whole abdomen hyperthermia in patients with refractory ovarian cancer.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 5089.Link to Item
-
Alvarez Secord, Angeles, Robyn Sayer, Stacey A. Snyder, Gloria Broadwater, Gustavo C. Rodriguez, Andrew Berchuck, and Kimberly Blackwell. “The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.” Gynecol Oncol 94, no. 1 (July 2004): 74–79. https://doi.org/10.1016/j.ygyno.2004.03.043.Full Text Link to Item
-
Lu, Karen H., Andrea P. Patterson, Lin Wang, Rebecca T. Marquez, Edward N. Atkinson, Keith A. Baggerly, Lance R. Ramoth, et al. “Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.” Clin Cancer Res 10, no. 10 (May 15, 2004): 3291–3300. https://doi.org/10.1158/1078-0432.CCR-03-0409.Full Text Link to Item
-
Rendi, Mara H., Nanjoo Suh, William W. Lamph, Stan Krajewski, John C. Reed, Richard A. Heyman, Andrew Berchuck, et al. “The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.” Cancer Res 64, no. 10 (May 15, 2004): 3566–71. https://doi.org/10.1158/0008-5472.CAN-04-0234.Full Text Link to Item
-
Berchuck, Andrew, Edwin S. Iversen, Johnathan M. Lancaster, Holly K. Dressman, Mike West, Joseph R. Nevins, and Jeffrey R. Marks. “Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.” Am J Obstet Gynecol 190, no. 4 (April 2004): 910–25. https://doi.org/10.1016/j.ajog.2004.02.005.Full Text Link to Item
-
Lancaster, Johnathan M., Holly K. Dressman, Regina S. Whitaker, Laura Havrilesky, Jonathan Gray, Jeffrey R. Marks, Joseph R. Nevins, and Andrew Berchuck. “Gene expression patterns that characterize advanced stage serous ovarian cancers.” J Soc Gynecol Investig 11, no. 1 (January 2004): 51–59. https://doi.org/10.1016/j.jsgi.2003.07.004.Full Text Link to Item
-
Berchuck, A., A. A. Alvarez, and J. E. Stout. “Abdominal pain and bloating in two 20-something patients.” Contemporary Ob/Gyn 48, no. 1 (December 1, 2003): 51–58.
-
Khabbaz, A., C. V. Lutman, and A. Berchuck. “What caused this woman's 'myoma'?” Contemporary Ob/Gyn 48, no. 11 (December 1, 2003): 108–12.
-
Havrilesky, Laura, kathleen M. Darcy, Hasnah Hamdan, Roger L. Priore, Jorge Leon, Jeffrey Bell, Andrew Berchuck, and Andrew Gynecologic Oncology Group Study. “Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.” J Clin Oncol 21, no. 20 (October 15, 2003): 3814–25. https://doi.org/10.1200/JCO.2003.11.052.Full Text Link to Item
-
Tanyi, J. L., Y. Hasegawa, R. Lapushin, A. J. Morris, J. K. Wolf, A. Berchuck, K. Lu, et al. “Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.” Clinical Cancer Research 9, no. 10 I (October 1, 2003): 3534–45.
-
Wenham, Robert M., Joellen M. Schildkraut, Kia McLean, Brian Calingaert, Rex C. Bentley, Jeffrey Marks, and Andrew Berchuck. “Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.” Clin Cancer Res 9, no. 12 (October 1, 2003): 4396–4403.Link to Item
-
Tanyi, J. L., Y. Hasegawa, R. Lapushin, A. J. Morris, J. K. Wolf, A. Berchuck, K. Lu, et al. “Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.” Clinical Cancer Research 9, no. 10 (September 1, 2003): 3534–45.Link to Item
-
Tanyi, Janos L., Yutaka Hasegawa, Ruth Lapushin, Andrew J. Morris, Judith K. Wolf, Andrew Berchuck, Karen Lu, et al. “Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.” Clin Cancer Res 9, no. 10 Pt 1 (September 1, 2003): 3534–45.Link to Item
-
Wenham, Robert M., Brian Calingaert, Shazia Ali, Kia McClean, Regina Whitaker, Rex Bentley, Johnathan M. Lancaster, Joellen Schildkraut, Jeffrey Marks, and Andrew Berchuck. “Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer.” J Soc Gynecol Investig 10, no. 6 (September 2003): 381–87. https://doi.org/10.1016/s1071-5576(03)00141-2.Full Text Link to Item
-
Havrilesky, Laura J., Bercedis L. Peterson, Damla K. Dryden, John T. Soper, Daniel L. Clarke-Pearson, and Andrew Berchuck. “Predictors of clinical outcomes in the laparoscopic management of adnexal masses.” Obstet Gynecol 102, no. 2 (August 2003): 243–51. https://doi.org/10.1016/s0029-7844(03)00480-0.Full Text Link to Item
-
Jones, Ellen L., Thaddeus V. Samulski, Mark W. Dewhirst, Angeles Alvarez-Secord, Andrew Berchuck, Daniel Clarke-Pearson, Laura J. Havrilesky, John Soper, and Leonard R. Prosnitz. “A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma.” Cancer 98, no. 2 (July 15, 2003): 277–82. https://doi.org/10.1002/cncr.11475.Full Text Link to Item
-
Havrilesky, Laura J., Terence Z. Wong, Angeles Alvarez Secord, Andrew Berchuck, Daniel L. Clarke-Pearson, and Ellen L. Jones. “The role of PET scanning in the detection of recurrent cervical cancer.” Gynecol Oncol 90, no. 1 (July 2003): 186–90. https://doi.org/10.1016/s0090-8258(03)00256-7.Full Text Link to Item
-
Vine, Marilyn F., Brian Calingaert, Andrew Berchuck, and Joellen M. Schildkraut. “Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls.” Gynecol Oncol 90, no. 1 (July 2003): 75–82. https://doi.org/10.1016/s0090-8258(03)00175-6.Full Text Link to Item
-
Brûle, Frédéric van den, Stéphane Califice, Frédérique Garnier, Pedro L. Fernandez, Andrew Berchuck, and Vincent Castronovo. “Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin.” Lab Invest 83, no. 3 (March 2003): 377–86. https://doi.org/10.1097/01.lab.0000059949.01480.40.Full Text Link to Item
-
Lancaster, Johnathan M., Robert M. Wenham, Susan Halabi, Brian Calingaert, Jeffrey R. Marks, Patricia G. Moorman, Rex C. Bentley, Andrew Berchuck, and Joellen M. Schildkraut. “No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.” Cancer Epidemiol Biomarkers Prev 12, no. 3 (March 2003): 226–27.Link to Item
-
Risinger, John I., G Larry Maxwell, Andrew Berchuck, and J Carl Barrett. “Promoter hypermethylation as an epigenetic component in Type I and Type II endometrial cancers.” Ann N Y Acad Sci 983 (March 2003): 208–12. https://doi.org/10.1111/j.1749-6632.2003.tb05975.x.Full Text Link to Item
-
Lancaster, Johnathan M., Robyn Sayer, Carrie Blanchette, Brian Calingaert, Regina Whitaker, Joellen Schildkraut, Jeffrey Marks, and Andrew Berchuck. “High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival.” Clin Cancer Res 9, no. 2 (February 2003): 762–66.Link to Item
-
Gray, Joe W., Seiji Suzuki, Wen-Lin Kuo, Daniel Polikoff, Michael Deavers, Karen Smith-McCune, Andrew Berchuck, Dan Pinkel, Donna Albertson, and Gordon B. Mills. “Specific keynote: genome copy number abnormalities in ovarian cancer.” Gynecol Oncol 88, no. 1 Pt 2 (January 2003): S16–21. https://doi.org/10.1006/gyno.2002.6677.Full Text Link to Item
-
Havrilesky, Laura J., Angeles A. Alvarez, Robyn A. Sayer, Johnathan M. Lancaster, John T. Soper, Andrew Berchuck, Daniel L. Clarke-Pearson, Gustavo C. Rodriguez, and Michael E. Carney. “Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.” Gynecol Oncol 88, no. 1 (January 2003): 51–57. https://doi.org/10.1006/gyno.2002.6859.Full Text Link to Item
-
Lancaster, J. M., L. J. Havrilesky, and A. Berchuck. “The Genetic Etiology of Sporadic Ovarian Cancer,” January 1, 2003, 139–55. https://doi.org/10.1016/B978-012053642-9/50016-8.Full Text
-
Risinger, John I., G Larry Maxwell, G. V. R. Chandramouli, Amir Jazaeri, Olga Aprelikova, Tricia Patterson, Andrew Berchuck, and J Carl Barrett. “Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer.” Cancer Res 63, no. 1 (January 1, 2003): 6–11.Link to Item
-
Moorman, Patricia G., Joellen M. Schildkraut, Brian Calingaert, Susan Halabi, Marilyn F. Vine, and Andrew Berchuck. “Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States).” Cancer Causes Control 13, no. 9 (November 2002): 807–11. https://doi.org/10.1023/a:1020678100977.Full Text Link to Item
-
Wenham, Robert M., Johnathan M. Lancaster, and Andrew Berchuck. “Molecular aspects of ovarian cancer.” Best Pract Res Clin Obstet Gynaecol 16, no. 4 (August 2002): 483–97. https://doi.org/10.1053/beog.2002.0298.Full Text Link to Item
-
Dixon, Darlene, Gordon P. Flake, Alicia B. Moore, Hong He, Joseph K. Haseman, John I. Risinger, Johnathan M. Lancaster, Andrew Berchuck, J Carl Barrett, and Stanley J. Robboy. “Cell proliferation and apoptosis in human uterine leiomyomas and myometria.” Virchows Arch 441, no. 1 (July 2002): 53–62. https://doi.org/10.1007/s00428-001-0568-7.Full Text Link to Item
-
Wenham, R. M., and A. Berchuck. “The molecular biology of Sertoli-Leydig cell tumors of the ovary.” Cme Journal of Gynecologic Oncology 7, no. 2 (July 1, 2002): 121–25.
-
Rodriguez, Gustavo C., Nimesh P. Nagarsheth, Karen L. Lee, Rex C. Bentley, David K. Walmer, Mark Cline, Regina S. Whitaker, et al. “Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta.” J Natl Cancer Inst 94, no. 1 (January 2, 2002): 50–60. https://doi.org/10.1093/jnci/94.1.50.Full Text Link to Item
-
Haaften-Day, C. van, Y. Shen, F. Xu, Y. Yu, A. Berchuck, L. J. Havrilesky, H. W. de Bruijn, A. G. van der Zee, R. C. Bast, and N. F. Hacker. “OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.” Cancer 92, no. 11 (December 1, 2001): 2837–44. https://doi.org/10.1002/1097-0142(20011201)92:11<2837::aid-cncr10093>3.0.co;2-5.Full Text Link to Item
-
Havrilesky, L. J., A. A. Alvarez, R. S. Whitaker, J. R. Marks, and A. Berchuck. “Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.” Gynecol Oncol 83, no. 3 (December 2001): 491–500. https://doi.org/10.1006/gyno.2001.6464.Full Text Link to Item
-
Vine, M. F., R. B. Ness, B. Calingaert, J. M. Schildkraut, and A. Berchuck. “Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor.” Gynecol Oncol 83, no. 3 (December 2001): 466–71. https://doi.org/10.1006/gyno.2001.6411.Full Text Link to Item
-
Stout, J. E., C. W. Woods, A. A. Alvarez, A. Berchuck, and C. Dukes Hamilton. “Mycobacterium bovis peritonitis mimicking ovarian cancer in a young woman.” Clin Infect Dis 33, no. 4 (August 15, 2001): E14–16. https://doi.org/10.1086/321908.Full Text Link to Item
-
Alvarez, A. A., A. R. Lambers, J. M. Lancaster, G. L. Maxwell, S. Ali, C. Gumbs, A. Berchuck, and P. A. Futreal. “Allele loss on chromosome 1p36 in epithelial ovarian cancers.” Gynecol Oncol 82, no. 1 (July 2001): 94–98. https://doi.org/10.1006/gyno.2001.6175.Full Text Link to Item
-
Moorman, P. G., B. Calingaert, M. Vine, S. Halabi, A. Berchuck, and J. M. Schildkraut. “Comparison of two methods for calculating lifetime ovulatory cycles.” American Journal of Epidemiology 153, no. 11 (June 1, 2001): S138–S138.Link to Item
-
Vine, M. F., R. B. Ness, B. Calingaert, J. M. Schildkraut, and A. Berchuck. “Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor.” American Journal of Epidemiology 153, no. 11 (June 1, 2001): S112–S112.Link to Item
-
Lancaster, J. M., J. I. Risinger, M. E. Carney, J. C. Barrett, and A. Berchuck. “Mutational analysis of the PTEN gene in human uterine sarcomas.” Am J Obstet Gynecol 184, no. 6 (May 2001): 1051–53. https://doi.org/10.1067/mob.2001.114508.Full Text Link to Item
-
Havrilesky, L. J., C. P. McMahon, E. K. Lobenhofer, R. Whitaker, J. R. Marks, and A. Berchuck. “Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones.” J Soc Gynecol Investig 8, no. 2 (March 2001): 104–13.Link to Item
-
Maxwell, G. L., J. I. Risinger, A. A. Alvarez, J. C. Barrett, and A. Berchuck. “Favorable survival associated with microsatellite instability in endometrioid endometrial cancers.” Obstet Gynecol 97, no. 3 (March 2001): 417–22. https://doi.org/10.1016/s0029-7844(00)01165-0.Full Text Link to Item
-
Alvarez, A. A., W. F. Moore, S. J. Robboy, R. C. Bentley, C. Gumbs, P. A. Futreal, and A. Berchuck. “K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary.” Gynecol Oncol 80, no. 2 (February 2001): 201–6. https://doi.org/10.1006/gyno.2000.6066.Full Text Link to Item
-
Suzuki, S., D. H. Moore, D. G. Ginzinger, T. E. Godfrey, J. Barclay, B. Powell, D. Pinkel, et al. “An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer.” Cancer Res 60, no. 19 (October 1, 2000): 5382–85.Link to Item
-
Maxwell, G. L., J. I. Risinger, K. A. Hayes, A. A. Alvarez, R. K. Dodge, J. C. Barrett, and A. Berchuck. “Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers.” Clin Cancer Res 6, no. 8 (August 2000): 2999–3005.Link to Item
-
Peng, H., F. Xu, R. Pershad, K. K. Hunt, M. L. Frazier, A. Berchuck, J. W. Gray, D. Hogg, R. C. Bast, and Y. Yu. “ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers.” Int J Cancer 86, no. 5 (June 1, 2000): 690–94. https://doi.org/10.1002/(sici)1097-0215(20000601)86:5<690::aid-ijc14>3.0.co;2-k.Full Text Link to Item
-
Moore, W. F., R. C. Bentley, A. Berchuck, and S. J. Robboy. “Some mullerian inclusion cysts in lymph nodes may sometimes be metastases from serous borderline tumors of the ovary.” Am J Surg Pathol 24, no. 5 (May 2000): 710–18. https://doi.org/10.1097/00000478-200005000-00010.Full Text Link to Item
-
Ahmed, M. N., K. Kim, B. Haddad, A. Berchuck, and M. B. Qumsiyeh. “Comparative genomic hybridization studies in hydatidiform moles and choriocarcinoma: amplification of 7q21-q31 and loss of 8p12-p21 in choriocarcinoma.” Cancer Genet Cytogenet 116, no. 1 (January 1, 2000): 10–15. https://doi.org/10.1016/s0165-4608(99)00103-x.Full Text Link to Item
-
Berchuck, A., and E. Myers. “Letter to the editor.” Gynecol Oncol 76, no. 1 (January 2000): 142–43. https://doi.org/10.1006/gyno.1999.5674.Full Text Link to Item
-
Bösze, P., R. C. Bast, A. Berchuck, H. B. Burke, R. E. Buller, W. T. Creasman, L. Dubeau, et al. “Conseusus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGO.” Eur J Gynaecol Oncol 21, no. 5 (2000): 513–26.Link to Item
-
Schildkraut, J. M., S. Halabi, E. Bastos, P. A. Marchbanks, J. A. McDonald, and A. Berchuck. “Prognostic factors in early-onset epithelial ovarian cancer: a population-based study.” Obstet Gynecol 95, no. 1 (January 2000): 119–27. https://doi.org/10.1016/s0029-7844(99)00535-9.Full Text Link to Item
-
Sevinc, A., S. Buyukberber, and R. Sari. “Elevated serum CA-125 levels: hepatitis or ascites?” Gynecol Oncol 76, no. 1 (January 2000): 141–42. https://doi.org/10.1006/gyno.1999.5670.Full Text Link to Item
-
Berchuck, A., A. Alvarez, and P. A. Futreal. “Prognosis of BRCA1 and 2-associated ovarian cancers.” Cme Journal of Gynecologic Oncology 4, no. 1 (December 1, 1999): 108–11.
-
Berchuck, A., A. Lambers, and J. M. Schildkraut. “Relationship between alterations in the p53 tumor suppressor gene and prognosis of ovarian cancer.” Cme Journal of Gynecologic Oncology 4, no. 2 (December 1, 1999): 215–18.
-
Berchuck, A., J. M. Schildkraut, J. R. Marks, and P. A. Futreal. “Managing hereditary ovarian cancer risk.” Cancer 86, no. 11 Suppl (December 1, 1999): 2517–24. https://doi.org/10.1002/(sici)1097-0142(19991201)86:11+<2517::aid-cncr8>3.0.co;2-b.Full Text Link to Item
-
Zweemer, R. P., A. Berchuck, and I. J. Jacobs. “Somatic genetic events in BRCA1 and BRCA2-related ovarian cancer.” Cme Journal of Gynecologic Oncology 4, no. 1 (December 1, 1999): 112–15.
-
Ashih, H., T. Gustilo-Ashby, E. R. Myers, J. Andrews, D. L. Clarke-Pearson, D. Berry, and A. Berchuck. “Cost-effectiveness of treatment of early stage endometrial cancer.” Gynecol Oncol 74, no. 2 (August 1999): 208–16. https://doi.org/10.1006/gyno.1999.5427.Full Text Link to Item
-
Brown, M. R., R. Chuaqui, C. D. Vocke, A. Berchuck, L. P. Middleton, M. R. Emmert-Buck, and E. C. Kohn. “Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors.” Gynecol Oncol 74, no. 1 (July 1999): 98–102. https://doi.org/10.1006/gyno.1999.5439.Full Text Link to Item
-
Lambers, A. R., C. Gumbs, S. Ali, J. R. Marks, J. D. Iglehart, A. Berchuck, and P. A. Futreal. “Bcl10 is not a target for frequent mutation in human carcinomas.” Br J Cancer 80, no. 10 (July 1999): 1575–76. https://doi.org/10.1038/sj.bjc.6690564.Full Text Link to Item
-
Zweemer, R. P., P. A. Shaw, R. M. Verheijen, A. Ryan, A. Berchuck, B. A. Ponder, H. Risch, et al. “Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.” J Clin Pathol 52, no. 5 (May 1999): 372–75. https://doi.org/10.1136/jcp.52.5.372.Full Text Link to Item
-
Zhang, Z., S. D. Barnhill, H. Zhang, F. Xu, Y. Yu, I. Jacobs, R. P. Woolas, A. Berchuck, K. R. Madyastha, and R. C. Bast. “Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses.” Gynecol Oncol 73, no. 1 (April 1999): 56–61. https://doi.org/10.1006/gyno.1999.5320.Full Text Link to Item
-
Berchuck, A., M. E. Carney, and P. A. Futreal. “Genetic susceptibility testing and prophylactic oophorectomy.” Eur J Obstet Gynecol Reprod Biol 82, no. 2 (February 1999): 159–64. https://doi.org/10.1016/s0301-2115(98)00220-6.Full Text Link to Item
-
Berchuck, A., J. M. Schildkraut, J. R. Marks, and P. A. Futreal. “Managing hereditary ovarian cancer risk.” Cancer 86, no. 8 SUPPL. (1999): 1697–1704.
-
Moore, W. F., A. Berchuck, and S. J. Robboy. “Mullerian inclusion cysts - Possible metastases of serous borderline tumors of the ovary.” Laboratory Investigation 79, no. 1 (January 1, 1999): 120A-120A.Link to Item
-
Heijden, O. van der, H. C. Chiu, T. C. Park, H. Takahashi, V. A. LiVolsi, J. I. Risinger, J. C. Barrett, et al. “Allelotype analysis of uterine leiomyoma: localization of a potential tumor suppressor gene to a 4-cM region of chromosome 7q.” Mol Carcinog 23, no. 4 (December 1998): 243–47. https://doi.org/10.1002/(sici)1098-2744(199812)23:4<243::aid-mc7>3.0.co;2-e.Full Text Link to Item
-
Maxwell, G. L., J. I. Risinger, H. Shaw, A. Alvarez, J. C. Barrett, P. A. Futreal, and A. Berchuck. “Mutations in the PTEN tumor suppressor gene in cervical carcinomas.” International Journal of Gynecological Cancer 8, no. 6 (December 1, 1998): 489–93. https://doi.org/10.1046/j.1525-1438.1998.98102.x.Full Text
-
Risinger, J. I., K. Hayes, G. L. Maxwell, M. E. Carney, R. K. Dodge, J. C. Barrett, and A. Berchuck. “PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics.” Clin Cancer Res 4, no. 12 (December 1998): 3005–10.Link to Item
-
Berchuck, A., K. A. Heron, M. E. Carney, J. M. Lancaster, E. G. Fraser, V. L. Vinson, A. M. Deffenbaugh, et al. “Frequency of germline and somatic BRCA1 mutations in ovarian cancer.” Clin Cancer Res 4, no. 10 (October 1998): 2433–37.Link to Item
-
Carney, M. E., G. L. Maxwell, J. M. Lancaster, C. Gumbs, J. Marks, A. Berchuck, and P. A. Futreal. “Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers.” Journal of the Society for Gynecologic Investigation 5, no. 5 (September 1998): 281–85. https://doi.org/10.1016/s1071-5576(98)00018-5.Full Text
-
Bast, R. C., L. Pusztai, B. J. Kerns, J. A. MacDonald, P. Jordan, L. Daly, C. M. Boyer, J. Mendelsohn, and A. Berchuck. “Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues.” Hybridoma 17, no. 4 (August 1998): 313–21. https://doi.org/10.1089/hyb.1998.17.313.Full Text
-
Boente, M. P., A. Berchuck, R. S. Whitaker, A. Kalén, F. J. Xu, D. L. Clarke-Pearson, R. M. Bell, and R. C. Bast. “Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines.” Gynecologic Oncology 70, no. 1 (July 1998): 49–55. https://doi.org/10.1006/gyno.1998.5050.Full Text
-
Lancaster, J. M., A. Berchuck, M. E. Carney, R. Wiseman, and J. A. Taylor. “Progesterone receptor gene polymorphism and risk for breast and ovarian cancer.” Br J Cancer 78, no. 2 (July 1998): 277. https://doi.org/10.1038/bjc.1998.480.Full Text Link to Item
-
Maxwell, G. L., J. I. Risinger, B. Tong, H. Shaw, J. C. Barrett, A. Berchuck, and P. A. Futreal. “Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.” Gynecologic Oncology 70, no. 1 (July 1998): 13–16. https://doi.org/10.1006/gyno.1998.5039.Full Text
-
Maxwell, G. L., J. I. Risinger, C. Gumbs, H. Shaw, R. C. Bentley, J. C. Barrett, A. Berchuck, and P. A. Futreal. “Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias.” Cancer Res 58, no. 12 (June 15, 1998): 2500–2503.Link to Item
-
Arrigo, L., Y. Pierre, A. Berchuck, D. L. Morris, K. K. Yeung, and D. L. Very. “The Bayer Immuno 1 (TM) CA 125 II (TM) assay: An automated assay for the clinical management of ovarian cancer patients.” Clinical Chemistry 44 (June 1, 1998): A44–A44.Link to Item
-
Berchuck, A. “Molecular genetics of hereditary ovarian cancer - The Boyd article reviewed.” Oncology New York 12, no. 3 (March 1, 1998): 410-+.Link to Item
-
Berchuck, A., M. Carney, J. M. Lancaster, J. Marks, and A. P. Futreal. “Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2.” Clin Obstet Gynecol 41, no. 1 (March 1998): 157–66. https://doi.org/10.1097/00003081-199803000-00022.Full Text Link to Item
-
Young, S. R., W. H. Liu, and A. Berchuck. “Dual-color FISH studies of HER2/neu and centromere 17 in archived paraffin-embedded ovarian cancer samples.” Cytogenetics and Cell Genetics 82, no. 1–2 (January 1, 1998): 136–37.Link to Item
-
Layfield, L. J., E. A. Saria, A. Berchuck, R. K. Dodge, J. K. Thompson, D. H. Conlon, and B. J. Kerns. “Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis.” Journal of Surgical Oncology 66, no. 4 (December 1997): 230–36. https://doi.org/10.1002/(sici)1096-9098(199712)66:4<230::aid-jso2>3.0.co;2-c.Full Text
-
Schildkraut, J. M., E. Bastos, S. Halabi, and A. Berchuck. “Response.” Jnci Journal of the National Cancer Institute 89, no. 22 (November 19, 1997): 1727–1727. https://doi.org/10.1093/jnci/89.22.1727.Full Text
-
Berchuck, A., and J. Schildkraut. “Oral contraceptive pills. Prevention of ovarian cancer and other benefits.” N C Med J 58, no. 6 (November 1997): 404–7.Link to Item
-
Choi, C., S. Cho, I. Horikawa, A. Berchuck, N. Wang, E. Cedrone, S. W. Jhung, et al. “Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas.” Genes Chromosomes Cancer 20, no. 3 (November 1997): 234–42.Link to Item
-
Risinger, J. I., A. K. Hayes, A. Berchuck, and J. C. Barrett. “PTEN/MMAC1 mutations in endometrial cancers.” Cancer Res 57, no. 21 (November 1, 1997): 4736–38.Link to Item
-
Berchuck, A., and M. Carney. “Human ovarian cancer of the surface epithelium.” Biochem Pharmacol 54, no. 5 (September 1, 1997): 541–44. https://doi.org/10.1016/s0006-2952(97)00061-0.Full Text Link to Item
-
Packenham, J. P., S. du Manoir, E. Schrock, J. I. Risinger, D. Dixon, D. N. Denz, J. A. Evans, et al. “Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization.” Mol Carcinog 19, no. 4 (August 1997): 273–79. https://doi.org/10.1002/(sici)1098-2744(199708)19:4<273::aid-mc9>3.0.co;2-d.Full Text Link to Item
-
Lancaster, J. M., A. Berchuck, P. A. Futreal, and R. W. Wiseman. “Dideoxy fingerprinting assay for BRCA1 mutation analysis.” Mol Carcinog 19, no. 3 (July 1997): 176–79.Link to Item
-
Schildkraut, J. M., E. Bastos, and A. Berchuck. “Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer.” Journal of the National Cancer Institute 89, no. 13 (July 1997): 932–38. https://doi.org/10.1093/jnci/89.13.932.Full Text
-
Clifford, S. L., C. P. Kaminetsky, F. D. Cirisano, R. Dodge, J. T. Soper, D. L. Clarke-Pearson, and A. Berchuck. “Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer.” American Journal of Obstetrics and Gynecology 176, no. 6 (June 1997): S229–32. https://doi.org/10.1016/s0002-9378(97)70380-6.Full Text
-
Mooney, E. E., S. J. Robboy, C. B. Hammond, A. Berchuck, and R. C. Bentley. “Signet-ring cell carcinoma of the endometrium: a primary tumor masquerading as a metastasis.” Int J Gynecol Pathol 16, no. 2 (April 1997): 169–72. https://doi.org/10.1097/00004347-199704000-00014.Full Text Link to Item
-
Berchuck, A. “Endometrial carcinoma and its precursors.” Curr Ther Endocrinol Metab 6 (1997): 599–602.Link to Item
-
Berchuck, A., and F. Cirisano. “Genetics of ovarian cancer.” Endocrinologist 7, no. 2 (January 1, 1997): 103–6. https://doi.org/10.1097/00019616-199707020-00006.Full Text
-
Brule, F. A. van den, C. Buicu, A. Berchuck, R. C. Bast, M. Deprez, F. T. Liu, D. N. Cooper, C. Pieters, M. E. Sobel, and V. Castronovo. “Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma.” Hum Pathol 27, no. 11 (November 1996): 1185–91. https://doi.org/10.1016/s0046-8177(96)90313-5.Full Text Link to Item
-
Kohler, M. F., P. Carney, R. Dodge, J. T. Soper, D. L. Clarke-Pearson, J. R. Marks, and A. Berchuck. “p53 overexpression in advanced-stage endometrial adenocarcinoma.” Am J Obstet Gynecol 175, no. 5 (November 1996): 1246–52. https://doi.org/10.1016/s0002-9378(96)70036-4.Full Text Link to Item
-
Lancaster, J. M., H. A. Brownlee, D. A. Bell, P. A. Futreal, J. R. Marks, A. Berchuck, R. W. Wiseman, and J. A. Taylor. “Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer.” Mol Carcinog 17, no. 3 (November 1996): 160–62. https://doi.org/10.1002/(SICI)1098-2744(199611)17:3<160::AID-MC8>3.0.CO;2-J.Full Text Link to Item
-
Rubin, S. C., I. Benjamin, K. Behbakht, H. Takahashi, M. A. Morgan, V. A. LiVolsi, A. Berchuck, et al. “Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.” The New England Journal of Medicine 335, no. 19 (November 1996): 1413–16. https://doi.org/10.1056/nejm199611073351901.Full Text
-
Vaughn, J. P., F. D. Cirisano, G. Huper, A. Berchuck, P. A. Futreal, J. R. Marks, and J. D. Iglehart. “Cell cycle control of BRCA2.” Cancer Res 56, no. 20 (October 15, 1996): 4590–94.Link to Item
-
Berchuck, A., F. Cirisano, J. M. Lancaster, J. M. Schildkraut, R. W. Wiseman, A. Futreal, and J. R. Marks. “Role of BRCA1 mutation screening in the management of familial ovarian cancer.” Am J Obstet Gynecol 175, no. 3 Pt 1 (September 1996): 738–46. https://doi.org/10.1053/ob.1996.v175.a74288.Full Text Link to Item
-
Berchuck, A., F. Cirisano, J. M. Lancaster, J. M. Schildkraut, R. W. Wiseman, A. Futreal, and J. R. Marks. “Role of BRCA1 mutation screening in the management of familial ovarian cancer.” American Journal of Obstetrics and Gynecology 175, no. 3 (September 1996): 738–46.Link to Item
-
Elbendary, A. A., F. D. Cirisano, A. C. Evans, P. L. Davis, J. D. Iglehart, J. R. Marks, and A. Berchuck. “Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 2, no. 9 (September 1996): 1571–75.
-
Risinger, J. I., A. Umar, J. Boyd, A. Berchuck, T. A. Kunkel, and J. C. Barrett. “Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair.” Nature Genetics 14, no. 1 (September 1996): 102–5. https://doi.org/10.1038/ng0996-102.Full Text
-
Terry, L. A., J. Boyd, D. Alcorta, T. Lyon, G. Solomon, G. Hannon, A. Berchuck, D. Beach, and J. C. Barrett. “Mutational analysis of the p21/WAF1/CIP1/SDI1 coding region in human tumor cell lines.” Mol Carcinog 16, no. 4 (August 1996): 221–28. https://doi.org/10.1002/(SICI)1098-2744(199608)16:4<221::AID-MC6>3.0.CO;2-I.Full Text Link to Item
-
Lancaster, J. M., R. Wooster, J. Mangion, C. M. Phelan, C. Cochran, C. Gumbs, S. Seal, et al. “BRCA2 mutations in primary breast and ovarian cancers.” Nat Genet 13, no. 2 (June 1996): 238–40. https://doi.org/10.1038/ng0696-238.Full Text Link to Item
-
Vaughn, J. P., P. L. Davis, M. D. Jarboe, G. Huper, A. C. Evans, R. W. Wiseman, A. Berchuck, J. D. Iglehart, P. A. Futreal, and J. R. Marks. “BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells.” Cell Growth Differ 7, no. 6 (June 1996): 711–15.Link to Item
-
Lancaster, J. M., C. J. Cochran, H. A. Brownlee, A. C. Evans, A. Berchuck, P. A. Futreal, and R. W. Wiseman. “Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test.” J Natl Cancer Inst 88, no. 8 (April 17, 1996): 552–54. https://doi.org/10.1093/jnci/88.8.552.Full Text Link to Item
-
Olt, G., J. Soper, S. Ramakrishnan, F. Xu, A. Berchuck, D. Clarke-Pearson, R. Dodge, and R. C. Bast. “Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer.” American Journal of Obstetrics and Gynecology 174, no. 4 (April 1996): 1316–19. https://doi.org/10.1016/s0002-9378(96)70678-6.Full Text
-
Boente, M. P., T. C. Hamilton, A. K. Godwin, K. Buetow, M. F. Kohler, W. M. Hogan, A. Berchuck, and R. C. Young. “Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment.” Curr Probl Cancer 20, no. 2 (March 1996): 83–137.Link to Item
-
Lancaster, J. M., R. W. Wiseman, and A. Berchuck. “An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene.” Obstetrics and Gynecology 87, no. 2 (February 1996): 306–9. https://doi.org/10.1016/0029-7844(95)00405-x.Full Text
-
Berchuck, A., M. F. Kohler, and R. C. Bast. “Molecular genetic features of ovarian cancer.” Prog Clin Biol Res 394 (1996): 269–84.Link to Item
-
Boente, M. P., A. K. Godwin, M. F. Kohler, A. Berchuck, T. C. Hamilton, K. Buetow, W. Michael Hogan, and R. C. Young. “Early ovarian cancer: A review of ITS genetic and biologic factors, detection, and treatment.” Current Problems in Cancer 20, no. 2 (January 1, 1996): 86–137. https://doi.org/10.1016/S0147-0272(96)80005-5.Full Text
-
Fayed, S., S. Wu, Y. Lidor, M. Super, A. Berchuck, J. Bast, and J. R. Wiener. “Detection and partial purification of a 30 kDa ovarian carcinoma-associated protein.” Cancer Molecular Biology 3, no. 5 (January 1, 1996): 915–26.
-
Hussein, A. M., W. P. Petros, M. Ross, J. J. Vredenburgh, M. L. Affrontil, R. B. Jones, E. J. Shpall, et al. “A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies.” Cancer Chemother Pharmacol 37, no. 6 (1996): 561–68. https://doi.org/10.1007/s002800050429.Full Text Link to Item
-
Risinger, J. I., A. Umar, J. C. Boyer, A. C. Evans, A. Berchuck, T. A. Kunkel, and J. C. Barrett. “Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity.” Cancer Res 55, no. 23 (December 1, 1995): 5664–69.Link to Item
-
Soper, J. T., D. L. Clarke-Pearson, A. Berchuck, G. Rodriguez, and C. B. Hammond. “5-Day methotrexate for women with metastatic gestational trophoblastic disease.” Acog Current Journal Review 8, no. 1 (December 1, 1995).
-
Berchuck, A., and J. Boyd. “Molecular basis of endometrial cancer.” Cancer 76, no. 10 Suppl (November 1995): 2034–40. https://doi.org/10.1002/1097-0142(19951115)76:10+<2034::aid-cncr2820761321>3.0.co;2-u.Full Text
-
Berchuck, A., and R. C. Bast. “p53-based gene therapy of ovarian cancer: magic bullet?” Gynecol Oncol 59, no. 2 (November 1995): 169–70. https://doi.org/10.1006/gyno.1995.0001.Full Text Link to Item
-
Evans, A. C., J. T. Soper, D. L. Clarke-Pearson, A. Berchuck, G. C. Rodriguez, and C. B. Hammond. “Gestational trophoblastic disease metastatic to the central nervous system.” Gynecol Oncol 59, no. 2 (November 1995): 226–30. https://doi.org/10.1006/gyno.1995.0013.Full Text Link to Item
-
Hurteau, J. A., R. P. Woolas, I. J. Jacobs, D. C. Oram, C. C. Kurman, L. A. Rubin, D. L. Nelson, A. Berchuck, R. C. Bast, and G. B. Mills. “Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.” Cancer 76, no. 9 (November 1995): 1615–20. https://doi.org/10.1002/1097-0142(19951101)76:9<1615::aid-cncr2820760918>3.0.co;2-g.Full Text
-
LoCoco, S., A. Covens, M. Carney, E. Franssen, R. Dogde, B. Rosen, R. Osborne, I. Kerr, R. Buckman, and J. Soper. “Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study.” Gynecol Oncol 59, no. 2 (November 1995): 194–99. https://doi.org/10.1006/gyno.1995.0007.Full Text Link to Item
-
Berchuck, A., C. Anspach, A. C. Evans, J. T. Soper, G. C. Rodriguez, R. Dodge, S. Robboy, and D. L. Clarke-Pearson. “Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma.” Gynecologic Oncology 59, no. 1 (October 1995): 20–24. https://doi.org/10.1006/gyno.1995.1262.Full Text
-
FUTRCAL, P. A., C. GUMBS, A. BERCHUCK, and R. W. WISEMAN. “FREQUENT ALLELIC DELETION OF CHROMOSOME 1P IN PRIMARY OVARIAN-CANCER - MAPPING OF 2 TUMOR SUPRESSOR GENE REGIONS AND PRELIMINARY-ANALYSIS OF CANDIDATE GENES.” American Journal of Human Genetics 57, no. 4 (October 1, 1995): 11–11.Link to Item
-
Liu, J. R., M. Conaway, G. C. Rodriguez, J. T. Soper, D. L. Clarke-Pearson, and A. Berchuck. “Relationship between race and interval to treatment in endometrial cancer.” Obstetrics and Gynecology 86, no. 4 Pt 1 (October 1995): 486–90. https://doi.org/10.1016/0029-7844(95)00238-m.Full Text
-
Woolas, R. P., M. R. Conaway, F. Xu, I. J. Jacobs, Y. Yu, L. Daly, A. P. Davies, K. O’Briant, A. Berchuck, and J. T. Soper. “Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses.” Gynecol Oncol 59, no. 1 (October 1995): 111–16. https://doi.org/10.1006/gyno.1995.1276.Full Text Link to Item
-
Kohler, M. F., A. Berkholz, J. I. Risinger, A. Elbendary, J. Boyd, and A. Berchuck. “Mutational analysis of the estrogen-receptor gene in endometrial carcinoma.” Obstetrics and Gynecology 86, no. 1 (July 1995): 33–37. https://doi.org/10.1016/0029-7844(95)00113-6.Full Text
-
Havrilesky, L. J., A. Elbendary, J. A. Hurteau, R. S. Whitaker, G. C. Rodriguez, and A. Berchuck. “Chemotherapy-induced apoptosis in epithelial ovarian cancers.” Obstetrics and Gynecology 85, no. 6 (June 1995): 1007–10. https://doi.org/10.1016/0029-7844(95)00058-y.Full Text
-
Lessey, B. A., S. Albelda, C. A. Buck, A. J. Castelbaum, I. Yeh, M. Kohler, and A. Berchuck. “Distribution of integrin cell adhesion molecules in endometrial cancer.” Am J Pathol 146, no. 3 (March 1995): 717–26.Link to Item
-
Schildkraut, J. M., N. K. Collins, G. A. Dent, J. A. Tucker, J. C. Barrett, A. Berchuck, and J. Boyd. “Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer.” American Journal of Obstetrics and Gynecology 172, no. 3 (March 1995): 908–13. https://doi.org/10.1016/0002-9378(95)90020-9.Full Text
-
Soper, J. T., A. C. Evans, G. Rodriguez, A. Berchuck, D. L. Clarke-Pearson, and C. B. Hammond. “Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease.” Gynecologic Oncology 56, no. 3 (March 1995): 421–24. https://doi.org/10.1006/gyno.1995.1074.Full Text
-
Havrilesky, L. J., J. A. Hurteau, R. S. Whitaker, A. Elbendary, S. Wu, G. C. Rodriguez, R. C. Bast, and A. Berchuck. “Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta.” Cancer Res 55, no. 4 (February 15, 1995): 944–48.Link to Item
-
Soper, J. T., G. Rodriguez, A. Berchuck, and D. L. Clarke-Pearson. “Long and short gracilis myocutaneous flaps for vulvovaginal reconstruction after radical pelvic surgery: comparison of flap-specific complications.” Gynecol Oncol 56, no. 2 (February 1995): 271–75. https://doi.org/10.1006/gyno.1995.1045.Full Text Link to Item
-
Bast, R. C., C. M. Boyer, F. J. Xu, J. Wiener, R. Dabel, R. Woolas, I. Jacobs, and A. Berchuck. “Molecular approaches to prevention and detection of epithelial ovarian cancer.” J Cell Biochem Suppl 23 (1995): 219–22. https://doi.org/10.1002/jcb.240590929.Full Text Link to Item
-
Berchuck, A. “Biomarkers in the endometrium.” J Cell Biochem Suppl 23 (1995): 174–78. https://doi.org/10.1002/jcb.240590923.Full Text Link to Item
-
Berchuck, A. “Biomarkers in the ovary.” Journal of Cellular Biochemistry. Supplement 23 (January 1995): 223–26.
-
Liu, J. R., M. Conaway, G. C. Rodriguez, J. T. Soper, D. L. Clarke-Pearson, and A. Berchuck. “Relationship between race and interval to treatment in endometrial cancer.” Obstetrics and Gynecology 86, no. 4 PART 1 (January 1, 1995): 486–90. https://doi.org/10.1016/S0029-7844(95)80002-6.Full Text
-
Elbendary, A., A. Berchuck, P. Davis, L. Havrilesky, R. C. Bast, J. D. Iglehart, and J. R. Marks. “Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.” Cell Growth & Differentiation : The Molecular Biology Journal of the American Association for Cancer Research 5, no. 12 (December 1994): 1301–7.
-
Soper, J. T., A. C. Evans, M. R. Conaway, D. L. Clarke-Pearson, A. Berchuck, and C. B. Hammond. “Evaluation of prognostic factors and staging in gestational trophoblastic tumor.” Obstet Gynecol 84, no. 6 (December 1994): 969–73.Link to Item
-
Rodriguez, G. C., C. L. Hughes, J. T. Soper, A. Berchuck, D. L. Clarke-Pearson, and C. B. Hammond. “Serum progesterone for the exclusion of early pregnancy in women at risk for recurrent gestational trophoblastic neoplasia.” Obstetrics and Gynecology 84, no. 5 (November 1994): 794–97.
-
Futreal, P. A., Q. Liu, D. Shattuck-Eidens, C. Cochran, K. Harshman, S. Tavtigian, L. M. Bennett, A. Haugen-Strano, J. Swensen, and Y. Miki. “BRCA1 mutations in primary breast and ovarian carcinomas.” Science 266, no. 5182 (October 7, 1994): 120–22. https://doi.org/10.1126/science.7939630.Full Text Link to Item
-
Fujino, T., J. I. Risinger, N. K. Collins, F. S. Liu, H. Nishii, H. Takahashi, E. M. Westphal, J. C. Barrett, H. Sasaki, and M. F. Kohler. “Allelotype of endometrial carcinoma.” Cancer Res 54, no. 16 (August 15, 1994): 4294–98.Link to Item
-
Berchuck, A., A. Elbendary, L. Havrilesky, G. C. Rodriguez, and R. C. Bast. “Pathogenesis of ovarian cancers.” Journal of the Society for Gynecologic Investigation 1, no. 3 (July 1994): 181–90. https://doi.org/10.1177/107155769400100302.Full Text
-
Hurteau, J., G. C. Rodriguez, R. S. Whitaker, S. Shah, G. Mills, R. C. Bast, and A. Berchuck. “Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites.” Cancer 74, no. 1 (July 1, 1994): 93–99. https://doi.org/10.1002/1097-0142(19940701)74:1<93::aid-cncr2820740117>3.0.co;2-p.Full Text Link to Item
-
Soper, J. T., D. L. Clarke-Pearson, A. Berchuck, G. Rodriguez, and C. B. Hammond. “5-day methotrexate for women with metastatic gestational trophoblastic disease.” Gynecologic Oncology 54, no. 1 (July 1994): 76–79. https://doi.org/10.1006/gyno.1994.1169.Full Text
-
Lukes, A. S., M. F. Kohler, C. F. Pieper, B. J. Kerns, R. Bentley, G. C. Rodriguez, J. T. Soper, D. L. Clarke-Pearson, R. C. Bast, and A. Berchuck. “Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.” Cancer 73, no. 9 (May 1, 1994): 2380–85. https://doi.org/10.1002/1097-0142(19940501)73:9<2380::aid-cncr2820730922>3.0.co;2-g.Full Text Link to Item
-
Risinger, J. I., A. Berchuck, M. F. Kohler, and J. Boyd. “Mutations of the E-cadherin gene in human gynecologic cancers.” Nat Genet 7, no. 1 (May 1994): 98–102. https://doi.org/10.1038/ng0594-98.Full Text Link to Item
-
Wiener, J. R., J. A. Hurteau, B. J. Kerns, R. S. Whitaker, M. R. Conaway, A. Berchuck, and R. C. Bast. “Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas.” Am J Obstet Gynecol 170, no. 4 (April 1994): 1177–83. https://doi.org/10.1016/s0002-9378(94)70118-0.Full Text Link to Item
-
Wu, S., W. A. Meeker, J. R. Wiener, A. Berchuck, R. C. Bast, and C. M. Boyer. “Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-alpha) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-alpha.” Gynecol Oncol 53, no. 1 (April 1994): 59–63. https://doi.org/10.1006/gyno.1994.1088.Full Text Link to Item
-
Xu, F. J., Y. H. Yu, L. Daly, L. Anselmino, G. M. Hass, A. Berchuck, G. C. Rodriguez, J. T. Soper, D. L. Clarke-Pearson, and D. Hollis. “OVX1 as a marker for early stage endometrial carcinoma.” Cancer 73, no. 7 (April 1994): 1855–58. https://doi.org/10.1002/1097-0142(19940401)73:7<1855::aid-cncr2820730713>3.0.co;2-#.Full Text
-
Myers, E. R., D. L. Clarke-Pearson, G. J. Olt, J. T. Soper, and A. Berchuck. “Preoperative coagulation testing on a gynecologic oncology service.” Obstetrics and Gynecology 83, no. 3 (March 1994): 438–44.
-
Rodriguez, G. C., D. L. Clarke-Pearson, J. T. Soper, A. Berchuck, I. Synan, and R. K. Dodge. “The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer.” Obstetrics and Gynecology 83, no. 3 (March 1994): 445–48.
-
Wiener, J. R., B. J. Kerns, E. L. Harvey, M. R. Conaway, J. D. Iglehart, A. Berchuck, and R. C. Bast. “Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression.” Journal of the National Cancer Institute 86, no. 5 (March 1994): 372–78. https://doi.org/10.1093/jnci/86.5.372.Full Text
-
Berchuck, A., M. F. Kohler, M. P. Hopkins, P. A. Humphrey, S. J. Robboy, G. C. Rodriguez, J. T. Soper, D. L. Clarke-Pearson, and R. C. Bast. “Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.” Gynecol Oncol 52, no. 2 (February 1994): 232–36. https://doi.org/10.1006/gyno.1994.1037.Full Text Link to Item
-
Kerns, B. J., P. A. Jordan, L. L. Faerman, A. Berchuck, R. C. Bast, and L. J. Layfield. “Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis.” Am J Clin Pathol 101, no. 2 (February 1994): 192–97. https://doi.org/10.1093/ajcp/101.2.192.Full Text Link to Item
-
BERCHUCK, A., M. F. KOHLER, J. R. MARKS, R. WISEMAN, J. BOYD, and R. C. BAST. “THE P53 TUMOR-SUPPRESSOR GENE FREQUENTLY IS ALTERED IN GYNECOLOGIC CANCERS.” American Journal of Obstetrics and Gynecology 170, no. 1 (January 1994): 246–52.Link to Item
-
Bast, R. C., F. Xu, Y. Yu, J. Crews, Y. Argon, L. Maier, Y. Lidor, A. Berchuck, and C. M. Boyer. “Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer.” Immunology Series 61 (January 1994): 23–30.
-
Berchuck, A., M. F. Kohler, J. R. Marks, R. Wiseman, J. Boyd, and R. C. Bast. “The p53 tumor suppressor gene frequently is altered in gynecologic cancers.” Am J Obstet Gynecol 170, no. 1 Pt 1 (January 1994): 246–52. https://doi.org/10.1016/s0002-9378(94)70414-7.Full Text Link to Item
-
Brûle, F. A. van den, A. Berchuck, R. C. Bast, F. T. Liu, C. Gillet, M. E. Sobel, and V. Castronovo. “Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas.” Eur J Cancer 30A, no. 8 (1994): 1096–99. https://doi.org/10.1016/0959-8049(94)90464-2.Full Text Link to Item
-
Liu, F. S., M. F. Kohler, J. R. Marks, R. C. Bast, J. Boyd, and A. Berchuck. “Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.” Obstetrics and Gynecology 83, no. 1 (January 1994): 118–24.
-
Secord, A. A., R. Sayer, S. A. Snyder, G. Broadwater, G. C. Rodriguez, A. Berchuck, and K. Blackwell. “Second-look laparotomy in ovarian cancer.” Gynecologic Oncology 55, no. 3 (January 1, 1994): S122–27. https://doi.org/10.1006/gyno.1994.1350.Full Text
-
Soper, J. T., A. C. Evans, D. L. Clarke-Pearson, A. Berchuck, G. Rodriguez, and C. B. Hammond. “Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease.” Obstetrics and Gynecology 83, no. 1 (January 1994): 113–17.
-
Berchuck, A., and R. K. Dodge. “Interval to treatment in endometrial cancer.” Am J Obstet Gynecol 169, no. 6 (December 1993): 1655–56. https://doi.org/10.1016/0002-9378(93)90461-q.Full Text Link to Item
-
Leopold, K. A., J. R. Oleson, D. Clarke-Pearson, J. Soper, A. Berchuck, T. V. Samulski, R. L. Page, J. Blivin, J. K. Tomberlin, and M. W. Dewhirst. “Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma.” International Journal of Radiation Oncology, Biology, Physics 27, no. 5 (December 1993): 1245–51. https://doi.org/10.1016/0360-3016(93)90550-f.Full Text
-
Soisson, A. P., G. Olt, J. T. Soper, A. Berchuck, G. Rodriguez, and D. L. Clarke-Pearson. “Prevention of superficial wound separation with subcutaneous retention sutures.” Gynecologic Oncology 51, no. 3 (December 1993): 330–34. https://doi.org/10.1006/gyno.1993.1299.Full Text
-
Woolas, R. P., F. J. Xu, I. J. Jacobs, Y. H. Yu, L. Daly, A. Berchuck, J. T. Soper, D. L. Clarke-Pearson, D. H. Oram, and R. C. Bast. “Elevation of multiple serum markers in patients with stage I ovarian cancer.” J Natl Cancer Inst 85, no. 21 (November 3, 1993): 1748–51. https://doi.org/10.1093/jnci/85.21.1748.Full Text Link to Item
-
Risinger, J. I., A. Berchuck, M. F. Kohler, P. Watson, H. T. Lynch, and J. Boyd. “Genetic instability of microsatellites in endometrial carcinoma.” Cancer Res 53, no. 21 (November 1, 1993): 5100–5103.Link to Item
-
WOOLAS, R., F. J. XU, L. DALY, J. T. SOPER, A. BERCHUCK, G. RODRIGUEZ, D. L. CLARKEPEARSON, C. M. BOYER, and R. C. BAST. “SCREENING STRATEGIES FOR OVARIAN-CANCER.” Diagnostic Oncology 3, no. 6 (November 1, 1993): 287–93.Link to Item
-
BOYD, J., M. F. KOHLER, A. BERCHUCK, P. WATSON, H. T. LYNCH, and J. I. RISINGER. “MICROSATELLITE INSTABILITY IN SPORADIC ENDOMETRIAL CARCINOMAS AND THOSE ASSOCIATED WITH HNPCC.” American Journal of Human Genetics 53, no. 3 (September 1, 1993): 22–22.Link to Item
-
Boente, M. P., J. Hurteau, G. C. Rodriguez, R. C. Bast, and A. Berchuck. “The biology of ovarian cancer.” Curr Opin Oncol 5, no. 5 (September 1993): 900–907. https://doi.org/10.1097/00001622-199309000-00020.Full Text Link to Item
-
Kohler, M. F., H. Nishii, P. A. Humphrey, H. Saski, J. Marks, R. C. Bast, D. L. Clarke-Pearson, J. Boyd, and A. Berchuck. “Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias.” American Journal of Obstetrics and Gynecology 169, no. 3 (September 1993): 690–94. https://doi.org/10.1016/0002-9378(93)90644-x.Full Text
-
Kohler, M. F., J. R. Marks, R. W. Wiseman, I. J. Jacobs, A. M. Davidoff, D. L. Clarke-Pearson, J. T. Soper, R. C. Bast, and A. Berchuck. “Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer.” Journal of the National Cancer Institute 85, no. 18 (September 1993): 1513–19. https://doi.org/10.1093/jnci/85.18.1513.Full Text
-
Lidor, Y. J., F. J. Xu, O. Martínez-Maza, G. J. Olt, J. R. Marks, A. Berchuck, S. Ramakrishnan, J. S. Berek, and R. C. Bast. “Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells.” Exp Cell Res 207, no. 2 (August 1993): 332–39. https://doi.org/10.1006/excr.1993.1200.Full Text Link to Item
-
Xu, F. J., Y. H. Yu, L. Daly, K. DeSombre, L. Anselmino, G. M. Hass, A. Berchuck, J. T. Soper, D. L. Clarke-Pearson, and C. Boyer. “OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 11, no. 8 (August 1993): 1506–10. https://doi.org/10.1200/jco.1993.11.8.1506.Full Text
-
Jordan, P. A., B. J. Kerns, J. C. Pence, M. F. Kohler, R. C. Bast, R. B. Kinney, and A. Berchuck. “Determination of proliferation index in advanced ovarian cancer using quantitative image analysis.” Am J Clin Pathol 99, no. 6 (June 1993): 736–40. https://doi.org/10.1093/ajcp/99.6.736.Full Text Link to Item
-
McKenzie, S. J., K. A. DeSombre, B. S. Bast, D. R. Hollis, R. S. Whitaker, A. Berchuck, C. M. Boyer, and R. C. Bast. “Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer.” Cancer 71, no. 12 (June 1993): 3942–46. https://doi.org/10.1002/1097-0142(19930615)71:12<3942::aid-cncr2820711224>3.0.co;2-3.Full Text
-
KOHLER, M. F., B. J. M. KERNS, P. A. HUMPHREY, J. R. MARKS, R. C. BAST, and A. BERCHUCK. “MUTATION AND OVEREXPRESSION OF P53 IN EARLY-STAGE EPITHELIAL OVARIAN-CANCER.” Obstetrics and Gynecology 81, no. 5 (May 1993): 643–50.Link to Item
-
Kohler, M. F., B. J. Kerns, P. A. Humphrey, J. R. Marks, R. C. Bast, and A. Berchuck. “Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.” Obstetrics and Gynecology 81, no. 5 ( Pt 1) (May 1993): 643–50.
-
Sasaki, H., H. Nishii, H. Takahashi, A. Tada, M. Furusato, Y. Terashima, G. P. Siegal, S. L. Parker, M. F. Kohler, and A. Berchuck. “Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma.” Cancer Res 53, no. 8 (April 15, 1993): 1906–10.Link to Item
-
Wu, S., C. M. Boyer, R. S. Whitaker, A. Berchuck, J. R. Wiener, J. B. Weinberg, and R. C. Bast. “Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression.” Cancer Res 53, no. 8 (April 15, 1993): 1939–44.Link to Item
-
Clarke-Pearson, D. L., I. S. Synan, R. Dodge, J. T. Soper, A. Berchuck, and R. E. Coleman. “A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery.” Am J Obstet Gynecol 168, no. 4 (April 1993): 1146–53. https://doi.org/10.1016/0002-9378(93)90360-u.Full Text Link to Item
-
Jacobs, I. J., S. A. Smith, R. W. Wiseman, P. A. Futreal, T. Harrington, R. J. Osborne, V. Leech, A. Molyneux, A. Berchuck, and B. A. Ponder. “A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus.” Cancer Res 53, no. 6 (March 15, 1993): 1218–21.Link to Item
-
Bast, R. C., C. M. Boyer, I. Jacobs, F. J. Xu, S. Wu, J. Wiener, M. Kohler, and A. Berchuck. “Cell growth regulation in epithelial ovarian cancer.” Cancer 71, no. 4 Suppl (February 1993): 1597–1601. https://doi.org/10.1002/cncr.2820710426.Full Text
-
Xu, F., R. Lupu, G. C. Rodriguez, R. S. Whitaker, M. P. Boente, A. Berchuck, Y. Yu, K. A. DeSombre, C. M. Boyer, and R. C. Bast. “Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.” Int J Cancer 53, no. 3 (February 1, 1993): 401–8. https://doi.org/10.1002/ijc.2910530310.Full Text Link to Item
-
Berchuck, A., M. F. Kohler, M. P. Boente, G. C. Rodriguez, R. S. Whitaker, and R. C. Bast. “Growth regulation and transformation of ovarian epithelium.” Cancer 71, no. 2 Suppl (January 15, 1993): 545–51. https://doi.org/10.1002/cncr.2820710209.Full Text Link to Item
-
Kohler, M. F., B. J. M. Kerns, P. A. Humphrey, J. R. Marks, R. C. B. Jr, and A. Berchuck. “Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.” Obstetrics and Gynecology 81, no. 5 I (1993): 643–50.
-
Rodríguez, G. C., M. P. Boente, A. Berchuck, R. S. Whitaker, K. C. O’Briant, F. Xu, and R. C. Bast. “The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines.” American Journal of Obstetrics and Gynecology 168, no. 1 Pt 1 (January 1993): 228–32. https://doi.org/10.1016/s0002-9378(12)90918-7.Full Text
-
Jacobs, I. J., M. F. Kohler, R. W. Wiseman, J. R. Marks, R. Whitaker, B. A. Kerns, P. Humphrey, A. Berchuck, B. A. Ponder, and R. C. Bast. “Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation.” J Natl Cancer Inst 84, no. 23 (December 2, 1992): 1793–98. https://doi.org/10.1093/jnci/84.23.1793.Full Text Link to Item
-
Boente, M. P., A. Berchuck, G. C. Rodriguez, A. Davidoff, R. Whitaker, F. J. Xu, J. Marks, D. L. Clarke-Pearson, and R. C. Bast. “The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells.” Am J Obstet Gynecol 167, no. 6 (December 1992): 1877–82. https://doi.org/10.1016/0002-9378(92)91790-h.Full Text Link to Item
-
Soisson, A. P., J. T. Soper, A. Berchuck, R. Dodge, and D. Clarke-Pearson. “Radical hysterectomy in obese women.” Obstet Gynecol 80, no. 6 (December 1992): 940–43.Link to Item
-
Soper, J. T., P. Johnson, V. Johnson, A. Berchuck, and D. L. Clarke-Pearson. “Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma.” Obstet Gynecol 80, no. 6 (December 1992): 949–53.Link to Item
-
Olt, G., A. Berchuck, A. P. Soisson, C. M. Boyer, and R. C. Bast. “Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer.” Cancer 70, no. 8 (October 15, 1992): 2137–42. https://doi.org/10.1002/1097-0142(19921015)70:8<2137::aid-cncr2820700821>3.0.co;2-w.Full Text Link to Item
-
Rodriguez, G. C., J. T. Soper, A. Berchuck, J. Oleson, R. Dodge, G. Montana, and D. L. Clarke-Pearson. “Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery.” J Clin Oncol 10, no. 10 (October 1992): 1553–60. https://doi.org/10.1200/JCO.1992.10.10.1553.Full Text Link to Item
-
Wiener, J. R., A. Berchuck, and R. C. Bast. “Biology and therapy with biologic agents in gynecologic cancer.” Curr Opin Oncol 4, no. 5 (October 1992): 946–54. https://doi.org/10.1097/00001622-199210000-00020.Full Text Link to Item
-
Berchuck, A., M. F. Kohler, and R. C. Bast. “Oncogenes in ovarian cancer.” Hematol Oncol Clin North Am 6, no. 4 (August 1992): 813–27.Link to Item
-
Ignar-Trowbridge, D., J. I. Risinger, G. A. Dent, M. Kohler, A. Berchuck, J. A. McLachlan, and J. Boyd. “Mutations of the Ki-ras oncogene in endometrial carcinoma.” Am J Obstet Gynecol 167, no. 1 (July 1992): 227–32. https://doi.org/10.1016/s0002-9378(11)91663-9.Full Text Link to Item
-
Kerns, B. J., P. A. Jordan, M. B. Moore, P. A. Humphrey, A. Berchuck, M. F. Kohler, R. C. Bast, J. D. Iglehart, and J. R. Marks. “p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry.” J Histochem Cytochem 40, no. 7 (July 1992): 1047–51. https://doi.org/10.1177/40.7.1607637.Full Text Link to Item
-
O’Briant, K., N. Chrysson, V. Hunter, F. Tyson, M. Tanner, L. Daly, S. L. George, A. Berchuck, J. Soper, and W. Fowler. “Ha-ras polymorphisms in epithelial ovarian cancer.” Gynecol Oncol 45, no. 3 (June 1992): 299–302. https://doi.org/10.1016/0090-8258(92)90308-6.Full Text Link to Item
-
Soper, J. T., A. Berchuck, R. Dodge, and D. L. Clarke-Pearson. “Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging.” Obstet Gynecol 79, no. 6 (June 1992): 993–97.Link to Item
-
Bast, R. C., I. Jacobs, and A. Berchuck. “Malignant transformation of ovarian epithelium.” J Natl Cancer Inst 84, no. 8 (April 15, 1992): 556–58. https://doi.org/10.1093/jnci/84.8.556.Full Text Link to Item
-
Kohler, M. F., A. Berchuck, A. M. Davidoff, P. A. Humphrey, R. K. Dodge, J. D. Iglehart, J. T. Soper, D. L. Clarke-Pearson, R. C. Bast, and J. R. Marks. “Overexpression and mutation of p53 in endometrial carcinoma.” Cancer Res 52, no. 6 (March 15, 1992): 1622–27.Link to Item
-
Berchuck, A., M. P. Boente, and R. C. Bast. “The use of tumor markers in the management of patients with gynecologic carcinomas.” Clin Obstet Gynecol 35, no. 1 (March 1992): 45–54. https://doi.org/10.1097/00003081-199203000-00009.Full Text Link to Item
-
Berchuck, A., G. Rodriguez, G. Olt, R. Whitaker, M. P. Boente, B. A. Arrick, D. L. Clarke-Pearson, and R. C. Bast. “Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta.” Am J Obstet Gynecol 166, no. 2 (February 1992): 676–84. https://doi.org/10.1016/0002-9378(92)91697-9.Full Text Link to Item
-
Berchuck, A., M. P. Boente, B. J. Kerns, R. B. Kinney, J. T. Soper, D. L. Clarke-Pearson, R. C. Bast, and S. S. Bacus. “Ploidy analysis of epithelial ovarian cancers using image cytometry.” Gynecol Oncol 44, no. 1 (January 1992): 61–65. https://doi.org/10.1016/0090-8258(92)90013-9.Full Text Link to Item
-
XU, F. J., S. RAMAKRISHNAN, L. DALY, J. T. SOPER, A. BERCHUCK, D. CLARKEPEARSON, and R. C. BAST. “INCREASED SERUM LEVELS OF MACROPHAGE COLONY-STIMULATING FACTOR IN OVARIAN-CANCER.” American Journal of Obstetrics and Gynecology 165, no. 5 (November 1, 1991): 1356–62.Link to Item
-
Xu, F. J., S. Ramakrishnan, L. Daly, J. T. Soper, A. Berchuck, D. Clarke-Pearson, and R. C. Bast. “Increased serum levels of macrophage colony-stimulating factor in ovarian cancer.” Am J Obstet Gynecol 165, no. 5 Pt 1 (November 1991): 1356–62. https://doi.org/10.1016/0002-9378(91)90368-2.Full Text Link to Item
-
Soper, J. T., A. Berchuck, and D. L. Clarke-Pearson. “Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging.” Cancer 68, no. 4 (August 15, 1991): 725–29. https://doi.org/10.1002/1097-0142(19910815)68:4<725::aid-cncr2820680410>3.0.co;2-1.Full Text Link to Item
-
Marks, J. R., A. M. Davidoff, B. J. Kerns, P. A. Humphrey, J. C. Pence, R. K. Dodge, D. L. Clarke-Pearson, J. D. Iglehart, R. C. Bast, and A. Berchuck. “Overexpression and mutation of p53 in epithelial ovarian cancer.” Cancer Res 51, no. 11 (June 1, 1991): 2979–84.Link to Item
-
Soper, J. T., G. Couchman, A. Berchuck, and D. Clarke-Pearson. “The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma.” Gynecol Oncol 41, no. 3 (June 1991): 239–44. https://doi.org/10.1016/0090-8258(91)90316-w.Full Text Link to Item
-
Cliby, W., A. P. Soisson, A. Berchuck, and D. L. Clarke-Pearson. “Stage I small cell carcinoma of the vulva treated with vulvectomy, lymphadenectomy, and adjuvant chemotherapy.” Cancer 67, no. 9 (May 1, 1991): 2415–17. https://doi.org/10.1002/1097-0142(19910501)67:9<2415::aid-cncr2820670934>3.0.co;2-w.Full Text Link to Item
-
Rodriguez, G. C., A. Berchuck, R. S. Whitaker, D. Schlossman, D. L. Clarke-Pearson, and R. C. Bast. “Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor.” Am J Obstet Gynecol 164, no. 3 (March 1991): 745–50. https://doi.org/10.1016/0002-9378(91)90508-o.Full Text Link to Item
-
Berchuck, A., G. C. Rodriguez, A. Kamel, R. K. Dodge, J. T. Soper, D. L. Clarke-Pearson, and R. C. Bast. “Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.” Am J Obstet Gynecol 164, no. 2 (February 1991): 669–74. https://doi.org/10.1016/s0002-9378(11)80044-x.Full Text Link to Item
-
Berchuck, A., G. Rodriguez, R. B. Kinney, J. T. Soper, R. K. Dodge, D. L. Clarke-Pearson, and R. C. Bast. “Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease.” Am J Obstet Gynecol 164, no. 1 Pt 1 (January 1991): 15–21. https://doi.org/10.1016/0002-9378(91)90615-x.Full Text Link to Item
-
Soper, J. T., A. Berchuck, and D. L. Clarke-Pearson. “The clinical significance of blood transfusion at the time of radical hysterectomy.” Obstet Gynecol 77, no. 1 (January 1991): 165–66.Link to Item
-
Xu, F. J., R. C. Bast, and D. Clarke-Pearson. “Increased serum levels of macrophage colony-stimulating factor in ovarian cancer.” American Journal of Obstetrics and Gynecology 165, no. 4 (January 1, 1991): 1356–62. https://doi.org/10.1016/S0002-9378(12)90761-9.Full Text
-
Hunter, V. J., L. Daly, M. Helms, J. T. Soper, A. Berchuck, D. L. Clarke-Pearson, and R. C. Bast. “The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.” Am J Obstet Gynecol 163, no. 4 Pt 1 (October 1990): 1164–67. https://doi.org/10.1016/0002-9378(90)90680-6.Full Text Link to Item
-
Kohler, M. F., A. Berchuck, M. E. Baker, C. A. Szpak, J. T. Soper, and D. L. Clarke-Pearson. “Computed tomography-guided fine-needle aspiration of retroperitoneal lymph nodes in gynecologic oncology.” Obstet Gynecol 76, no. 4 (October 1990): 612–16.Link to Item
-
Soper, J. T., A. Berchuck, G. J. Olt, A. P. Soisson, D. L. Clarke-Pearson, and R. C. Bast. “Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma.” Am J Obstet Gynecol 163, no. 4 Pt 1 (October 1990): 1204–9. https://doi.org/10.1016/0002-9378(90)90692-z.Full Text Link to Item
-
BERCHUCK, A., G. RODRIGUEZ, A. KAMEL, J. T. SOPER, D. L. CLARKEPEARSON, and R. C. BAST. “EXPRESSION OF EPIDERMAL GROWTH-FACTOR RECEPTOR AND HER-2 NEU IN NORMAL AND NEOPLASTIC CERVIX, VULVA, AND VAGINA.” Obstetrics and Gynecology 76, no. 3 (September 1, 1990): 381–87.Link to Item
-
Berchuck, A., G. Rodriguez, A. Kamel, J. T. Soper, D. L. Clarke-Pearson, and R. C. Bast. “Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina.” Obstet Gynecol 76, no. 3 Pt 1 (September 1990): 381–87.Link to Item
-
Olt, G., A. Berchuck, and R. C. Bast. “The role of tumor markers in gynecologic oncology.” Obstet Gynecol Surv 45, no. 9 (September 1990): 570–77. https://doi.org/10.1097/00006254-199009000-00002.Full Text Link to Item
-
Shpall, E. J., D. Clarke-Pearson, J. T. Soper, A. Berchuck, R. B. Jones, R. C. Bast, M. Ross, Y. Lidor, K. Vanacek, and T. Tyler. “High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer.” Gynecol Oncol 38, no. 3 (September 1990): 386–91. https://doi.org/10.1016/0090-8258(90)90079-z.Full Text Link to Item
-
Berchuck, A., A. Kamel, R. Whitaker, B. Kerns, G. Olt, R. Kinney, J. T. Soper, R. Dodge, D. L. Clarke-Pearson, and P. Marks. “Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.” Cancer Res 50, no. 13 (July 1, 1990): 4087–91.Link to Item
-
Soisson, A. P., G. Geszler, J. T. Soper, A. Berchuck, and D. L. Clarke-Pearson. “A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent cervical carcinoma after radical hysterectomy.” Obstet Gynecol 76, no. 1 (July 1990): 106–9.Link to Item
-
Soisson, A. P., J. T. Soper, D. L. Clarke-Pearson, A. Berchuck, G. Montana, and W. T. Creasman. “Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer.” Gynecol Oncol 37, no. 3 (June 1990): 390–95. https://doi.org/10.1016/0090-8258(90)90374-t.Full Text Link to Item
-
Berchuck, A., G. J. Olt, A. P. Soisson, A. Kamel, J. T. Soper, C. M. Boyer, D. L. Clarke-Pearson, D. S. Leslie, and R. C. Bast. “Heterogeneity of antigen expression in advanced epithelial ovarian cancer.” Am J Obstet Gynecol 162, no. 4 (April 1990): 883–88. https://doi.org/10.1016/0002-9378(90)91288-n.Full Text Link to Item
-
Berchuck, A., G. J. Olt, L. Everitt, A. P. Soisson, R. C. Bast, and C. M. Boyer. “The role of peptide growth factors in epithelial ovarian cancer.” Obstet Gynecol 75, no. 2 (February 1990): 255–62.Link to Item
-
Berchuck, A., G. Rodriguez, A. Kamel, J. T. Soper, D. L. Clarke-Pearson, and R. C. Bast. “Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina.” Obstetrics and Gynecology 76, no. 3 (January 1, 1990): 381–87.
-
Berchuck, A., S. C. Rubin, W. J. Hoskins, P. E. Saigo, V. K. Pierce, and J. L. Lewis. “Treatment of endometrial stromal tumors.” Gynecol Oncol 36, no. 1 (January 1990): 60–65. https://doi.org/10.1016/0090-8258(90)90109-x.Full Text Link to Item
-
Olt, G. J., A. Berchuck, and R. C. Bast. “Gynecologic tumor markers.” Semin Surg Oncol 6, no. 6 (1990): 305–13. https://doi.org/10.1002/ssu.2980060604.Full Text Link to Item
-
Berchuck, A., A. P. Soisson, G. J. Olt, J. T. Soper, D. L. Clarke-Pearson, R. C. Bast, and K. S. McCarty. “Epidermal growth factor receptor expression in normal and malignant endometrium.” Am J Obstet Gynecol 161, no. 5 (November 1989): 1247–52. https://doi.org/10.1016/0002-9378(89)90676-5.Full Text Link to Item
-
Soisson, A. P., A. Berchuck, B. A. Lessey, J. T. Soper, D. L. Clarke-Pearson, K. S. McCarty, and R. C. Bast. “Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels.” Am J Obstet Gynecol 161, no. 5 (November 1989): 1258–63. https://doi.org/10.1016/0002-9378(89)90678-9.Full Text Link to Item
-
Soper, J. T., D. Larson, V. J. Hunter, A. Berchuck, and D. L. Clarke-Pearson. “Short gracilis myocutaneous flaps for vulvovaginal reconstruction after radical pelvic surgery.” Obstet Gynecol 74, no. 5 (November 1989): 823–27.Link to Item
-
Berchuck, A., A. P. Soisson, J. T. Soper, D. L. Clarke-Pearson, R. C. Bast, and K. S. McCarty. “Reactivity of epidermal growth factor receptor monoclonal antibodies with human uterine tissues.” Arch Pathol Lab Med 113, no. 10 (October 1989): 1155–58.Link to Item
-
Berchuck, A., P. C. MacDonald, L. Milewich, and M. L. Casey. “Transforming growth factor-beta inhibits prostaglandin production in amnion and A431 cells.” Prostaglandins 38, no. 4 (October 1989): 453–64. https://doi.org/10.1016/0090-6980(89)90128-7.Full Text Link to Item
-
Soper, J. T., A. Berchuck, W. T. Creasman, and D. L. Clarke-Pearson. “Pelvic exenteration: factors associated with major surgical morbidity.” Gynecol Oncol 35, no. 1 (October 1989): 93–98. https://doi.org/10.1016/0090-8258(89)90020-6.Full Text Link to Item
-
Massad, L. S., K. Santoriello, and A. Berchuck. “Pneumoperitoneum due to peritoneovaginal fistula following hysterectomy.” Int J Gynaecol Obstet 29, no. 3 (July 1989): 257–61. https://doi.org/10.1016/0020-7292(89)90265-8.Full Text Link to Item
-
Berchuck, A., A. P. Soisson, D. L. Clarke-Pearson, J. T. Soper, C. M. Boyer, R. B. Kinney, K. S. McCarty, and R. C. Bast. “Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential.” Cancer Res 49, no. 8 (April 15, 1989): 2091–95.Link to Item
-
Yazigi, R., A. Berchuck, M. L. Casey, and P. C. MacDonald. “Effect of epidermal growth factor on ornithine decarboxylase activity in A431 cells.” Anticancer Res 9, no. 1 (January 1989): 209–13.Link to Item
-
Berchuck, A., S. C. Rubin, W. J. Hoskins, P. E. Saigo, V. K. Pierce, and J. L. Lewis. “Treatment of uterine leiomyosarcoma.” Obstet Gynecol 71, no. 6 Pt 1 (June 1988): 845–50.Link to Item
-
Berchuck, A., P. C. MacDonald, L. Milewich, and M. L. Casey. “Epidermal growth factor, vanadate, and 12-O-tetradecanoylphorbol-13-acetate inhibit growth and stimulate prostaglandin E2 production in A431 cells.” Mol Cell Endocrinol 57, no. 1–2 (May 1988): 87–92. https://doi.org/10.1016/0303-7207(88)90036-6.Full Text Link to Item
-
Berchuck, A., S. C. Rubin, W. J. Hoskins, P. E. Saigo, V. K. Pierce, and J. L. Lewis. “Treatment of uterine leiomyosarcoma.” Obstetrics and Gynecology 71, no. 6 (January 1, 1988): 845–50.
-
Berchuck, A., and T. J. Mullin. “Cervical adenoid cystic carcinoma associated with ascites.” Gynecol Oncol 22, no. 2 (October 1985): 201–11. https://doi.org/10.1016/0090-8258(85)90028-9.Full Text Link to Item
-
Berchuck, A., and R. J. Sokol. “Cervicovaginal fistula formation: a new complication of Shirodkar cerclage.” Am J Perinatol 1, no. 3 (April 1984): 263–65. https://doi.org/10.1055/s-2007-1000016.Full Text Link to Item
-
Berchuck, A., and R. J. Sokol. “Previous cesarean section, placenta increta, and uterine rupture in second-trimester abortion.” Am J Obstet Gynecol 145, no. 6 (March 15, 1983): 766–67. https://doi.org/10.1016/0002-9378(83)90591-4.Full Text Link to Item
-
-
Book Sections
-
Guillem, J. G., A. Berchuck, J. A. Norton, P. Subhedar, K. P. Seastedt, and B. R. Untch. “Role of surgery in cancer prevention.” In DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology, 402–19, 2018.
-
Guillem, J. G., A. Berchuck, J. F. Moley, J. A. Norton, S. G. A. Gabram-Mendola, and V. W. Hui. “Role of surgery in cancer prevention.” In DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology: Tenth Edition, 2015.
-
Guillem, J. G., A. Berchuck, J. F. Moley, J. A. Norton, S. G. A. Gabram-Mendola, and V. W. Hui. “Role of surgery in cancer prevention.” In DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology: Tenth Edition, 2015.
-
Gaillard, S., G. L. Maxwell, A. K. Sood, and A. Berchuck. “Biology and genetics.” In Berek and Hacker’s Gynecologic Oncology: Sixth Edition, 2–38, 2014.
-
Berchuck, A., D. A. Levine, J. H. Farley, and M. J. Birrer. “Molecular pathogenesis of gynecologic cancers.” In Principles and Practice of Gynecologic Oncology: Sixth Edition, 30–59, 2013.
-
Lu, K. H., A. Berchuck, and N. D. Kauff. “Hereditary gynecologic cancers.” In Principles and Practice of Gynecologic Oncology: Sixth Edition, 60–69, 2013.
-
Larry Maxwell, G., J. I. Risinger, J. Carl Barrett, and A. Berchuck. “The molecular genetics of endometrial cancer.” In Uterine Cancer, 69–89, 2005.
-
-
Other Articles
-
Meeks, Huong D., Honglin Song, Kyriaki Michailidou, Manjeet K. Bolla, Joe Dennis, Qin Wang, Daniel Barrowdale, et al. “BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.” J Natl Cancer Inst, February 2016. https://doi.org/10.1093/jnci/djv315.Full Text Link to Item
-
“Retraction. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.” J Clin Oncol, February 20, 2012. https://doi.org/10.1200/jco.2012.42.0331.Full Text Link to Item
-
Potti, Anil, Holly K. Dressman, Andrea Bild, Richard F. Riedel, Gina Chan, Robyn Sayer, Janiel Cragun, et al. “Retraction: Genomic signatures to guide the use of chemotherapeutics.” Nat Med, January 2011. https://doi.org/10.1038/nm0111-135.Full Text Link to Item
-
Potti, A., H. K. Dressman, A. Bild, R. F. Riedel, G. Chan, R. Sayer, J. Cragun, et al. “Corrigendum: Genomic signatures to guide the use of chemotherapeutics (Nature Medicine (2006) 12, (1294-1300)).” Nature Medicine, August 1, 2008. https://doi.org/10.1038/nm0808-889.Full Text
-
Potti, A., H. K. Dressman, A. Bild, R. F. Riedel, G. Chan, R. Sayer, J. Cragun, et al. “Erratum: Genomic signatures to guide the use of chemotherapeutics (Nature (2006) 12, (1294-1300)).” Nature Medicine, November 1, 2007. https://doi.org/10.1038/nm1107-1388.Full Text
-
Dressman, Holly K., Andrew Berchuck, Gina Chan, Jun Zhai, Andrea Bild, Robyn Sayer, Janiel Cragun, et al. “An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.” J Clin Oncol, February 10, 2007. https://doi.org/10.1200/JCO.2006.06.3743.Full Text Link to Item
-
Potti, Anil, Holly K. Dressman, Andrea Bild, Richard F. Riedel, Gina Chan, Robyn Sayer, Janiel Cragun, et al. “Genomic signatures to guide the use of chemotherapeutics.” Nat Med, November 2006. https://doi.org/10.1038/nm1491.Full Text Link to Item
-
Andrew, B., E. S. Iversen, J. M. Lancaster, H. K. Dressman, M. West, J. R. Nevins, J. R. Marks, and B. E. Miller. “Prediction of optimal versus suboptimal cytoreduction of advanced-stage serious ovarian cancer with the use of microarrays.” Women’S Oncology Review, September 1, 2004. https://doi.org/10.1080/14733400412331312585.Full Text
-
Berchuck, A., G. L. Maxwell, and J. R. Marks. “Relationship between alterations in the p53 gene and chemosensitivity of ovarian cancers.” Cme Journal of Gynecologic Oncology, December 1, 1999.
-
-
Conference Papers
-
Walsh, Kyle, Chenan Zhang, Lisa Calvocoressi, Helen Hansen, Andrew Berchuck, Joellen Schildkraut, Melissa Bondy, Joseph Wiemels, and Elizabeth Claus. “PLEIOTROPIC MLLT10 VARIATION CONFERS RISK OF MENINGIOMA, BREAST, AND OVARIAN CANCERS.” In Neuro Oncology, 21:142–142. OXFORD UNIV PRESS INC, 2019.Link to Item
-
Watson, Catherine H., Brittany Anne Davidson, Laura Jean Havrilesky, Paula S. Lee, Leah McNally, Haley Moss, Rebecca A. Previs, et al. “Management of high, moderate, and low penetrance ovarian cancer susceptibility gene mutations: An assessment of current practice patterns.” In Journal of Clinical Oncology, 37:1536–1536. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.1536.Full Text
-
Mittenzwei, Rhonda, Vivienne Meljen, Allison Puechl, Rex Bentley, Julia Elvin, Andrew Berchuck, Rebecca Previs, and Kyle Strickland. “Clinicopathologic and Molecular Characteristics of Copy-Number Low Endometrial Adenocarcinomas.” In Modern Pathology, Vol. 32. NATURE PUBLISHING GROUP, 2019.Link to Item
-
Mittenzwei, Rhonda, Vivienne Meljen, Allison Puechl, Rex Bentley, Julia Elvin, Andrew Berchuck, Rebecca Previs, and Kyle Strickland. “Clinicopathologic and Molecular Characteristics of Copy-Number Low Endometrial Adenocarcinomas.” In Laboratory Investigation, Vol. 99. NATURE PUBLISHING GROUP, 2019.Link to Item
-
Gaillard, Stephanie, Laurie M. Gay, Meghan Steiner, Kaitlyn Andreano, Brittany Anne Davidson, Laura Jean Havrilesky, Angeles Alvarez Secord, et al. “Assessment of activating estrogen receptor 1 (ESR1) mutations in gynecologic malignancies.” In Journal of Clinical Oncology, 36:5590–5590. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5590.Full Text
-
Millstein, Joshua, Timothy Budden, Michael Anglesio, Aline Talhouk, Alicia Beeghly-Fadiel, Andrew Berchuck, Georgia Chenevix-Trench, et al. “A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer.” In Journal of Clinical Oncology, 36:5583–5583. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5583.Full Text
-
Grant, Delores J., Ani Manichaikul, Lauren C. Peres, Xin-Qun Wang, Ann G. Schwartz, Anna Wu, Edward Peters, et al. “Abstract 1289: Evaluation of vitamin D receptor regulated genes reveals EGFR polymorphism is associated with high-grade serous ovarian cancer in African American women.” In Epidemiology. American Association for Cancer Research, 2017. https://doi.org/10.1158/1538-7445.am2017-1289.Full Text
-
Huang, Zhiqing, Brad Foster, Carole Grenier, Gregory Sfakianos, Regina Whitaker, Andrew Berchuck, and Susan K. Murphy. “Abstract 1991: Enhanced role of the extracellular matrix in ovarian cancer recurrence.” In Tumor Biology. American Association for Cancer Research, 2017. https://doi.org/10.1158/1538-7445.am2017-1991.Full Text
-
Gaillard, Stephanie, Chelsae Dumbauld, Alyssa Bilewski, Jessie A. Ehrisman, Angeles Alvarez Secord, Laura Jean Havrilesky, Andrew Berchuck, Kent Weinhold, Cliburn Chan, and John Yi. “Evaluating the repertoire of immune checkpoint markers expressed on peripheral and ascites CD8+ T cells in ovarian cancer.” In Journal of Clinical Oncology, 35:5571–5571. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.5571.Full Text
-
Moss, Haley, Evan Myers, Andrew Berchuck, and Laura Jean Havrilesky. “Cost-effectiveness of ovarian cancer screening: An analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) from a U.S. health system perspective.” In Journal of Clinical Oncology, 35:6608–6608. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.6608.Full Text
-
Doherty, Jennifer A., Casey S. Greene, James E. Rudd, Laura J. Tafe, Anthony J. Alberg, Elisa V. Bandera, Jill Barnholtz-Sloan, et al. “Abstract 3407: Gene expression subtypes of high grade serous ovarian cancer in African American women.” In Epidemiology. American Association for Cancer Research, 2016. https://doi.org/10.1158/1538-7445.am2016-3407.Full Text
-
Lee, Alice W., Ashley Bomkamp, Elisa V. Bandera, Allan Jensen, Susan J. Ramus, Marc T. Goodman, Mary Anne Rossing, et al. “Abstract 797: A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer.” In Epidemiology. American Association for Cancer Research, 2016. https://doi.org/10.1158/1538-7445.am2016-797.Full Text
-
Ehrisman, Jessie A., Sara Abbott, Zach Harmon, Angeles Alvarez Secord, Andrew Berchuck, Paula S. Lee, Fidel A. Valea, et al. “Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-Grade Endometrial Cancer.” In Modern Pathology, 29:282A-282A. NATURE PUBLISHING GROUP, 2016.Link to Item
-
Huang, Zhiqing, Zachery Visco, Gregory Sfakianos, Regina Whitaker, Andrew Berchuck, and Susan Murphy. “Abstract POSTER-BIOL-1319: Temporal shifts in the epigenetic regulation of tight junctions from primary to recurrent ovarian cancer.” In Biology of Ovarian Cancer. American Association for Cancer Research, 2015. https://doi.org/10.1158/1557-3265.ovcasymp14-poster-biol-1319.Full Text
-
Mo, Lihong, Margaret Kennedy, Andrew Berchuck, George Cianciolo, Robin E. Bachelder, and Salvatore V. Pizzo. “Abstract POSTER-THER-1420: Ascites drives ovarian cancer stem-like cell growth: therapeutic opportunities.” In Novel Therapeutics for Ovarian Cancer. American Association for Cancer Research, 2015. https://doi.org/10.1158/1557-3265.ovcasymp14-poster-ther-1420.Full Text
-
Huang, Zhiqing, Zachery Visco, Gregory Sfakianos, Regina Whitaker, Andrew Berchuck, and Susan K. Murphy. “Abstract 2236: Emergence of epigenetic regulation of tight junction genes in recurrent serous epithelial ovarian cancer.” In Tumor Biology. American Association for Cancer Research, 2015. https://doi.org/10.1158/1538-7445.am2015-2236.Full Text
-
Permuth-Wey, Jennifer, Brett M. Reid, Y Ann Chen, Hui-Yi Lin, Alvaro Monteiro, Zhihua Chen, Andrew Berchuck, et al. “Abstract 4635: Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility.” In Epidemiology. American Association for Cancer Research, 2015. https://doi.org/10.1158/1538-7445.am2015-4635.Full Text
-
Reid, Brett M., Jennifer Permuth-Wey, Y Ann Chen, Hui-Yi Lin, Alvaro Monteiro, Zhihua Chen, Andrew Berchuck, et al. “Abstract 4634: Variants within super-enhancer regulatory elements associate with epithelial ovarian cancer risk.” In Epidemiology. American Association for Cancer Research, 2015. https://doi.org/10.1158/1538-7445.am2015-4634.Full Text
-
Sellers, Thomas A., Brett M. Reid, Y Ann Chen, Hui-Yi Lin, Edward Richards, Jamie Teer, Alvaro Monteiro, et al. “Abstract 4633: Evidence that long non-coding RNA variants associate with epithelial ovarian cancer risk.” In Epidemiology. American Association for Cancer Research, 2015. https://doi.org/10.1158/1538-7445.am2015-4633.Full Text
-
Winham, Stacey J., Brooke L. Fridley, Melissa C. Larson, Zachary Fogarty, Andrew Berchuck, Yian Ann Chen, Hui-Yi Lin, et al. “Abstract 4636: Investigation of exome variants associated with overall survival in ovarian cancer.” In Epidemiology. American Association for Cancer Research, 2015. https://doi.org/10.1158/1538-7445.am2015-4636.Full Text
-
Berchuck, A., F. H. van der Baan, S. E. Johnatty, G. Chenevix-Trench, P. D. P. Pharoah, M. A. Rookus, and E. Goode. “KRAS variant rs61764370 is not associated with ovarian cancer risk or survival in the Ovarian Cancer Association Consortium (OCAC) or Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA).” In Gynecologic Oncology, 137:26–27. Elsevier BV, 2015. https://doi.org/10.1016/j.ygyno.2015.01.062.Full Text
-
Cobb, L. P., R. Whitaker, A. Hall, G. Broadwater, S. K. Murphy, A. Berchuck, and S. Gaillard. “Evaluation of ERRα expression and association with survival in advanced ovarian cancer.” In Gynecologic Oncology, 137:204–204. Elsevier BV, 2015. https://doi.org/10.1016/j.ygyno.2015.01.513.Full Text
-
Davidson, B. A., D. B. Mannschreck, G. Broadwater, M. Lopez-Acevedo, P. S. Lee, L. J. Havrilesky, F. A. Valea, A. Berchuck, and A. A. Secord. “Findings at laparoscopy, not debulking status, are associated with survival in advanced stage ovarian cancer after neoadjuvant chemotherapy.” In Gynecologic Oncology, 137:111–111. Elsevier BV, 2015. https://doi.org/10.1016/j.ygyno.2015.01.276.Full Text
-
Ehrisman, J. A., A. A. Secord, A. Berchuck, P. S. Lee, N. Di Santo, F. A. Valea, and L. J. Havrilesky. “Sentinel lymph node mapping in women with high risk histology endometrial cancer.” In Gynecologic Oncology, 137:93–93. Elsevier BV, 2015. https://doi.org/10.1016/j.ygyno.2015.01.229.Full Text
-
Witkowski, L., N. Donini, J. A. Knost, A. Berchuck, D. L. Thull, C. Lazaro, M. Longy, et al. “New cases of small cell carcinoma of the ovary, hypercalemic type caused by germline SMARCA4 mutations: An under-diagnosed entity?” In Gynecologic Oncology, 137:171–72. Elsevier BV, 2015. https://doi.org/10.1016/j.ygyno.2015.01.430.Full Text
-
Wysham, W. Z., T. H. Chen, L. Makowski, D. G. Mutch, A. Berchuck, B. Y. Karlan, D. A. Levine, and V. L. Bae-Jump. “Relationship between body mass index (BMI) and gene expression profiles of high grade serous ovarian cancers in The Cancer Genome Atlas (TCGA) project.” In Gynecologic Oncology, 137:62–63. Elsevier BV, 2015. https://doi.org/10.1016/j.ygyno.2015.01.146.Full Text
-
Teoh, Deanna, William J. Lowery, Xiaoyin Jiang, Jessie Ehrisman, Paige Halvorson, Gloria Broadwater, Rex Bentley, et al. “Vaginal cuff thermal injury by mode of colpotomy at total laparoscopic hysterectomy: a randomized clinical trial.” In Journal of Minimally Invasive Gynecology, 22:227–33, 2015. https://doi.org/10.1016/j.jmig.2014.10.002.Full Text
-
Kelemen, Linda E., Jonathan Tyrer, Catherine M. Phelan, Susan J. Ramus, Andrew Berchuck, Simon A. Gayther, Ellen L. Goode, et al. “Abstract 3283: GWAS identifies risk variants for mucinous ovarian carcinoma.” In Epidemiology. American Association for Cancer Research, 2014. https://doi.org/10.1158/1538-7445.am2014-3283.Full Text
-
Permuth-Wey, Jennifer, Y Ann Chen, Zhihua Chen, Andrew Berchuck, Georgia Chenevix-Trench, Jennifer Doherty, Simon Gayther, et al. “Abstract 946: Exome genotyping array identifies rare and low-frequency variants that may be associated with ovarian cancer risk.” In Epidemiology. American Association for Cancer Research, 2014. https://doi.org/10.1158/1538-7445.am2014-946.Full Text
-
Stevens, Ellen V., Regina Whitaker, Audrey Guinet, Ching-Yi Chang, Carole Grenier, Jeffrey Marks, Donald P. McDonnell, Susan K. Murphy, Andrew Berchuck, and Stephanie Gaillard. “Abstract 4570: Role of ERRalpha in ovarian cancer.” In Experimental and Molecular Therapeutics. American Association for Cancer Research, 2014. https://doi.org/10.1158/1538-7445.am2014-4570.Full Text
-
Witkowski, Leora, Jian Carrot-Zhang, Steffen Albrecht, Nancy Hamel, Eva Tomiak, David Grynspan, Emmanouil Saloustros, et al. “Abstract LB-89: Germ-line and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.” In Molecular and Cellular Biology. American Association for Cancer Research, 2014. https://doi.org/10.1158/1538-7445.am2014-lb-89.Full Text
-
Havrilesky, Laura Jean, Angeles Alvarez Secord, Jessie A. Ehrisman, Andrew Berchuck, Fidel A. Valea, Paula S. Lee, Stephanie Gaillard, et al. “Relative influence of factors determining a woman’s preference for treatment options in ovarian cancer.” In Journal of Clinical Oncology, 32:5544–5544. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5544.Full Text
-
Havrilesky, L. J., A. A. Secord, J. Ehrisman, A. Berchuck, F. A. Valea, P. S. Lee, D. Cella, K. Weinfurt, A. P. Abernethy, and S. D. Reed. “Relative Influence of Factors Determining a Woman’s Preference for Treatment Options in Ovarian Cancer: A Discrete Choice Experiment.” In Value in Health, 17:A93–A93. Elsevier BV, 2014. https://doi.org/10.1016/j.jval.2014.03.539.Full Text
-
Amankwah, Ernest K., Jonathan Tyrer, Hui-Yi Lin, Ya-Yu Tsai, Zhihua Chen, Gang Han, Xiaotao Qu, et al. “Abstract 1352: Epithelial-mesenchymal transition (EMT) gene variants influence epithelial ovarian cancer risk in women of European, African and Asian ancestry.” In Epidemiology. American Association for Cancer Research, 2013. https://doi.org/10.1158/1538-7445.am2013-1352.Full Text
-
Jim, Heather, Jonathan Tyrer, Hui-Yi Lin, Gang Han, Xiaotao Qu, Ellen L. Goode, Zhihua Chen, et al. “Abstract 4850: Variation in circadian rhythm genes influence epithelial ovarian cancer risk and invasiveness.” In Epidemiology. American Association for Cancer Research, 2013. https://doi.org/10.1158/1538-7445.am2013-4850.Full Text
-
Park, Jaemin, Zhiqing Huang, Andrew Berchuck, and Susan Murphy. “Abstract 4767: Preclinical mouse model of recurrent epithelial ovarian cancer.” In Endocrinology. American Association for Cancer Research, 2013. https://doi.org/10.1158/1538-7445.am2013-4767.Full Text
-
Siamakpour- Reihani, Sharareh, Chen Jiang, Taylor Turner, Kouros Owzar, Andrew Berchuck, Mark Dewhirst, and Angeles Alvarez Secord. “Abstract 330A: Differential expression of angiogenic genes in invasive high grade serous ovarian carcinomas.” In Clinical Research. American Association for Cancer Research, 2013. https://doi.org/10.1158/1538-7445.am2013-330a.Full Text
-
Barry, W., W. Chen, G. Sfakianos, P. Isner, M. Datto, N. Kuderer, G. Lyman, A. Abernethy, G. Ginsburg, and A. Berchuck. “OP 54 A genomic-based signature of response to chemotherapy in ovarian cancer fails to predict clinical outcome in two independent cohorts.” In European Journal of Cancer, 47:S8–S8. Elsevier BV, 2011. https://doi.org/10.1016/s0959-8049(11)72620-x.Full Text
-
Chino, J. P., L. Havrilesky, A. Berchuck, and E. Jones. “Secondary Malignancy after Radiation for Endometrial Cancer: Comparing No Radiation, External Beam, and Brachytherapy.” In International Journal of Radiation Oncology*Biology*Physics, 78:S404–S404. Elsevier BV, 2010. https://doi.org/10.1016/j.ijrobp.2010.07.952.Full Text
-
Baba, T., P. A. Convery, N. Matsumura, R. S. Whitaker, T. Perry, Z. Huang, S. Mori, et al. “Stem cell marker CD133 (PROMININ-1) is epigenetically regulated in ovarian cancer.” In Gynecologic Oncology, 108:S104–S104, 2008.Link to Item
-
Lee, P. S., V. Teaberry, A. E. Bland, Z. Huang, A Alvarez Secord, A. Berchuck, and S. K. Murphy. “MAL, a gene associated with survival in epithelial ovarian cancer, is epigenetically regulated.” In Gynecologic Oncology, 108:S125–S125. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2008.Link to Item
-
Rubatt, J. M., K. M. Darcy, A. Hutson, S. M. Bean, L. J. Havrilesky, P. S. Lee, L. A. Grace, A. Berchuck, and A Alvarez Secord. “Prognostic relevance of microvessel density in previously untreated, advanced-stage epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.” In Gynecologic Oncology, 108:S20–S20. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2008.Link to Item
-
Baba, Tsukasa, Patricia Convey, Noriomi Matsumura, Regina S. Whitaker, Tiffany Perry, Zhiqing Huang, Seiichi Mori, et al. “Stem cell marker CD133 (PROMININ-1) is epigenetically regulated in ovarian cancer.” In Cancer Biomarkers, 4:175–76, 2008.Link to Item
-
Berchuck, Andrew, Johnathan M. Lancaster, Edwin S. Iversen, Jingqin Luo, Douglas A. Levine, Jeffrey Boyd, Angeles Alvarez Secord, Jeffrey R. Marks, Joseph R. Nevins, and Holly Dressman. “Most early-stage serous ovarian cancers have gene expression profiles predictive of long-term survival.” In Gynecologic Oncology, 104:S15–16. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2007.Link to Item
-
Ramiah, Veshana S., Anil Potti, Rebecca Peterson, David Harpole, Andrew Berchuck, and Thomas L. Ortel. “Gene Expression Patterns Identify Patients with Non-Small Cell Lung Cancer (NSCLC) and Ovarian Cancer Who Are at Increased Risk for Venous Thromboembolism (VTE).” In Blood, 108:1470–1470. American Society of Hematology, 2006. https://doi.org/10.1182/blood.v108.11.1470.1470.Full Text
-
Secord, A Alvarez, L. J. Havrilesky, R. V. Higgins, L. R. Nycum, M. F. Kohler, L. E. Puls, R. Holloway, J. T. Soper, F. A. Valea, and A. Berchuck. “A comparison of combination docetaxel/carboplatin versus sequential docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.” In Journal of Clinical Oncology, 24:278S-278S. AMER SOC CLINICAL ONCOLOGY, 2006.Link to Item
-
WriQht, J. D., A. Alvarezsecord, T. M. Numnum, R. P. Rocconi, M. A. Powell, A. Berchuck, R. D. Alvarez, K. Trinkaus, J. S. Rader, and D. G. Mutch. “A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer.” In Journal of Clinical Oncology, 24:260S-260S. AMER SOC CLINICAL ONCOLOGY, 2006.Link to Item
-
Dressman, Holly K., Johnathan M. Lancaster, Gina Chan, Janiel M. Cragun, Andrea Bild, Robyn Sayer, Jennifer Clarke, et al. “Targeted approaches to the treatment of ovarian cancer.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Huang, Zhiqing, Alison H. Gusberg, Regina S. Whitaker, Andrew Berchuck, and Susan K. Murphy. “YY1 imprint status and role in ovarian carcinogenesis.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Murphy, Susan K., Alison H. Gusberg, Zhiqing Huang, Lauren R. Simel, Regina S. Whitaker, and Andrew Berchuck. “Overexpression of imprinted DLK1 in epithelial ovarian cancer.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Schildkraut, Joellen M., Amy French, Brian Calingaert, Rex C. Bentley, Susan Murphy, Jeffrey R. Marks, Patricia Moorman, Susan Halabi, and Andrew Berchuck. “Molecular epidemiology of cyclin E overexpression in epithelial ovarian cancer.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Bild, A. H., G. Yao, J. T. Chang, Q. L. Wang, A. Potti, D. Harpole, J. Lancaster, et al. “Oncogenic pathway signatures in human cancers as a guide to targeted therapies.” In Cancer Epidemiology Biomarkers & Prevention, 14:2743S-2743S. AMER ASSOC CANCER RESEARCH, 2005.Link to Item
-
Cragaun, J. M., A. Elahi, D. Boulware, C. Beam, R. Sayer, G. L. Maxwell, R. Sutphen, A. Berchuck, and J. M. Lancaster. “Characterization of the insulin-like growth factor pathway in endometrial cancers.” In Journal of Clinical Oncology, 23:474S-474S. AMER SOC CLINICAL ONCOLOGY, 2005.Link to Item
-
Lancaster, J. M., A. Bild, J. Pittman, R. Sayer, R. S. Whitaker, J. Marks, W. Mike, H. Dressman, J. Nevins, and A. Berchuck. “Gene expression profiles that predict response to platinum and identify patterns of pathway deregulation in advanced ovarian cancer.” In Journal of Clinical Oncology, 23:462S-462S. AMER SOC CLINICAL ONCOLOGY, 2005.Link to Item
-
Martino, M. A., A. Elahi, R. Sutphen, C. Klippel, T. Boren, H. K. Dressman, A. Berchuck, and J. M. Lancaster. “Expression analysis of genes involved in ovarian cancer metastasis.” In Journal of Clinical Oncology, 23:464S-464S. AMER SOC CLINICAL ONCOLOGY, 2005.Link to Item
-
Schildkraut, J. M., A. Berchuck, S. Murphy, J. Marks, P. Moorman, B. Calingaert, and S. Halabi. “Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer.” In Cancer Epidemiology Biomarkers & Prevention, 13:1897S-1897S. AMER ASSOC CANCER RESEARCH, 2004.Link to Item
-
Berchuck, A., A. A. Secord, L. J. Havrilesky, R. Wenham, J. T. Soper, and D. L. Clarke-Pearson. “Phase I/II trial of combination topotecan and vinorelbine in patients with refractory gynecologic cancer.” In Journal of Clinical Oncology, 22:487S-487S. AMER SOC CLINICAL ONCOLOGY, 2004.Link to Item
-
Jones, E. L., L. R. Prosnitz, T. V. Samulski, J. Soper, A. Berchuck, D. Clarke-Pearson, M. N. Dewhirst, and Z. Vujaskovic. “Intraperitoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma.” In Journal of Clinical Oncology, 22:458S-458S. AMER SOC CLINICAL ONCOLOGY, 2004.Link to Item
-
Secord, A. A., E. Jones, C. A. Hahn, L. J. Havrilesky, J. T. Soper, A. Berchuck, D. L. Clarke-Pearson, and L. R. Prosnitz. “Phase I/II trial of intravenous liposomal doxorubicin and whole abdomen hyperthermia in patients with refractory ovarian cancer.” In Journal of Clinical Oncology, 22:471S-471S. AMER SOC CLINICAL ONCOLOGY, 2004.Link to Item
-
Berchuck, A., E. Iversen, J. M. Lancaster, A. Henriott, H. Dressman, M. West, J. R. Nevins, and J. R. Marks. “Prediction of long-term versus short-term survival in advanced stage serous ovarian cancer using expression microarrays.” In Journal of the Society for Gynecologic Investigation, 11:182A-182A. ELSEVIER SCIENCE INC, 2004.Link to Item
-
Berchuck, A., A. Henriott, R. M. Wenham, B. Calingaert, S. Ali, G. C. Rodriguez, J. R. Marks, and J. M. Schildkraut. “Progesterone receptor promoter+331/G/A polymorphism is associated with deceased risk of epithelial ovarian cancer.” In Cancer Epidemiology Biomarkers & Prevention, 12:1340S-1340S. AMER ASSOC CANCER RESEARCH, 2003.Link to Item
-
Berchuck, Andrew, Molly Brewer, Gustavo Rodriguez, and Ian Campbell. “Discussion: Ovarian Cancer Prevention.” In Gynecologic Oncology, 88:S67–70. Elsevier BV, 2003. https://doi.org/10.1006/gyno.2002.6687.Full Text
-
Rodriguez, G. C., J. Barnes, K. Anderson, J. Petitte, J. Windham, J. Lancaster, R. Wenham, A. Berchuck, L. Kopelovich, and D. Carver. “Evaluation of ovarian cancer preventive agents in the chicken.” In Cancer Epidemiology Biomarkers & Prevention, 11:1193S-1193S. AMER ASSOC CANCER RESEARCH, 2002.Link to Item
-
Schildkraut, J. M., R. Wenham, J. Lancaster, B. Calingaert, K. McLean, S. Halabi, J. Marks, and A. Berchuck. “A case-control study of candidate ovarian cancer susceptibility polymorphisms.” In Cancer Epidemiology Biomarkers & Prevention, 11:1165S-1165S. AMER ASSOC CANCER RESEARCH, 2002.Link to Item
-
Berchuck, A., and F. Cirisano. “Pathogenesis of ovarian cancer: Role of ovulation and molecular changes.” In Ovary: Regulation, Dysfunction and Treatment, edited by M. Filicori and C. Flamigni, 1106:267–73. ELSEVIER SCIENCE PUBL B V, 1996.Link to Item
-
BERCHUCK, A., M. F. KOHLER, M. P. BOENTE, G. C. RODRIGUEZ, R. S. WHITAKER, and R. C. BAST. “GROWTH-REGULATION AND TRANSFORMATION OF OVARIAN EPITHELIUM.” In Cancer, 71:545–51. WILEY-LISS, 1993.Link to Item
-
BAST, R. C., C. M. BOYER, A. BERCHUCK, F. J. XU, S. WU, Y. LIDOR, L. A. MAIER, et al. “NEW STRATEGIES FOR THE MANAGEMENT OF OVARIAN AND BREAST-CANCER BASED ON BIOLOGY AND PHARMACOLOGY.” In Cancer Chemotherapy : Challenges for the Future, Vol 7, 1022:3–20, 1992.Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.